PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33867575-4	2021	The study also revealed that the HA-HCQ conjugate has multiple advantages of efficient drug delivery to its CD44 variant isoform receptors of the lower respiratory tract, highest interactive binding affinity with SARS-CoV-2 protein target.	Hydroxychloroquine	36-39	CD44 molecule (Indian blood group)	Homo sapiens	108-112
2825613-1	1987	The effect of chloroquine and hydroxychloroquine on neutrophil superoxide release stimulated by the chemotactic tripeptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) was examined.	Hydroxychloroquine	30-48	formyl peptide receptor 1	Homo sapiens	164-168
3500594-5	1987	Of the disease modifying agents tested, levamisole was ineffective while the antimalarials, chloroquine (100 microM) and hydroxychloroquine (100 microM), inhibited the action of IL-1.	Hydroxychloroquine	121-139	interleukin 1 alpha	Homo sapiens	178-182
6504946-4	1984	The results showed that in the hydroxychloroquine-treated group the transoperative increase in fibrinogen was associated with a reduction in plasma viscosity compared with an increase in the control group.	Hydroxychloroquine	31-49	fibrinogen beta chain	Homo sapiens	95-105
3179169-9	1988	The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).	Hydroxychloroquine	19-37	CD59 molecule (CD59 blood group)	Homo sapiens	143-148
3179169-9	1988	The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).	Hydroxychloroquine	19-37	CD59 molecule (CD59 blood group)	Homo sapiens	177-182
3019354-7	1986	Each drug also had different effects on surface receptor-dependent responses; thus HCQ inhibited FMLP- but not STZ-induced SO release, whereas CQ and MP inhibited the response to both stimuli.	Hydroxychloroquine	83-86	formyl peptide receptor 1	Homo sapiens	97-101
4853767-1	1974	In a series of patients given hydroxychloroquine sulphate by mouth before and after major surgery the incidence of deep venous thrombosis in the legs, as assessed by iodine-125-tagged fibrinogen scanning and venography, was reduced to 5% compared with an incidence of 16% in a similar untreated group of patients.	Hydroxychloroquine	30-57	fibrinogen beta chain	Homo sapiens	184-194
33528893-0	2021	The Effects of Hydroxychloroquine on Insulin Sensitivity, Insulin Clearance, and Inflammation in Insulin-Resistant Adults: a Randomized Trial.	Hydroxychloroquine	15-33	insulin	Homo sapiens	37-44
33865167-8	2021	However, the effects of LRRc17 knockdown were significantly blocked by the autophagy inhibitor hydroxychloroquine (HCQ), demonstrating that LRRc17 knockdown prevented BMSC senescence by activating mitophagy.	Hydroxychloroquine	95-113	leucine rich repeat containing 17	Mus musculus	140-146
33865167-8	2021	However, the effects of LRRc17 knockdown were significantly blocked by the autophagy inhibitor hydroxychloroquine (HCQ), demonstrating that LRRc17 knockdown prevented BMSC senescence by activating mitophagy.	Hydroxychloroquine	115-118	leucine rich repeat containing 17	Mus musculus	140-146
33528893-10	2021	HCQ did not affect insulin clearance but decreased circulating IL-6 (P=0.01) and increased adiponectin (P=0.045).	Hydroxychloroquine	0-3	adiponectin, C1Q and collagen domain containing	Homo sapiens	91-102
33528893-4	2021	We sought to determine the effect of HCQ on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation, and adipokines.	Hydroxychloroquine	37-40	insulin	Homo sapiens	70-77
33528893-12	2021	CONCLUSIONS: HCQ selectively enhances insulin sensitivity and glucose disposal in skeletal muscle, without affecting hepatic insulin sensitivity or insulin clearance.	Hydroxychloroquine	13-16	insulin	Homo sapiens	38-45
33528893-5	2021	METHODS: Insulin-resistant adults without rheumatic disease were randomized to 13 weeks of HCQ (400 mg/d PO) vs. placebo (double-blinded).	Hydroxychloroquine	91-94	insulin	Homo sapiens	9-16
33528893-13	2021	These findings offer a mechanistic explanation for the anti-diabetic properties of HCQ and suggest that this medication might be useful in conditions linked to insulin resistance such as type 2 diabetes.	Hydroxychloroquine	83-86	insulin	Homo sapiens	160-167
33528893-8	2021	RESULTS: Compared to placebo, HCQ significantly improved skeletal muscle insulin sensitivity by 26% (P=0.019) and enhanced systemic glucose clearance (P=0.025).	Hydroxychloroquine	30-33	insulin	Homo sapiens	73-80
33528893-10	2021	HCQ did not affect insulin clearance but decreased circulating IL-6 (P=0.01) and increased adiponectin (P=0.045).	Hydroxychloroquine	0-3	interleukin 6	Homo sapiens	63-67
32338164-6	2021	The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.	Hydroxychloroquine	126-144	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	171-175
34051669-2	2021	Herein, we designed a furin-responsive aggregated nanoplatform loaded with doxorubicin (DOX) and hydroxychloroquine (HCQ) (AuNPs-D&H-R&C) to combine chemotherapy, autophagy inhibition and macrophage polarization.	Hydroxychloroquine	97-115	furin, paired basic amino acid cleaving enzyme	Homo sapiens	22-27
33713277-8	2021	When LGR5(+) colorectal CSCs were co-treated with curcumin and the autophagy inhibitor (hydroxychloroquine), curcumin-induced cell proliferation inhibition decreased.	Hydroxychloroquine	88-106	leucine rich repeat containing G protein-coupled receptor 5	Homo sapiens	5-9
34058295-0	2021	Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG.	Hydroxychloroquine	70-88	ETS transcription factor ERG	Homo sapiens	92-96
34058295-7	2021	Molecular docking and patch clamp experiments showed that HCQ could bind to hERG and inhibit the efflux of potassium ion preferentially in the repolarization stage.	Hydroxychloroquine	58-61	ETS transcription factor ERG	Homo sapiens	76-80
34051669-2	2021	Herein, we designed a furin-responsive aggregated nanoplatform loaded with doxorubicin (DOX) and hydroxychloroquine (HCQ) (AuNPs-D&H-R&C) to combine chemotherapy, autophagy inhibition and macrophage polarization.	Hydroxychloroquine	117-120	furin, paired basic amino acid cleaving enzyme	Homo sapiens	22-27
34011935-5	2021	We found that downregulation of the MMP1 protein was a key abnormal feature in the neurofibromatosis 1 fibroblasts and that the decreased MMP1 was restored by the lysosomal blockers CQ and HCQ, but not by the blockers of the Ras pathway.	Hydroxychloroquine	189-192	matrix metallopeptidase 1	Homo sapiens	36-40
34011935-5	2021	We found that downregulation of the MMP1 protein was a key abnormal feature in the neurofibromatosis 1 fibroblasts and that the decreased MMP1 was restored by the lysosomal blockers CQ and HCQ, but not by the blockers of the Ras pathway.	Hydroxychloroquine	189-192	matrix metallopeptidase 1	Homo sapiens	138-142
33974624-13	2021	The underlying mechanisms may comprise a CYP3A4 enzyme interaction, and may be relevant for any future therapy combining hydroxychloroquine with antiviral agents.	Hydroxychloroquine	121-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
34002944-0	2021	SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.	Hydroxychloroquine	72-90	SMAD family member 4	Homo sapiens	0-5
34002944-4	2021	We studied whether HCQ treatment in SMAD4 deficient PDA may prevent therapeutic resistance induced by autophagy upregulation.	Hydroxychloroquine	19-22	SMAD family member 4	Homo sapiens	36-41
34002944-8	2021	The effect of SMAD4 loss on response to HCQ and chemotherapy was studied for association with clinical outcome.	Hydroxychloroquine	40-43	SMAD family member 4	Homo sapiens	14-19
34002944-12	2021	76% of HCQ-treated patients with SMAD4 loss obtained a histopathologic response greater than or equal to 2A, compared with only 37% with SMAD4 intact (p = 0.006).	Hydroxychloroquine	7-10	SMAD family member 4	Homo sapiens	33-38
34002944-14	2021	The addition of HCQ to neoadjuvant chemotherapy in patients with PDA may improve treatment response in those with SMAD4 loss.	Hydroxychloroquine	16-19	SMAD family member 4	Homo sapiens	114-119
33960280-0	2021	A novel KCNV2 mutation in a patient taking hydroxychloroquine associated with cone dystrophy with supernormal rod response.	Hydroxychloroquine	43-61	potassium voltage-gated channel modifier subfamily V member 2	Homo sapiens	8-13
34017843-10	2021	GS/BS patients" increased ACE2 and Ang 1-7 levels and their characteristic chronic metabolic alkalosis suggest a mechanism similar to that of chloroquine/hydroxychloroquine effect on ACE2 glycosylation alteration with resulting SARS-COV-2 binding inhibition and blockage/inhibition of viral entry.	Hydroxychloroquine	154-172	angiotensin converting enzyme 2	Homo sapiens	183-187
33674391-0	2021	COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels.	Hydroxychloroquine	31-49	ETS transcription factor ERG	Homo sapiens	94-98
33961943-0	2021	Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.	Hydroxychloroquine	0-18	interleukin 6	Homo sapiens	27-40
33961943-5	2021	At six months, the IL-6 levels were lower in the hydroxychloroquine group (p = 0.042, between groups), and in the on-treatment analysis, the difference at this time point was even more pronounced (p = 0.019, respectively).	Hydroxychloroquine	49-67	interleukin 6	Homo sapiens	19-23
33961943-8	2021	CONCLUSIONS: In patients with myocardial infarction, hydroxychloroquine reduced IL-6 levels significantly more than did placebo without causing any clinically significant adverse events.	Hydroxychloroquine	53-71	interleukin 6	Homo sapiens	80-84
33674391-5	2021	Here we study the effects of chloroquine, hydroxychloroquine, azithromycin, and remdesivir on hERG channels.	Hydroxychloroquine	42-60	ETS transcription factor ERG	Homo sapiens	94-98
33674391-10	2021	Significance Statement This work demonstrates that among off-label potential COVID-19 treatment drugs chloroquine, hydroxychloroquine, azithromycin, and remdesivir, the former two drugs block hERG potassium channels while the latter two drugs do not.	Hydroxychloroquine	115-133	ETS transcription factor ERG	Homo sapiens	192-196
33866528-3	2022	We developed a "smart" combination intravaginal ring (IVR) that will (1) provide continuous release of hydroxychloroquine (HCQ) to induce T cell immune quiescence as the first-line of defense and (2) release nanoparticles containing anti-CCR5 siRNA only during sexual intercourse when triggered by the presence of seminal fluid as the second-line of defense.	Hydroxychloroquine	123-126	C-C motif chemokine receptor 5	Homo sapiens	238-242
33416933-8	2021	Studies indicate that one of the possible anti-inflammatory mechanisms of chloroquine and hydroxychloroquine is inhibition of the activity of NLRP3 inflammasome.	Hydroxychloroquine	90-108	NLR family pyrin domain containing 3	Homo sapiens	142-147
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	interleukin 1 beta	Homo sapiens	50-67
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	corticotropin releasing hormone	Homo sapiens	69-100
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	corticotropin releasing hormone	Homo sapiens	102-105
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	solute carrier family 6 member 4	Homo sapiens	110-131
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	solute carrier family 6 member 4	Homo sapiens	133-139
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	allograft inflammatory factor 1	Homo sapiens	165-169
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	brain derived neurotrophic factor	Homo sapiens	227-260
33953673-6	2021	Furthermore, HCQ decreased the mRNA expression of interleukin-1beta, corticotropin-releasing hormone (Crh), a serotonin transporter (Slc6a4), and a microglia maker (Aif1) in the hippocampus and decreased the mRNA expression of brain-derived neurotrophic factor (Bdnf) in both the hippocampus and amygdala.	Hydroxychloroquine	13-16	brain derived neurotrophic factor	Homo sapiens	262-266
33876698-0	2021	Binding of hydroxychloroquine and chloroquine dimers to palmitoyl-protein thioesterase 1 (PPT1) and its glycosylated forms: a computational approach.	Hydroxychloroquine	11-29	palmitoyl-protein thioesterase 1	Homo sapiens	56-88
33876698-0	2021	Binding of hydroxychloroquine and chloroquine dimers to palmitoyl-protein thioesterase 1 (PPT1) and its glycosylated forms: a computational approach.	Hydroxychloroquine	11-29	palmitoyl-protein thioesterase 1	Homo sapiens	90-94
33876698-4	2021	Potent and selective inhibitors of PPT1 have been designed, in particular 4-amino-7-chloro-quinoline derivatives such as hydroxychloroquine (HCQ) and the dimeric analogues Lys05 and DC661.	Hydroxychloroquine	121-139	palmitoyl-protein thioesterase 1	Homo sapiens	35-39
33876698-4	2021	Potent and selective inhibitors of PPT1 have been designed, in particular 4-amino-7-chloro-quinoline derivatives such as hydroxychloroquine (HCQ) and the dimeric analogues Lys05 and DC661.	Hydroxychloroquine	141-144	palmitoyl-protein thioesterase 1	Homo sapiens	35-39
33959154-0	2021	Hydroxychloroquine Potentiates Apoptosis Induced by PPARalpha Antagonist in 786-O Clear Cell Renal Cell Carcinoma Cells Associated with Inhibiting Autophagy.	Hydroxychloroquine	0-18	peroxisome proliferator activated receptor alpha	Homo sapiens	52-61
33936063-9	2021	The effects of HCQ on renal fibrosis and macrophages decreased after depletion of TLR-9 in vivo and in vitro.	Hydroxychloroquine	15-18	toll-like receptor 9	Mus musculus	82-87
33859162-5	2021	Importantly, BCL-XL inhibition elicits protective autophagy, and concomitant blockade of BCL-XL and autophagic machinery with A-1155463 and hydroxychloroquine (HCQ), the US Food and Drug Administration (FDA)-approved autophagy inhibitor, synergistically enhances anti-MPM effects in vitro and in vivo.	Hydroxychloroquine	140-158	BCL2 like 1	Homo sapiens	89-95
33859162-5	2021	Importantly, BCL-XL inhibition elicits protective autophagy, and concomitant blockade of BCL-XL and autophagic machinery with A-1155463 and hydroxychloroquine (HCQ), the US Food and Drug Administration (FDA)-approved autophagy inhibitor, synergistically enhances anti-MPM effects in vitro and in vivo.	Hydroxychloroquine	160-163	BCL2 like 1	Homo sapiens	89-95
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	0-18	toll-like receptor 7	Mus musculus	47-67
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	0-18	toll-like receptor 7	Mus musculus	69-74
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	0-18	toll-like receptor 9	Mus musculus	80-85
33497271-10	2021	The HCQ group showed greater reduction in the inflammatory indices erythrocyte sedimentation rate and C-reactive protein (CRP) level (p < .05), and a significantly lower incidence of angiographic progression than the non-HCQ group (19.0% vs. 51.7%, p = .035).	Hydroxychloroquine	4-7	C-reactive protein	Homo sapiens	102-120
33497271-10	2021	The HCQ group showed greater reduction in the inflammatory indices erythrocyte sedimentation rate and C-reactive protein (CRP) level (p < .05), and a significantly lower incidence of angiographic progression than the non-HCQ group (19.0% vs. 51.7%, p = .035).	Hydroxychloroquine	4-7	C-reactive protein	Homo sapiens	122-125
33497271-11	2021	After adjustment for age and usage of tocilizumab, angiographic progression was found to be independently associated with CRP (hazard ratio [95% confidence interval], HR [95% CI]: 1.102 [1.000-1.024], p = .046), and the usage of HCQ (HR [95% CI]: 0.266 [0.075-0.940], p = .040).	Hydroxychloroquine	229-232	C-reactive protein	Homo sapiens	122-125
33869228-2	2021	A recent study suggested that treatment with autophagy inhibitors, in particular hydroxychloroquine, would be a potential therapeutic option for PBD-ZSD patients carrying the PEX1-G843D mutation.	Hydroxychloroquine	81-99	peroxisomal biogenesis factor 1	Homo sapiens	175-179
33548795-0	2021	Corrigendum to "Hydroxychloroquine inhibiting neutrophil extracellular trap formation alleviates hepatic ischemia/reperfusion by blocking TLR9 in mice" [Clinical Immunology 216 (2020) 108461].	Hydroxychloroquine	16-34	toll-like receptor 9	Mus musculus	138-142
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	20-23	toll-like receptor 7	Mus musculus	47-67
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	20-23	toll-like receptor 7	Mus musculus	69-74
33936063-2	2021	Hydroxychloroquine (HCQ), which mainly targets toll-like receptor-7 (TLR-7) and TLR-9, is associated with a lower risk of incident CKD.	Hydroxychloroquine	20-23	toll-like receptor 9	Mus musculus	80-85
33476807-9	2021	All five completed RCTs focused on the use of HCQ as either PrEP or PEP and these and the cross-sectional studies reported no prophylactic effect.	Hydroxychloroquine	46-49	prolyl endopeptidase	Homo sapiens	60-64
33675790-0	2021	Myeloid dendritic cells are major producers of interferon-beta in dermatomyositis and may contribute to hydroxychloroquine refractoriness.	Hydroxychloroquine	104-122	interferon beta 1	Homo sapiens	47-62
33781188-13	2021	Furthermore, one of these studies reported the binding of chloroquine and hydroxychloroquine to Mpro.	Hydroxychloroquine	74-92	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	96-100
33706683-3	2021	The results of the docking simulation revealed that methyl-1,4,5-tri-O-cafeoyl quinate has a stronger bond, high affinity and gives the best docking scores compared to, the co-crystallized inhibitor (PRD_002214) of the enzyme ACE2, chloroquine, hydroxychloroquine, captopril and simerprevir antiviral drugs.	Hydroxychloroquine	245-263	angiotensin converting enzyme 2	Homo sapiens	226-230
33694220-7	2021	For HIV, the virus that was most investigated, while two early studies suggested HCQ reduced viral levels, four subsequent ones did not, and in two of these CQ or HCQ increased viral levels and reduced CD4 counts.	Hydroxychloroquine	163-166	CD4 molecule	Homo sapiens	202-205
33284679-2	2021	Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention.	Hydroxychloroquine	49-67	3-hydroxyanthranilate 3,4-dioxygenase	Homo sapiens	68-71
33737451-9	2021	Gene expression of P-selectin (SELP) was inversely correlated with HCQ dose (r=-0.41, p=0.003), which was validated at the protein level.	Hydroxychloroquine	67-70	selectin P	Homo sapiens	19-29
33842650-8	2021	Studies have found that an increased myeloid dendritic cell population with higher TNF-alpha expression may be predictive of poor treatment response to HCQ in CLE patients.	Hydroxychloroquine	152-155	tumor necrosis factor	Homo sapiens	83-92
33535144-5	2021	In this study, we focused on identifying a more potent analogue of HCQ and CQ against the spike protein of SAR-CoV-2 that can act as an effective antiviral agent for COVID-19 treatment.	Hydroxychloroquine	67-70	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	90-95
33531790-12	2021	This finding was of particular importance that other compounds including hydroxychloroquine sulphate, lopinavir and ivermectin could bind with the spike protein only by weak Vander wall bonds and no hydrogen bond formation was noticed.	Hydroxychloroquine	73-100	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	147-152
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	smoothened, frizzled class receptor	Homo sapiens	129-132
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	sphingosine kinase 1	Homo sapiens	135-162
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	sphingosine kinase 2	Homo sapiens	164-169
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	fatty acid amide hydrolase	Homo sapiens	202-206
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	epidermal growth factor receptor	Homo sapiens	266-270
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	hypoxia inducible factor 1 subunit alpha	Homo sapiens	272-277
33160044-7	2021	RESULTS: The results suggested that HCQ in the treatment of RA was mainly associated with 4 targets that are smoothened homolog (SMO), sphingosine kinase (SPHK) 1, SPHK2 and gatty-acid amide hydrolase (FAAH), with their related 3276 proteins" network which regulate ErbB, HIF-1, NF-kappaB, FoxO, chemokines, MAPK, PI3K/Akt pathways and so forth.	Hydroxychloroquine	36-39	AKT serine/threonine kinase 1	Homo sapiens	319-322
33160044-11	2021	SMO, SPHK1, SPHK2 and FAAH involving 3276 proteins become the multi-targets mechanism of HCQ in the treatment of RA.	Hydroxychloroquine	89-92	smoothened, frizzled class receptor	Homo sapiens	0-3
33160044-11	2021	SMO, SPHK1, SPHK2 and FAAH involving 3276 proteins become the multi-targets mechanism of HCQ in the treatment of RA.	Hydroxychloroquine	89-92	sphingosine kinase 1	Homo sapiens	5-10
33160044-11	2021	SMO, SPHK1, SPHK2 and FAAH involving 3276 proteins become the multi-targets mechanism of HCQ in the treatment of RA.	Hydroxychloroquine	89-92	sphingosine kinase 2	Homo sapiens	12-17
33160044-11	2021	SMO, SPHK1, SPHK2 and FAAH involving 3276 proteins become the multi-targets mechanism of HCQ in the treatment of RA.	Hydroxychloroquine	89-92	fatty acid amide hydrolase	Homo sapiens	22-26
33737451-9	2021	Gene expression of P-selectin (SELP) was inversely correlated with HCQ dose (r=-0.41, p=0.003), which was validated at the protein level.	Hydroxychloroquine	67-70	selectin P	Homo sapiens	31-35
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	114-132	lysine acetyltransferase 2B	Homo sapiens	148-151
33225411-0	2021	Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.	Hydroxychloroquine	15-33	KRAS proto-oncogene, GTPase	Homo sapiens	65-69
33225411-0	2021	Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.	Hydroxychloroquine	35-38	KRAS proto-oncogene, GTPase	Homo sapiens	65-69
33225411-7	2021	CONCLUSIONS: Our real-life data regarding KRAS-mutated PDAC patients who received treatment with the MEK inhibitor trametinib combined with hydroxychloroquine after experiencing disease progression are consistent with the preclinical data, pointing to the clinical benefits of this regimen.	Hydroxychloroquine	140-158	KRAS proto-oncogene, GTPase	Homo sapiens	42-46
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	134-137	lysine acetyltransferase 2B	Homo sapiens	148-151
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	114-132	tumor necrosis factor	Homo sapiens	175-206
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	134-137	tumor necrosis factor	Homo sapiens	175-206
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	114-132	transforming growth factor alpha	Homo sapiens	208-215
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	134-137	transforming growth factor alpha	Homo sapiens	208-215
33670717-4	2021	Under CAF-inducing conditions, like hypoxia or cancer cell co-cultures, p62 ablation or autophagy inhibition with hydroxychloroquine (HCQ) impaired CAF activation and reduced transforming growth factor beta (TGFbeta) production, which impeded tumor growth.	Hydroxychloroquine	134-137	lysine acetyltransferase 2B	Homo sapiens	6-9
33345848-0	2021	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.	Hydroxychloroquine	30-48	ETS transcription factor ERG	Homo sapiens	149-153
33679150-5	2021	In this study, we docked five clinically used drug molecules, favipiravir, hydroxychloroquine, remdesivir, lopinavir, and ritonavir onto three target proteins, the receptor-binding domain of SARS-CoV-2 spike protein, SARS-CoV-2 main protease, and human furin protease.	Hydroxychloroquine	75-93	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	202-207
33345848-3	2021	Clinically, however, many drugs, including those currently used in COVID-19, such as chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir, may cause cardiotoxicity by acting on cardiac potassium channels and the hERG channel through their off-target effects.	Hydroxychloroquine	98-116	ETS transcription factor ERG	Homo sapiens	230-234
33526094-7	2021	Hydroxychloroquine through its anti-inflammatory effects or alteration of intra-cellular metabolism may have an effect in treating cases of ABCA3 gene mutations.	Hydroxychloroquine	0-18	ATP binding cassette subfamily A member 3	Homo sapiens	140-145
32770567-7	2021	Moreover, out of three distinct binding sites (I, II and III) of spike core when HCQ binds only with site III (farthest from the nCoV-RBD of ACE2 contact), epigallocatechin gallate and theaflavin gallate bind all three sites.	Hydroxychloroquine	81-84	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	65-70
32770567-7	2021	Moreover, out of three distinct binding sites (I, II and III) of spike core when HCQ binds only with site III (farthest from the nCoV-RBD of ACE2 contact), epigallocatechin gallate and theaflavin gallate bind all three sites.	Hydroxychloroquine	81-84	angiotensin converting enzyme 2	Homo sapiens	141-145
32770567-0	2021	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.	Hydroxychloroquine	126-144	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	74-79
33465165-8	2021	We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone.	Hydroxychloroquine	18-36	transmembrane serine protease 2	Homo sapiens	182-189
33486596-16	2021	TRAIL REGISTRATION: ClinicalTrials.gov : NCT03122431, registered on April 20, 2017 Key Points   Reduced American Academy of Ophthalmology (2016-AAO) hydroxychloroquine (HCQ) dose (2-3 mg/kg/day, real body weight) is unable to sustain HCQ blood levels within the safe cut-off defined for flare risk.	Hydroxychloroquine	234-237	TNF superfamily member 10	Homo sapiens	0-5
33475021-5	2021	In our study, the antimalarial compounds have been screened and docked against SARS-CoV-2-RdRp (PDB ID: 7BTF), and it was observed that the antimalarials chloroquine, hydroxychloroquine, and amodiaquine exhibit good affinity.	Hydroxychloroquine	167-185	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	90-94
33465165-0	2021	Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.	Hydroxychloroquine	0-18	transmembrane serine protease 2	Homo sapiens	76-83
33465165-8	2021	We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone.	Hydroxychloroquine	18-36	cathepsin L	Homo sapiens	80-91
33172973-5	2021	In addition, we show that pretreatment of cell lines with TFEB-activating agent Torin 1 contributed to an increase of HCQ whole cell concentrations by 1.4 to 1.6-fold, which were also characterized by the in vitro PK model.	Hydroxychloroquine	118-121	transcription factor EB	Homo sapiens	58-62
33486596-16	2021	TRAIL REGISTRATION: ClinicalTrials.gov : NCT03122431, registered on April 20, 2017 Key Points   Reduced American Academy of Ophthalmology (2016-AAO) hydroxychloroquine (HCQ) dose (2-3 mg/kg/day, real body weight) is unable to sustain HCQ blood levels within the safe cut-off defined for flare risk.	Hydroxychloroquine	169-172	TNF superfamily member 10	Homo sapiens	0-5
33465165-8	2021	We also show that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 infection more potently than either drug alone.	Hydroxychloroquine	139-157	cathepsin L	Homo sapiens	80-91
32937032-3	2021	METHODS: We identified incident hydroxychloroquine users among youth with SLE (ages 10-24 years) using de-identified U.S. commercial insurance claims in Optum Clinformatics  Data Mart (2000-2016).	Hydroxychloroquine	32-50	septin 4	Homo sapiens	179-183
33842834-8	2021	The results of our analysis with some other suggested drugs indicated that chloroquine and hydroxychloroquine had high binding energy (low inhibitory effect) with all three proteins-Mpro, PLpro, and RdRp.	Hydroxychloroquine	91-109	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	182-186
33842834-8	2021	The results of our analysis with some other suggested drugs indicated that chloroquine and hydroxychloroquine had high binding energy (low inhibitory effect) with all three proteins-Mpro, PLpro, and RdRp.	Hydroxychloroquine	91-109	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	188-193
33842834-8	2021	The results of our analysis with some other suggested drugs indicated that chloroquine and hydroxychloroquine had high binding energy (low inhibitory effect) with all three proteins-Mpro, PLpro, and RdRp.	Hydroxychloroquine	91-109	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	199-203
33414432-2	2021	Here, we report that lysosomotropic agents, including azithromycin, chloroquine, and hydroxychloroquine, can trigger eIF2alpha phosphorylation in vitro (in cultured human cells) and, as validated for hydroxychloroquine, in vivo (in mice).	Hydroxychloroquine	85-103	eukaryotic translation initiation factor 2A	Homo sapiens	117-126
33414432-2	2021	Here, we report that lysosomotropic agents, including azithromycin, chloroquine, and hydroxychloroquine, can trigger eIF2alpha phosphorylation in vitro (in cultured human cells) and, as validated for hydroxychloroquine, in vivo (in mice).	Hydroxychloroquine	200-218	eukaryotic translation initiation factor 2A	Homo sapiens	117-126
33387204-5	2021	The expression of CD40L on platelets significantly increased after direct incubation with 1000 ng/ml and 2000 ng/ml concentrations of HCQ.	Hydroxychloroquine	134-137	CD40 ligand	Homo sapiens	18-23
33387204-6	2021	In contrast, after pre-incubation of HUAECs with 1000 ng/ml HCQ and following stimulation with platelets the expression of CD40L was significantly reduced also after stimulation with thrombin and TNF-alpha activated platelets.	Hydroxychloroquine	60-63	CD40 ligand	Homo sapiens	123-128
33387204-6	2021	In contrast, after pre-incubation of HUAECs with 1000 ng/ml HCQ and following stimulation with platelets the expression of CD40L was significantly reduced also after stimulation with thrombin and TNF-alpha activated platelets.	Hydroxychloroquine	60-63	coagulation factor II, thrombin	Homo sapiens	183-191
33387204-6	2021	In contrast, after pre-incubation of HUAECs with 1000 ng/ml HCQ and following stimulation with platelets the expression of CD40L was significantly reduced also after stimulation with thrombin and TNF-alpha activated platelets.	Hydroxychloroquine	60-63	tumor necrosis factor	Homo sapiens	196-205
33387204-8	2021	HCQ reduces the stimulatory effect of thrombin and TNF-alpha on platelet activation in the presence of endothelial cells.	Hydroxychloroquine	0-3	coagulation factor II, thrombin	Homo sapiens	38-46
33387204-8	2021	HCQ reduces the stimulatory effect of thrombin and TNF-alpha on platelet activation in the presence of endothelial cells.	Hydroxychloroquine	0-3	tumor necrosis factor	Homo sapiens	51-60
33387204-9	2021	Our experiments suggest that HCQ pre-incubated HUAEC cells result in a reduced platelets activation measured by means of CD40L expression.	Hydroxychloroquine	29-32	CD40 ligand	Homo sapiens	121-126
33387204-10	2021	Further, our results show that direct HCQ incubation of platelets (without the presence of EC) increased the expression of CD40L suggesting that the observed effect of HCQ on platelet activation may be EC mediated.	Hydroxychloroquine	38-41	CD40 ligand	Homo sapiens	123-128
33387204-10	2021	Further, our results show that direct HCQ incubation of platelets (without the presence of EC) increased the expression of CD40L suggesting that the observed effect of HCQ on platelet activation may be EC mediated.	Hydroxychloroquine	168-171	CD40 ligand	Homo sapiens	123-128
33640890-3	2021	Multiple in vivo and in vitro studies and epidemiological evidence from the rheumatologic cohorts have shown that low-dose hydroxychloroquine has beneficial effects on inflammation, endothelial function, insulin sensitivity, and metabolic syndrome.	Hydroxychloroquine	123-141	insulin	Homo sapiens	204-211
32579244-0	2021	Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.	Hydroxychloroquine	43-61	NLR family pyrin domain containing 3	Homo sapiens	111-116
33022387-6	2021	MATERIALS AND METHODS: We measured plasma lyso-Gb3 levels in male patients receiving Amiodarone or hydroxychloroquine and compared it with male patients with classic and late onset variant of FD.	Hydroxychloroquine	99-117	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	47-50
33022387-8	2021	Patients on treatment with Amiodarone or hydroxychloroquine had normal values for alpha-GalA activity and lyso-Gb3 in plasma.	Hydroxychloroquine	41-59	galactosidase alpha	Homo sapiens	88-92
33022387-9	2021	CONCLUSIONS: Even when Amiodarone or hydroxychloroquine may decrease alpha-GalA activity in vitro or in cell culture, our results showed that in all patients lyso-Gb3 plasma levels remain normal with no evidence of reduction in alpha-GalA activity, confirming the specificity of this biomarker for the diagnosis of FD.	Hydroxychloroquine	37-55	galactosidase alpha	Homo sapiens	75-79
33410109-9	2021	In vitro, indapamide had robust hydroxyl scavenging activity, while HCQ and indapamide alone and in combination protected against iron-induced neuronal killing; TNF-alpha levels in activated microglia were reduced by either drug alone, without additional combination effects.	Hydroxychloroquine	68-71	tumor necrosis factor	Mus musculus	161-170
33716372-3	2021	The addition of enantiomers and racemic mixture of hydroxychloroquine (R-HCQ, S-HCQ and RS-HCQ) drugs and their interaction with beta-CD led to a red shift in the surface plasmon resonance of beta-CD-AuNP.	Hydroxychloroquine	51-69	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	129-136
33716372-3	2021	The addition of enantiomers and racemic mixture of hydroxychloroquine (R-HCQ, S-HCQ and RS-HCQ) drugs and their interaction with beta-CD led to a red shift in the surface plasmon resonance of beta-CD-AuNP.	Hydroxychloroquine	51-69	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	192-199
33716372-3	2021	The addition of enantiomers and racemic mixture of hydroxychloroquine (R-HCQ, S-HCQ and RS-HCQ) drugs and their interaction with beta-CD led to a red shift in the surface plasmon resonance of beta-CD-AuNP.	Hydroxychloroquine	78-83	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	129-136
33716372-3	2021	The addition of enantiomers and racemic mixture of hydroxychloroquine (R-HCQ, S-HCQ and RS-HCQ) drugs and their interaction with beta-CD led to a red shift in the surface plasmon resonance of beta-CD-AuNP.	Hydroxychloroquine	78-83	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	192-199
33716372-4	2021	The changes associated with the introduction of HCQ in beta-CD-AuNP were studied using various characterization techniques such as UV-vis, FT-IR, XRD, dynamic light scattering, zeta potential, transmission electron microscopy, fluorescence spectroscopy and electrochemical techniques.	Hydroxychloroquine	48-51	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	55-62
33716372-6	2021	The surface plasmon resonance at 521 nm for beta-CD-AuNP was shifted to 600, 620 and 670 nm on the addition of S-HCQ, R-HCQ and RS-HCQ, respectively, with a color change from pink to blue.	Hydroxychloroquine	111-116	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	44-51
32659769-7	2021	Furthermore, we found significant associations of both the testosterone serum levels and the SRD5A2 V89L polymorphism with opioid craving assessed by the HCQ.	Hydroxychloroquine	154-157	steroid 5 alpha-reductase 2	Homo sapiens	93-99
33410109-10	2021	In mice with a lysolecithin lesion that manifests demyelination and axonal loss in the spinal cord, the combination but not individual treatment of HCQ and indapamide reduced CD68+ microglia/macrophage representation in lesions, attenuated axonal injury, and lowered levels of lipid peroxidation.	Hydroxychloroquine	148-151	CD68 antigen	Mus musculus	175-179
33594347-6	2021	Case summary: We present a 43-year-old man with mixed connective tissue disease treated with hydroxychloroquine who rapidly developed CS 4 days from symptom onset with fever and cough, showing positive polymerase chain reaction nasopharyngeal swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.	Hydroxychloroquine	93-111	citrate synthase	Homo sapiens	134-136
33369679-0	2021	CD34+ CD133+ CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients - a case-control study and meta-regression analysis.	Hydroxychloroquine	91-109	CD34 molecule	Homo sapiens	0-4
33369679-0	2021	CD34+ CD133+ CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients - a case-control study and meta-regression analysis.	Hydroxychloroquine	91-109	prominin 1	Homo sapiens	6-11
33369679-0	2021	CD34+ CD133+ CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients - a case-control study and meta-regression analysis.	Hydroxychloroquine	91-109	kinase insert domain receptor	Homo sapiens	13-18
33313438-7	2020	Importantly, genetic (using AGER siRNA) or pharmacological (using glycyrrhizin, chloroquine, hydroxychloroquine, and FPS-ZM1) inhibition of the HMGB1-AGER pathway blocks ACE2 expression.	Hydroxychloroquine	93-111	high mobility group box 1	Homo sapiens	144-149
33490900-0	2021	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models.	Hydroxychloroquine	0-18	programmed cell death 1	Mus musculus	53-56
33490900-2	2021	Here, we evaluate the influence of HCQ treatment on the effect of anti-PD1 tumor immunotherapy.	Hydroxychloroquine	35-38	programmed cell death 1	Mus musculus	71-74
32991900-4	2020	Since the proteolytic cleavage of the S protein is critical for virus penetration into cells, a set of drugs, such as chloroquine, hydroxychloroquine, camostat mesylate have been tested in clinical trials to suppress this event.	Hydroxychloroquine	131-149	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	0-1
33490900-3	2021	Anti-PD1 therapy-sensitive tumor lines MC38, CT26, and RIL-175 were used to investigate the impact of HCQ on anti-PD1 therapy efficacy.	Hydroxychloroquine	102-105	programmed cell death 1	Mus musculus	114-117
33490900-5	2021	HCQ treatment impaired both antigen-specific and nonspecific T-cell production of TNFalpha and IFNgamma in vitro and in vivo.	Hydroxychloroquine	0-3	tumor necrosis factor	Mus musculus	82-90
33490900-5	2021	HCQ treatment impaired both antigen-specific and nonspecific T-cell production of TNFalpha and IFNgamma in vitro and in vivo.	Hydroxychloroquine	0-3	interferon gamma	Mus musculus	95-103
33490900-6	2021	Importantly, in all the three tumor models, HCQ treatment significantly impaired the response to anti-PD1 treatment, accompanying diminished in vivo T-cell activation and reduced tumor-infiltrating, antigen-specific CD8+ T cells.	Hydroxychloroquine	44-47	programmed cell death 1	Mus musculus	102-105
33390974-6	2020	An analysis of the pharmacology of HCQ in COVID-19 reveals certain possible reasons for this failure-a pharmacokinetic failure due to failure to achieve adequate drug concentration at the target site and attenuation of its inhibitory effect due to the presence of TMPRSS2 in airway epithelial cells.	Hydroxychloroquine	35-38	transmembrane serine protease 2	Homo sapiens	264-271
33332057-2	2020	Celebrities and mainstream media joined the discussion and promoted (hydroxy-)chloroquine to a true hype and the miracle cure for COVID-19.	Hydroxychloroquine	68-89	FIC domain protein adenylyltransferase	Homo sapiens	100-104
33332057-4	2020	Was (hydroxy-)chloroquine just a hype?	Hydroxychloroquine	4-25	FIC domain protein adenylyltransferase	Homo sapiens	33-37
33332057-8	2020	In our opinion, the use of (hydroxy-)chloroquine for COVID-19 was indeed a hype.	Hydroxychloroquine	27-48	FIC domain protein adenylyltransferase	Homo sapiens	75-79
33313438-7	2020	Importantly, genetic (using AGER siRNA) or pharmacological (using glycyrrhizin, chloroquine, hydroxychloroquine, and FPS-ZM1) inhibition of the HMGB1-AGER pathway blocks ACE2 expression.	Hydroxychloroquine	93-111	advanced glycosylation end-product specific receptor	Homo sapiens	150-154
32522067-7	2020	In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy.Abbreviation: ACE2: angiotensin I converting enzyme 2; CoV: coronavirus; CQ: chloroquine; ER: endoplasmic reticulum; HCQ: hydroxychloroquine; MERS-CoV: Middle East respiratory syndrome coronavirus; SARS-CoV: severe acute respiratory syndrome coronavirus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.	Hydroxychloroquine	338-341	angiotensin converting enzyme 2	Homo sapiens	235-239
32522067-7	2020	In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy.Abbreviation: ACE2: angiotensin I converting enzyme 2; CoV: coronavirus; CQ: chloroquine; ER: endoplasmic reticulum; HCQ: hydroxychloroquine; MERS-CoV: Middle East respiratory syndrome coronavirus; SARS-CoV: severe acute respiratory syndrome coronavirus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.	Hydroxychloroquine	343-361	angiotensin converting enzyme 2	Homo sapiens	235-239
33049581-8	2020	In addition, HCQ reduced the level of chemokine receptor 7 (CCR7) and L-selectin on peripheral blood DCs and diminished percentage of LN DCs.	Hydroxychloroquine	13-16	chemokine (C-C motif) receptor 7	Mus musculus	38-58
33049581-0	2020	The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling.	Hydroxychloroquine	18-36	toll-like receptor 9	Mus musculus	115-135
33049581-5	2020	In current study, we found that HCQ efficiently inhibited CD86, chemokine (C-X-C motif) receptor 4 (CXCR4) expression and interferon-alpha (IFN-alpha) secretion of healthy donor derived purified DCs stimulated by RA patient serum.	Hydroxychloroquine	32-35	CD86 antigen	Mus musculus	58-62
33049581-5	2020	In current study, we found that HCQ efficiently inhibited CD86, chemokine (C-X-C motif) receptor 4 (CXCR4) expression and interferon-alpha (IFN-alpha) secretion of healthy donor derived purified DCs stimulated by RA patient serum.	Hydroxychloroquine	32-35	chemokine (C-X-C motif) receptor 4	Mus musculus	64-98
33049581-5	2020	In current study, we found that HCQ efficiently inhibited CD86, chemokine (C-X-C motif) receptor 4 (CXCR4) expression and interferon-alpha (IFN-alpha) secretion of healthy donor derived purified DCs stimulated by RA patient serum.	Hydroxychloroquine	32-35	chemokine (C-X-C motif) receptor 4	Mus musculus	100-105
33049581-5	2020	In current study, we found that HCQ efficiently inhibited CD86, chemokine (C-X-C motif) receptor 4 (CXCR4) expression and interferon-alpha (IFN-alpha) secretion of healthy donor derived purified DCs stimulated by RA patient serum.	Hydroxychloroquine	32-35	interferon alpha	Mus musculus	122-138
33049581-5	2020	In current study, we found that HCQ efficiently inhibited CD86, chemokine (C-X-C motif) receptor 4 (CXCR4) expression and interferon-alpha (IFN-alpha) secretion of healthy donor derived purified DCs stimulated by RA patient serum.	Hydroxychloroquine	32-35	interferon alpha	Mus musculus	140-149
33049581-7	2020	We found HCQ inhibited DC maturation and migration to lymph nodes (LNs), manifested as down-regulated expression of CD40, CD80, CD86, MHCII (I-Aq) on LN DCs.	Hydroxychloroquine	9-12	CD40 antigen	Mus musculus	116-120
33049581-7	2020	We found HCQ inhibited DC maturation and migration to lymph nodes (LNs), manifested as down-regulated expression of CD40, CD80, CD86, MHCII (I-Aq) on LN DCs.	Hydroxychloroquine	9-12	CD80 antigen	Mus musculus	122-126
33049581-7	2020	We found HCQ inhibited DC maturation and migration to lymph nodes (LNs), manifested as down-regulated expression of CD40, CD80, CD86, MHCII (I-Aq) on LN DCs.	Hydroxychloroquine	9-12	CD86 antigen	Mus musculus	128-132
33049581-7	2020	We found HCQ inhibited DC maturation and migration to lymph nodes (LNs), manifested as down-regulated expression of CD40, CD80, CD86, MHCII (I-Aq) on LN DCs.	Hydroxychloroquine	9-12	histocompatibility-2, MHC	Mus musculus	134-139
32933997-12	2020	CONCLUSIONS: These results suggest that YAP, MEK1/2, and lysosome function are necessary and critical targets for the therapy of GNAQ/11-driven melanoma, and identify trametinib plus hydroxychloroquine as a potential treatment strategy for metastatic uveal melanoma.	Hydroxychloroquine	183-201	Yes1 associated transcriptional regulator	Homo sapiens	40-43
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	18-36	toll-like receptor 7	Mus musculus	74-82
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	18-36	interleukin 10	Mus musculus	124-129
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	18-36	tumor necrosis factor	Mus musculus	135-143
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	38-41	toll-like receptor 7	Mus musculus	74-82
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	38-41	interleukin 10	Mus musculus	124-129
33089917-5	2020	Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFalpha levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury.	Hydroxychloroquine	38-41	tumor necrosis factor	Mus musculus	135-143
33089917-6	2020	HCQ treatment decreased fibroadipogenic progenitor cell proliferation and partially inhibited ERK1/2 phosphorylation in the injured tissue, suggesting it may act through a combination of TLR7/8/9 and ERK signaling mechanisms.	Hydroxychloroquine	0-3	mitogen-activated protein kinase 3	Mus musculus	94-100
33089917-6	2020	HCQ treatment decreased fibroadipogenic progenitor cell proliferation and partially inhibited ERK1/2 phosphorylation in the injured tissue, suggesting it may act through a combination of TLR7/8/9 and ERK signaling mechanisms.	Hydroxychloroquine	0-3	toll-like receptor 7	Mus musculus	187-195
33089917-6	2020	HCQ treatment decreased fibroadipogenic progenitor cell proliferation and partially inhibited ERK1/2 phosphorylation in the injured tissue, suggesting it may act through a combination of TLR7/8/9 and ERK signaling mechanisms.	Hydroxychloroquine	0-3	mitogen-activated protein kinase 1	Mus musculus	94-97
33098839-8	2020	It was found that PI3K/Akt, VEGF, ERBB2 pathways must be given consideration for understanding the role of HCQ and AZM in QT interval prolongation.	Hydroxychloroquine	107-110	AKT serine/threonine kinase 1	Homo sapiens	23-26
33098839-8	2020	It was found that PI3K/Akt, VEGF, ERBB2 pathways must be given consideration for understanding the role of HCQ and AZM in QT interval prolongation.	Hydroxychloroquine	107-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-39
33049581-8	2020	In addition, HCQ reduced the level of chemokine receptor 7 (CCR7) and L-selectin on peripheral blood DCs and diminished percentage of LN DCs.	Hydroxychloroquine	13-16	chemokine (C-C motif) receptor 7	Mus musculus	60-64
33049581-8	2020	In addition, HCQ reduced the level of chemokine receptor 7 (CCR7) and L-selectin on peripheral blood DCs and diminished percentage of LN DCs.	Hydroxychloroquine	13-16	selectin, lymphocyte	Mus musculus	70-80
33049581-10	2020	Mechanistically, HCQ down-regulated the expression of TLR9 not only in healthy donor PBMC-derived DCs stimulated by RA patient serum, but also in LN DCs of CIA mice and CpG-activated BMDCs.	Hydroxychloroquine	17-20	toll-like receptor 9	Mus musculus	54-58
33049581-12	2020	Collectively, activation of DCs contributes to the pathogenesis of RA and HCQ shows protective effects on RA by inhibition of DC activation via blocking TLR9.	Hydroxychloroquine	74-77	toll-like receptor 9	Mus musculus	153-157
33166694-4	2020	Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive.	Hydroxychloroquine	20-23	prolyl endopeptidase	Homo sapiens	166-169
32859477-10	2020	The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry.	Hydroxychloroquine	27-30	C-reactive protein	Homo sapiens	109-127
33075513-0	2020	Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspension in Syrspend pH4 dry.	Hydroxychloroquine	54-72	prolyl 4-hydroxylase, transmembrane	Homo sapiens	101-104
33166694-6	2020	The PEP group received HCQ 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks.	Hydroxychloroquine	23-26	prolyl endopeptidase	Homo sapiens	4-7
33166694-14	2020	PEP with HCQ has the potential for the prevention of COVID-19 in at-risk individuals.	Hydroxychloroquine	9-12	prolyl endopeptidase	Homo sapiens	0-3
33081587-11	2020	SIGLEC1 expression correlates inversely with the amount of therapeutically applied hydroxychloroquine (p < 0.001).	Hydroxychloroquine	83-101	sialic acid binding Ig like lectin 1	Homo sapiens	0-7
32956664-4	2020	The result indicate that Molecules N  3, 7 and 14 have more binding energy with SARS-CoV-2 main protease recently crystallized (pdb code 6LU7) in comparison with the other imidazole derivatives and the two drug; Chloroquine and hydroxychloroquine.	Hydroxychloroquine	228-246	n  3, 7 and 14	None	35-49
33191279-0	2021	Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus.	Hydroxychloroquine	0-18	interferon alpha 1	Homo sapiens	30-40
32920291-6	2020	We further analyzed the binding character of CQ and HCQ to ACE2 by molecular docking and surface plasmon resonance (SPR) assays, 2019-nCoV spike pseudotyped virus was also used to observe the viropexis effect of CQ and HCQ in ACE2h cells.	Hydroxychloroquine	52-55	angiotensin converting enzyme 2	Homo sapiens	59-63
32920291-7	2020	RESULTS: Results showed that HCQ is slightly more toxic to ACE2h cells than CQ.	Hydroxychloroquine	29-32	angiotensin converting enzyme 2	Homo sapiens	59-63
32920291-8	2020	Both CQ and HCQ could bind to ACE2 with KD = (7.31 +- 0.62)e-7 M and (4.82 +- 0.87)e-7 M, respectively.	Hydroxychloroquine	12-15	angiotensin converting enzyme 2	Homo sapiens	30-34
32920291-10	2020	CONCLUSIONS: CQ and HCQ both inhibit the entrance 2019-nCoV into cells by blocking the binding of the virus with ACE2.	Hydroxychloroquine	20-23	angiotensin converting enzyme 2	Homo sapiens	113-117
33330573-0	2020	Case Report: Treatment of Anti-MDA5-Positive Amyopathic Dermatomyositis Accompanied by a Rapidly Progressive Interstitial Lung Diseases With Methylprednisolone Pulse Therapy Combined With Cyclosporine A and Hydroxychloroquine.	Hydroxychloroquine	207-225	interferon induced with helicase C domain 1	Homo sapiens	31-35
32920291-0	2020	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.	Hydroxychloroquine	16-34	angiotensin converting enzyme 2	Homo sapiens	38-42
32920291-0	2020	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.	Hydroxychloroquine	16-34	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	86-91
32920291-4	2020	PURPOSE: The objective of this study is to investigate whether CQ and HCQ could be ACE2 blockers and used to inhibit 2019-nCoV virus infection.	Hydroxychloroquine	70-73	angiotensin converting enzyme 2	Homo sapiens	83-87
32920291-5	2020	METHODS: In our study, we used CCK-8 staining, flow cytometry and immunofluorescent staining to evaluate the toxicity and autophagy of CQ and HCQ, respectively, on ACE2 high-expressing HEK293T cells (ACE2h cells).	Hydroxychloroquine	142-145	angiotensin converting enzyme 2	Homo sapiens	164-168
33294038-10	2020	Patients currently on hydroxychloroquine exhibited decreased levels of PCSK9 compared with those that were not taking hydroxychloroquine [beta coefficient -30 (95% CI -54 to -6) ng/ml, p = 0.015].	Hydroxychloroquine	22-40	proprotein convertase subtilisin/kexin type 9	Homo sapiens	71-76
33200683-6	2022	Inspired by this fact, we have carried out molecular docking and dynamics simulation studies of FDA approved CQ and HCQ against SARS-CoV-2 PLpro.	Hydroxychloroquine	116-119	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	139-144
33200683-9	2022	We showed that the CQ and HCQ can bind with better binding affinity with PLpro as compared to reference known PLpro inhibitor.	Hydroxychloroquine	26-29	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	73-78
33200683-9	2022	We showed that the CQ and HCQ can bind with better binding affinity with PLpro as compared to reference known PLpro inhibitor.	Hydroxychloroquine	26-29	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	110-115
33200683-10	2022	Based on the presented findings, it can be anticipated that the SARS-CoV-2 PLpro may act as molecular target of CQ and HCQ, and can be projected for further exploration to design potent inhibitors of SARS-CoV-2 PLpro in the near future.	Hydroxychloroquine	119-122	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	75-80
33191279-0	2021	Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus.	Hydroxychloroquine	0-18	TNF superfamily member 13b	Homo sapiens	61-85
33191279-10	2021	After 16 weeks of treatment with HCQ, the expression of IFN- inducible genes decreased in eight of nine patients, and the IFN-3 score decreased significantly (p=0.012).	Hydroxychloroquine	33-36	interferon alpha 1	Homo sapiens	56-59
33191279-12	2021	CONCLUSION: HCQ suppresses IFN score and BAFF levels in patients with incomplete or new onset SLE, and there is a trend towards lowering IP-10 levels.	Hydroxychloroquine	12-15	interferon alpha 1	Homo sapiens	27-30
33191279-12	2021	CONCLUSION: HCQ suppresses IFN score and BAFF levels in patients with incomplete or new onset SLE, and there is a trend towards lowering IP-10 levels.	Hydroxychloroquine	12-15	TNF superfamily member 13b	Homo sapiens	41-45
33170091-7	2022	Intriguingly, rosiglitazone (RGZ) and hydroxychloroquine (HCQ) were found to be mild-to-moderate inhibitors of hAChE (human acetylcholinesterase) in our enzyme inhibition studies which are complementary to our computational studies.	Hydroxychloroquine	38-56	acetylcholinesterase (Cartwright blood group)	Homo sapiens	111-116
33172397-1	2020	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects.	Hydroxychloroquine	12-30	CD79a molecule	Homo sapiens	113-116
33172397-1	2020	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects.	Hydroxychloroquine	12-30	IGAN1	Homo sapiens	131-135
33172397-1	2020	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects.	Hydroxychloroquine	32-35	CD79a molecule	Homo sapiens	113-116
33172397-1	2020	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects.	Hydroxychloroquine	32-35	IGAN1	Homo sapiens	131-135
33172397-2	2020	We investigated the effects of HCQ in patients with IgAN whose proteinuria remained above 1 g/d after conventional immunosuppressive (IS) therapy.	Hydroxychloroquine	31-34	IGAN1	Homo sapiens	52-56
33172397-4	2020	Twenty-six patients with IgAN who received HCQ and had insufficient responses to IS therapy (corticosteroid (CS) therapy with/without IS agents) were included.	Hydroxychloroquine	43-46	IGAN1	Homo sapiens	25-29
33172397-8	2020	A significant reduction in proteinuria was noted in IgAN patients with HCQ treatment (2.35 [IQR, 1.47, 2.98] vs. 1.10 [IQR, 0.85, 1.61] g/d, p = 0.002).	Hydroxychloroquine	71-74	IGAN1	Homo sapiens	52-56
33172397-12	2020	CONCLUSIONS: Use of HCQ achieved has similar reduction in proteinuria compared to conventional IS therapy in patients with IgAN who had insufficient responses to IS therapy.	Hydroxychloroquine	20-23	IGAN1	Homo sapiens	123-127
33176880-11	2020	Favipiravir, chloroquine and hydroxychloroquine also showed some significant MPro inhibition.	Hydroxychloroquine	29-47	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	77-81
33170091-7	2022	Intriguingly, rosiglitazone (RGZ) and hydroxychloroquine (HCQ) were found to be mild-to-moderate inhibitors of hAChE (human acetylcholinesterase) in our enzyme inhibition studies which are complementary to our computational studies.	Hydroxychloroquine	38-56	acetylcholinesterase (Cartwright blood group)	Homo sapiens	124-144
33170091-7	2022	Intriguingly, rosiglitazone (RGZ) and hydroxychloroquine (HCQ) were found to be mild-to-moderate inhibitors of hAChE (human acetylcholinesterase) in our enzyme inhibition studies which are complementary to our computational studies.	Hydroxychloroquine	58-61	acetylcholinesterase (Cartwright blood group)	Homo sapiens	111-116
33170091-7	2022	Intriguingly, rosiglitazone (RGZ) and hydroxychloroquine (HCQ) were found to be mild-to-moderate inhibitors of hAChE (human acetylcholinesterase) in our enzyme inhibition studies which are complementary to our computational studies.	Hydroxychloroquine	58-61	acetylcholinesterase (Cartwright blood group)	Homo sapiens	124-144
33170091-8	2022	On the basis of our computational and experimental studies, it can be suggested that the beneficial effect of RGZ and HCQ in AD patients reported in the literature may partly be due to their AChE inhibitory property.	Hydroxychloroquine	118-121	acetylcholinesterase (Cartwright blood group)	Homo sapiens	191-195
32763298-5	2020	Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ.	Hydroxychloroquine	71-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
32763298-8	2020	Therefore, CYP450 genotyping especially for CYP2D6 might be helpful to refine HCQ dosage.	Hydroxychloroquine	78-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
33051297-8	2020	Additionally, hydroxychloroquine (Ki = 0.36 microM) and chloroquine (Ki = 0.56 microM) were also found to potently inhibit SARS-CoV-2 Mpro We anticipate that the FEP-ABFE prediction-based virtual screening approach will be useful in many other drug repurposing or discovery efforts.	Hydroxychloroquine	14-32	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	134-138
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	estrogen receptor 1	Homo sapiens	166-170
32779755-6	2020	We found that, the elevated IL-6, a risk factor in severe patients were reduced to normal level after HCQ treatment.	Hydroxychloroquine	102-105	interleukin 6	Homo sapiens	28-32
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	cyclin dependent kinase 2	Homo sapiens	107-132
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	cyclin dependent kinase 2	Homo sapiens	134-138
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	estrogen receptor 1	Homo sapiens	141-164
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	cyclin dependent kinase 1	Homo sapiens	176-180
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	AKT serine/threonine kinase 1	Homo sapiens	202-205
32854577-7	2020	RESULTS: The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3beta as well as interferon (IFN) signaling pathway.	Hydroxychloroquine	50-53	glycogen synthase kinase 3 alpha	Homo sapiens	206-214
32854577-11	2020	Three key targets (CDK2, ESR1 and CDK1) involving 1766 proteins become the multi-targets mechanism of HCQ in the treatment of SLE.	Hydroxychloroquine	102-105	cyclin dependent kinase 2	Homo sapiens	19-23
32854577-11	2020	Three key targets (CDK2, ESR1 and CDK1) involving 1766 proteins become the multi-targets mechanism of HCQ in the treatment of SLE.	Hydroxychloroquine	102-105	estrogen receptor 1	Homo sapiens	25-29
32854577-11	2020	Three key targets (CDK2, ESR1 and CDK1) involving 1766 proteins become the multi-targets mechanism of HCQ in the treatment of SLE.	Hydroxychloroquine	102-105	cyclin dependent kinase 1	Homo sapiens	34-38
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	C-C motif chemokine ligand 2	Homo sapiens	71-75
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	cathepsin B	Homo sapiens	77-81
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	C-X-C motif chemokine ligand 8	Homo sapiens	83-88
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	interleukin 1 beta	Homo sapiens	90-94
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	interleukin 6	Homo sapiens	96-99
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	tumor necrosis factor	Homo sapiens	104-107
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	BCL2 like 1	Homo sapiens	178-184
32920000-6	2020	Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases.	Hydroxychloroquine	12-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	189-195
32920000-7	2020	In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6.	Hydroxychloroquine	48-66	tumor necrosis factor	Homo sapiens	114-117
32920000-7	2020	In contrast to lopinavir/ritonavir, chloroquine/hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6.	Hydroxychloroquine	48-66	interleukin 6	Homo sapiens	122-125
33007039-5	2020	We tested the effects of high-dose HCQ administration over 5 days on hemolysis in our novel G6PD A- mice.	Hydroxychloroquine	35-38	glucose-6-phosphate dehydrogenase 2	Mus musculus	92-96
33049937-3	2020	A remarkable example of our advances in these challenging tasks is the highly polymorphic CYP2D6 gene, which encodes a cytochrome P450 enzyme involved in the metabolization of many of the most marketed drugs (including SARS-Cov-2 therapies such as hydroxychloroquine).	Hydroxychloroquine	248-266	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
32878881-6	2020	In silico screening, molecular mechanics and molecular dynamics simulation (MDS) analysis suggest ribavirin, ascorbate, lopinavir and hydroxychloroquine have strong interaction at the RBD-hACE2 interface.	Hydroxychloroquine	134-152	angiotensin converting enzyme 2	Homo sapiens	188-193
33007039-9	2020	CONCLUSIONS: Though the effects of high doses over prolonged periods was not assessed, this study provides early, novel safety data of the use of HCQ in the setting of G6PD deficiency secondary to G6PD A-.	Hydroxychloroquine	146-149	glucose-6-phosphate dehydrogenase 2	Mus musculus	168-172
33117441-5	2020	Mechanistically, hydroxychloroquine inhibits SARS-CoV-2 virus uptake into cells by inhibiting angiotensin-converting enzyme 2 glycosylation.	Hydroxychloroquine	17-35	angiotensin converting enzyme 2	Homo sapiens	94-125
32562764-3	2020	Furthermore, it is emphasized that the viral spike protein is prevented from binding gangliosides, which are composed of a glycosphingolipid with one or more sialic acids, in the presence of chloroquine or hydroxychloroquine.	Hydroxychloroquine	206-224	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	45-50
32992777-7	2020	(3) Results: Hydroxychloroquine did not inhibit BCRP or the OATPs tested but inhibited P-gp at concentrations exceeding 10 microM.	Hydroxychloroquine	13-31	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
32813925-8	2020	RESULTS: With respect to HSP70, the highest dock score (-4.768) and glide score (-4.818) was seen with hydroxychloroquine (HCQ), followed by epigallocatechin gallate (green tea), methotrexate and curcumin.	Hydroxychloroquine	103-121	heat shock protein family A (Hsp70) member 4	Homo sapiens	25-30
32813925-8	2020	RESULTS: With respect to HSP70, the highest dock score (-4.768) and glide score (-4.818) was seen with hydroxychloroquine (HCQ), followed by epigallocatechin gallate (green tea), methotrexate and curcumin.	Hydroxychloroquine	123-126	heat shock protein family A (Hsp70) member 4	Homo sapiens	25-30
32813925-9	2020	The highest dock (-9.525) and glide score (-9.584) in TNFalpha was seen in with epigallocatechin gallate, followed by HCQ, dapsone and methotrexate.	Hydroxychloroquine	118-121	tumor necrosis factor	Homo sapiens	54-62
32562561-7	2020	Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon beta in 2 cases each.	Hydroxychloroquine	0-18	interferon beta 1	Homo sapiens	92-107
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Hydroxychloroquine	7-10	interleukin 2	Homo sapiens	89-93
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Hydroxychloroquine	7-10	interleukin 6	Homo sapiens	95-99
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Hydroxychloroquine	7-10	interleukin 17A	Homo sapiens	101-106
32418114-9	2020	The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group.	Hydroxychloroquine	202-205	interleukin 6	Homo sapiens	36-40
33062720-2	2020	CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22.	Hydroxychloroquine	7-10	interleukin 22	Homo sapiens	112-117
33062720-3	2020	Also, CQ and HCQ inhibit the production of interferon- (IFN-) alpha and IFN-gamma and/or tumor necrotizing factor- (TNF-) alpha.	Hydroxychloroquine	13-16	interferon alpha 1	Homo sapiens	43-67
33062720-3	2020	Also, CQ and HCQ inhibit the production of interferon- (IFN-) alpha and IFN-gamma and/or tumor necrotizing factor- (TNF-) alpha.	Hydroxychloroquine	13-16	interferon gamma	Homo sapiens	72-81
33062720-3	2020	Also, CQ and HCQ inhibit the production of interferon- (IFN-) alpha and IFN-gamma and/or tumor necrotizing factor- (TNF-) alpha.	Hydroxychloroquine	13-16	tumor necrosis factor	Homo sapiens	89-127
32992777-8	2020	P-gp overexpressing cells were 5.2-fold more resistant to hydroxychloroquine than control cells stressing its substrate characteristics.	Hydroxychloroquine	58-76	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
32992777-10	2020	(4) Conclusions: This is the first evidence that hydroxychloroquine"s interaction potential with drug transporters is low, albeit bioavailability of simultaneously orally administered P-gp substrates might be increased by hydroxychloroquine.	Hydroxychloroquine	49-67	ATP binding cassette subfamily B member 1	Homo sapiens	184-188
32992777-10	2020	(4) Conclusions: This is the first evidence that hydroxychloroquine"s interaction potential with drug transporters is low, albeit bioavailability of simultaneously orally administered P-gp substrates might be increased by hydroxychloroquine.	Hydroxychloroquine	222-240	ATP binding cassette subfamily B member 1	Homo sapiens	184-188
32956151-0	2022	Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.	Hydroxychloroquine	15-33	glucose-6-phosphate dehydrogenase	Homo sapiens	90-123
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	105-123	palmitoyl-protein thioesterase 1	Mus musculus	32-64
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	105-123	palmitoyl-protein thioesterase 1	Mus musculus	66-70
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	105-123	programmed cell death 1	Mus musculus	171-175
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	125-128	palmitoyl-protein thioesterase 1	Mus musculus	32-64
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	125-128	palmitoyl-protein thioesterase 1	Mus musculus	66-70
32780726-2	2020	Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in melanoma.	Hydroxychloroquine	125-128	programmed cell death 1	Mus musculus	171-175
32780726-8	2020	Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1) pathway activation and the secretion of interferon beta (IFN-beta) in macrophages which was a key component for augmented T cell-mediated cytotoxicity.	Hydroxychloroquine	19-22	palmitoyl-protein thioesterase 1	Mus musculus	0-4
32780726-8	2020	Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1) pathway activation and the secretion of interferon beta (IFN-beta) in macrophages which was a key component for augmented T cell-mediated cytotoxicity.	Hydroxychloroquine	19-22	cyclic GMP-AMP synthase	Mus musculus	42-65
32780726-8	2020	Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1) pathway activation and the secretion of interferon beta (IFN-beta) in macrophages which was a key component for augmented T cell-mediated cytotoxicity.	Hydroxychloroquine	19-22	cyclic GMP-AMP synthase	Mus musculus	67-71
32780726-8	2020	Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1) pathway activation and the secretion of interferon beta (IFN-beta) in macrophages which was a key component for augmented T cell-mediated cytotoxicity.	Hydroxychloroquine	19-22	TANK-binding kinase 1	Mus musculus	114-135
32780726-8	2020	Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1) pathway activation and the secretion of interferon beta (IFN-beta) in macrophages which was a key component for augmented T cell-mediated cytotoxicity.	Hydroxychloroquine	19-22	TANK-binding kinase 1	Mus musculus	137-141
32686260-5	2020	CQ and HCQ act on the renin angiotensin system, with possible implications on the cardiorespiratory system.	Hydroxychloroquine	7-10	renin	Homo sapiens	22-27
32401405-3	2020	Although the mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear, evidence suggests that this drug may exert multifaceted effects on glucose regulation, including improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance, and reduction of systemic inflammation.	Hydroxychloroquine	80-83	insulin	Homo sapiens	259-266
32738306-9	2020	For HCQ, two results (ACE2 and Mpro) were firmly bound to the receptors, however CTSL and RBD showed low interaction energies.	Hydroxychloroquine	4-7	angiotensin converting enzyme 2	Homo sapiens	22-26
32738306-9	2020	For HCQ, two results (ACE2 and Mpro) were firmly bound to the receptors, however CTSL and RBD showed low interaction energies.	Hydroxychloroquine	4-7	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	31-35
32738306-10	2020	The differences in better interactions and affinity between HCQ and CQ with ACE2 and Mpro were probably due to structural differences between the drugs.	Hydroxychloroquine	60-63	angiotensin converting enzyme 2	Homo sapiens	76-80
32738306-10	2020	The differences in better interactions and affinity between HCQ and CQ with ACE2 and Mpro were probably due to structural differences between the drugs.	Hydroxychloroquine	60-63	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	85-89
32740858-5	2020	The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.	Hydroxychloroquine	106-109	pk/pd	None	78-83
32999660-0	2020	Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.	Hydroxychloroquine	141-159	KRAS proto-oncogene, GTPase	Homo sapiens	79-83
32973504-0	2020	The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.	Hydroxychloroquine	67-85	C-C motif chemokine receptor 4	Homo sapiens	4-33
32973504-6	2020	Using the unbiased chemical similarity ensemble approach (SEA), we identified C-C chemokine receptor type 4 (CCR4) as an immunomodulatory target of hydroxychloroquine.	Hydroxychloroquine	148-166	C-C motif chemokine receptor 4	Homo sapiens	78-107
32973504-6	2020	Using the unbiased chemical similarity ensemble approach (SEA), we identified C-C chemokine receptor type 4 (CCR4) as an immunomodulatory target of hydroxychloroquine.	Hydroxychloroquine	148-166	C-C motif chemokine receptor 4	Homo sapiens	109-113
32973504-8	2020	In silico, hydroxychloroquine interacts with Thr-189 within the CCR4 active site, presumably blocking endogenous ligand binding.	Hydroxychloroquine	11-29	C-C motif chemokine receptor 4	Homo sapiens	64-68
32815796-10	2022	Also, dynamical residue cross-correlation map with principal component analysis depicted the stable binding of Nos-Hcq conjugate to Mpro domains with optimal secondary structure statistics of complex dynamics.	Hydroxychloroquine	115-118	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	132-136
32402766-6	2020	The antimalarial drugs chloroquine phosphate (CQ) and hydroxychloroquine (HCQ) impair in vitro the terminal glycosylation of ACE2 without significant change of cell-surface ACE2 and, therefore, might be potent inhibitors of SARS-CoV-2 infections.	Hydroxychloroquine	54-72	angiotensin converting enzyme 2	Homo sapiens	125-129
32402766-6	2020	The antimalarial drugs chloroquine phosphate (CQ) and hydroxychloroquine (HCQ) impair in vitro the terminal glycosylation of ACE2 without significant change of cell-surface ACE2 and, therefore, might be potent inhibitors of SARS-CoV-2 infections.	Hydroxychloroquine	74-77	angiotensin converting enzyme 2	Homo sapiens	125-129
32854751-0	2020	Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial.	Hydroxychloroquine	0-18	sorcin	Homo sapiens	86-89
32854751-3	2020	This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread.	Hydroxychloroquine	65-83	prolyl endopeptidase	Homo sapiens	121-124
32854751-3	2020	This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread.	Hydroxychloroquine	85-88	prolyl endopeptidase	Homo sapiens	121-124
32854751-4	2020	Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients.	Hydroxychloroquine	52-55	prolyl endopeptidase	Homo sapiens	60-63
32854751-7	2020	DISCUSSION: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19.	Hydroxychloroquine	93-96	prolyl endopeptidase	Homo sapiens	100-103
32999660-3	2020	Recent preclinical studies demonstrated that RAS-mutated cells escape from therapeutic MEK inhibition by the development of autophagy, and this escape may be prevented by the administration of an antimalarial drug, hydroxychloroquine.	Hydroxychloroquine	215-233	mitogen-activated protein kinase kinase 7	Homo sapiens	87-90
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	112-118
32490532-0	2020	HyPE study: hydroxychloroquine prophylaxis-related adverse events" analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.	Hydroxychloroquine	12-30	FIC domain protein adenylyltransferase	Homo sapiens	0-4
32864162-7	2020	We also identified other variants, that are associated with adverse effects, most notable in hydroxychloroquine/chloroquine (G6PD; hemolysis), ribavirin (ITPA; hemolysis), and interferon beta -1b (IRF6; liver toxicity).	Hydroxychloroquine	93-111	glucose-6-phosphate dehydrogenase	Homo sapiens	125-129
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	120-126
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier organic anion transporter family member 1A2	Homo sapiens	128-135
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier organic anion transporter family member 1B1	Homo sapiens	141-148
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	ATP binding cassette subfamily B member 1	Homo sapiens	165-170
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	184-191
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier family 28 member 2	Homo sapiens	193-200
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier family 28 member 3	Homo sapiens	206-213
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	solute carrier organic anion transporter family member 1B1	Homo sapiens	241-248
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	ATP binding cassette subfamily C member 2	Homo sapiens	250-255
32864162-6	2020	We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A).	Hydroxychloroquine	80-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	257-262
32817933-13	2020	HCQ blocked both GM1 and PIP 2 domains ability to attract and cluster ACE2.	Hydroxychloroquine	0-3	angiotensin converting enzyme 2	Homo sapiens	70-74
32817933-20	2020	Meaning: Since lipids cluster ACE2 and facilitate viral entry, hydroxychloroquine and anesthetics appear to inhibit viral entry by disrupting the lipid clustering and ACE2 localization.	Hydroxychloroquine	63-81	angiotensin converting enzyme 2	Homo sapiens	167-171
32784543-6	2020	Of specific interest are chloroquine/hydroxychloroquine"s ability to inhibit SARS-CoV infection by impairing ACE2, the SARS-CoV2 entry point, through terminal glycosylation via effects on TGN/post-Golgi pH homeostasis.	Hydroxychloroquine	37-55	angiotensin converting enzyme 2	Homo sapiens	109-113
32824072-4	2020	Furthermore, CQ and HCQ also influenced the proofreading and capping of viral RNA in SARS-CoV-2, performed by nsp10/nsp14 and nsp10/nsp16.	Hydroxychloroquine	20-23	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	110-115
32824072-4	2020	Furthermore, CQ and HCQ also influenced the proofreading and capping of viral RNA in SARS-CoV-2, performed by nsp10/nsp14 and nsp10/nsp16.	Hydroxychloroquine	20-23	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	126-131
32633733-1	2020	Using a combination of enhanced sampling molecular dynamics techniques and non-equilibrium alchemical transformations with full atomistic details, we have shown that hydroxychloroquine (HCQ) may act as a mild inhibitor of important functional proteins for SARS-CoV2 replication, with potency increasing in the series PLpro, 3CLpro, RdRp.	Hydroxychloroquine	166-184	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	317-322
32752944-5	2021	Hydroxychloroquine and ivermectin have been identified to act by creating the acidic condition in cells and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Hydroxychloroquine	0-18	inositol monophosphatase 1	Homo sapiens	133-147
32752951-4	2021	In this study, molecular docking and reactivity were applied for eighteen drugs, which are similar in structure to chloroquine and hydroxychloroquine, the potential inhibitors to angiotensin-converting enzyme (ACE2).	Hydroxychloroquine	131-149	angiotensin I converting enzyme	Homo sapiens	179-208
32752951-4	2021	In this study, molecular docking and reactivity were applied for eighteen drugs, which are similar in structure to chloroquine and hydroxychloroquine, the potential inhibitors to angiotensin-converting enzyme (ACE2).	Hydroxychloroquine	131-149	angiotensin converting enzyme 2	Homo sapiens	210-214
32633733-1	2020	Using a combination of enhanced sampling molecular dynamics techniques and non-equilibrium alchemical transformations with full atomistic details, we have shown that hydroxychloroquine (HCQ) may act as a mild inhibitor of important functional proteins for SARS-CoV2 replication, with potency increasing in the series PLpro, 3CLpro, RdRp.	Hydroxychloroquine	166-184	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	332-336
32633733-1	2020	Using a combination of enhanced sampling molecular dynamics techniques and non-equilibrium alchemical transformations with full atomistic details, we have shown that hydroxychloroquine (HCQ) may act as a mild inhibitor of important functional proteins for SARS-CoV2 replication, with potency increasing in the series PLpro, 3CLpro, RdRp.	Hydroxychloroquine	186-189	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	317-322
32633733-1	2020	Using a combination of enhanced sampling molecular dynamics techniques and non-equilibrium alchemical transformations with full atomistic details, we have shown that hydroxychloroquine (HCQ) may act as a mild inhibitor of important functional proteins for SARS-CoV2 replication, with potency increasing in the series PLpro, 3CLpro, RdRp.	Hydroxychloroquine	186-189	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	332-336
32793908-5	2020	Chloroquine or hydroxychloroquine increase cleaved active SP-domain of TMPRSS2, and this is potentiated by MEKi.	Hydroxychloroquine	15-33	transmembrane serine protease 2	Homo sapiens	71-78
32755965-5	2020	Treatment with corticosteroids, metformin and hydroxychloroquine allowed withdrawal of insulin therapy, with stabilisation of glycaemia and diminished signs of insulin resistance; however, morning fasting hypoglycaemic episodes persisted.	Hydroxychloroquine	46-64	insulin	Homo sapiens	87-94
32755965-5	2020	Treatment with corticosteroids, metformin and hydroxychloroquine allowed withdrawal of insulin therapy, with stabilisation of glycaemia and diminished signs of insulin resistance; however, morning fasting hypoglycaemic episodes persisted.	Hydroxychloroquine	46-64	insulin	Homo sapiens	160-167
32755965-10	2020	Treatment with metformin, hydroxychloroquine and methotrexate ameliorated extreme insulin resistance.	Hydroxychloroquine	26-44	insulin	Homo sapiens	82-89
32884875-0	2020	A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.	Hydroxychloroquine	149-167	glucose-6-phosphate dehydrogenase	Homo sapiens	28-61
32779341-9	2020	HCQ acts by different mechanisms including prevention of cellular entry of SARS-CoV-2 and inhibition of type I IFN signaling.	Hydroxychloroquine	0-3	type i ifn	None	104-114
32578132-6	2020	Here, we present a 65-year-old female with EAE refractory to numerous systemic therapies (corticosteroids, hydroxychloroquine, dapsone, doxycycline, methotrexate) who showed a good response to mepolizumab, a humanized monoclonal antibody that blocks interleukin-5.	Hydroxychloroquine	107-125	interleukin 5	Homo sapiens	250-263
32677545-4	2021	Molecular docking studies showed that hydroxychloroquine and chloroquine do not interact with SARS-CoV-2 proteins, but bind to the amino acids ASP350, ASP382, ALA348, PHE40 and PHE390 on the ACE2 allosteric site rather than the ACE2 active site.	Hydroxychloroquine	38-56	angiotensin converting enzyme 2	Homo sapiens	191-195
32681228-8	2021	At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P = 0.092 at 10 weeks).	Hydroxychloroquine	115-133	WD repeat and HMG-box DNA binding protein 1	Homo sapiens	61-81
32681228-8	2021	At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P = 0.092 at 10 weeks).	Hydroxychloroquine	115-133	WD repeat and HMG-box DNA binding protein 1	Homo sapiens	73-78
32696720-2	2021	In this paper, we demonstrate how hydroxychloroquine can act as a good inhibitor of SARS-CoV-2 Spike protein receptor-binding-domain using molecular docking studies.	Hydroxychloroquine	34-52	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	95-100
32696720-3	2021	We also unveil how hydroxychloroquine can interfere in the prevention of Lys353 in hACE2 from interacting with the corresponding binding hotspot present on the Spike protein.	Hydroxychloroquine	19-37	angiotensin converting enzyme 2	Homo sapiens	83-88
32696720-3	2021	We also unveil how hydroxychloroquine can interfere in the prevention of Lys353 in hACE2 from interacting with the corresponding binding hotspot present on the Spike protein.	Hydroxychloroquine	19-37	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	160-165
32677545-4	2021	Molecular docking studies showed that hydroxychloroquine and chloroquine do not interact with SARS-CoV-2 proteins, but bind to the amino acids ASP350, ASP382, ALA348, PHE40 and PHE390 on the ACE2 allosteric site rather than the ACE2 active site.	Hydroxychloroquine	38-56	angiotensin converting enzyme 2	Homo sapiens	228-232
32677545-5	2021	Our results showed that neither hydroxychloroquine and chloroquine bind to the active site of ACE2.	Hydroxychloroquine	32-50	angiotensin converting enzyme 2	Homo sapiens	94-98
32674481-6	2020	However, at lower concentrations, hydroxychloroquine and chloroquine appear to exert immunomodulatory effects by inhibiting nucleic acid sensors, including toll-like receptor 9 and cyclic GMP-AMP synthase.	Hydroxychloroquine	34-52	toll like receptor 9	Homo sapiens	156-176
32664879-9	2020	We further discussed that polymorphisms in ACE2 or TMPRSS2 could guide effective treatments (i.e., hydroxychloroquine and camostat) for COVID-19.	Hydroxychloroquine	99-117	angiotensin converting enzyme 2	Homo sapiens	43-47
32664879-9	2020	We further discussed that polymorphisms in ACE2 or TMPRSS2 could guide effective treatments (i.e., hydroxychloroquine and camostat) for COVID-19.	Hydroxychloroquine	99-117	transmembrane serine protease 2	Homo sapiens	51-58
32674481-6	2020	However, at lower concentrations, hydroxychloroquine and chloroquine appear to exert immunomodulatory effects by inhibiting nucleic acid sensors, including toll-like receptor 9 and cyclic GMP-AMP synthase.	Hydroxychloroquine	34-52	cyclic GMP-AMP synthase	Homo sapiens	181-204
32447719-4	2020	Following the addition of HCQ, the inhibition of autophagy aggravated TGF-beta1-induced fibrosis of hSCFs.	Hydroxychloroquine	26-29	transforming growth factor beta 1	Homo sapiens	70-79
32469265-0	2021	Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an in silico insight into the comparative efficacy of repurposing antiviral drugs.	Hydroxychloroquine	33-51	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	91-103
32413408-0	2020	Hydroxychloroquine reduces IL-6 and pro-thrombotic status.	Hydroxychloroquine	0-18	interleukin 6	Homo sapiens	27-31
32437924-0	2020	Hydroxychloroquine inhibiting neutrophil extracellular trap formation alleviates hepatic ischemia/reperfusion injury by blocking TLR9 in mice.	Hydroxychloroquine	0-18	toll-like receptor 9	Mus musculus	129-133
32437924-8	2020	HCQ inhibited PAD4 and Rac2 expressions by blocking TLR9.	Hydroxychloroquine	0-3	MMTV LTR integration site 4	Mus musculus	14-18
32437924-8	2020	HCQ inhibited PAD4 and Rac2 expressions by blocking TLR9.	Hydroxychloroquine	0-3	Rac family small GTPase 2	Mus musculus	23-27
32437924-8	2020	HCQ inhibited PAD4 and Rac2 expressions by blocking TLR9.	Hydroxychloroquine	0-3	toll-like receptor 9	Mus musculus	52-56
32437924-10	2020	HCQ blocking TLR9 protects against hepatic I/R injury by inhibiting NETs formation, which may suggest utility of HCQ or other TLR9 agonists for preventing hepatic I/R injury in clinical practices.	Hydroxychloroquine	0-3	toll-like receptor 9	Mus musculus	13-17
32437924-10	2020	HCQ blocking TLR9 protects against hepatic I/R injury by inhibiting NETs formation, which may suggest utility of HCQ or other TLR9 agonists for preventing hepatic I/R injury in clinical practices.	Hydroxychloroquine	0-3	toll-like receptor 9	Mus musculus	126-130
32437924-10	2020	HCQ blocking TLR9 protects against hepatic I/R injury by inhibiting NETs formation, which may suggest utility of HCQ or other TLR9 agonists for preventing hepatic I/R injury in clinical practices.	Hydroxychloroquine	113-116	toll-like receptor 9	Mus musculus	13-17
32369772-6	2020	Furthermore, hydroxychloroquine (HCQ) was effective in Men1 heterozygous-deficient (Men1+/DeltaN3-8) mice, a mouse PanNEN model that is considered to correspond to human low-grade PanNEN.	Hydroxychloroquine	13-31	multiple endocrine neoplasia 1	Mus musculus	55-59
32369772-6	2020	Furthermore, hydroxychloroquine (HCQ) was effective in Men1 heterozygous-deficient (Men1+/DeltaN3-8) mice, a mouse PanNEN model that is considered to correspond to human low-grade PanNEN.	Hydroxychloroquine	13-31	multiple endocrine neoplasia 1	Mus musculus	84-88
32369772-6	2020	Furthermore, hydroxychloroquine (HCQ) was effective in Men1 heterozygous-deficient (Men1+/DeltaN3-8) mice, a mouse PanNEN model that is considered to correspond to human low-grade PanNEN.	Hydroxychloroquine	33-36	multiple endocrine neoplasia 1	Mus musculus	55-59
32369772-6	2020	Furthermore, hydroxychloroquine (HCQ) was effective in Men1 heterozygous-deficient (Men1+/DeltaN3-8) mice, a mouse PanNEN model that is considered to correspond to human low-grade PanNEN.	Hydroxychloroquine	33-36	multiple endocrine neoplasia 1	Mus musculus	84-88
32369772-7	2020	HCQ administration decreased tumour size in Men1+/DeltaN3-8 mice.	Hydroxychloroquine	0-3	multiple endocrine neoplasia 1	Mus musculus	44-48
32369772-8	2020	In the HCQ group, histological analyses revealed that proliferative activity was unchanged, but apoptosis was accelerated, accompanied by CHOP expression.	Hydroxychloroquine	7-10	DNA-damage inducible transcript 3	Mus musculus	138-142
32503662-2	2020	Furthermore, we hypothesize that early treatment with hydroxychloroquine sulphate is associated with more rapid resolve of clinical symptoms as assessed by the National Early Warning Score 2 (NEWS2), decreased admission rate to intensive care units and mortality, and improvement in protein biomarker profiles (C-reactive protein, markers of renal and hepatic injury, and established cardiac biomarkers like cardiac troponin and B-type natriuretic peptide).	Hydroxychloroquine	54-81	C-reactive protein	Homo sapiens	311-329
32600363-3	2020	Evaluation of HCQ as a potential perpetrator in drug-drug interactions at the level of cytochrome P450 (CYP) 3A4 and CYP2D6 (major drug metabolizing enzymes).	Hydroxychloroquine	14-17	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	117-123
32600363-3	2020	Evaluation of HCQ as a potential perpetrator in drug-drug interactions at the level of cytochrome P450 (CYP) 3A4 and CYP2D6 (major drug metabolizing enzymes).	Hydroxychloroquine	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-112
32533263-0	2020	Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.	Hydroxychloroquine	81-99	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	0-18	TNF receptor superfamily member 11B	Rattus norvegicus	53-56
32367591-8	2020	The treatment with HCQ markedly increased the ERK phosphorylation.	Hydroxychloroquine	19-22	mitogen-activated protein kinase 1	Mus musculus	46-49
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	0-18	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	61-64
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	0-18	TNF superfamily member 11	Rattus norvegicus	124-129
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	20-23	TNF receptor superfamily member 11B	Rattus norvegicus	53-56
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	20-23	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	61-64
32367591-6	2020	Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-kappaB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation.	Hydroxychloroquine	20-23	TNF superfamily member 11	Rattus norvegicus	124-129
32305587-4	2020	After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative.	Hydroxychloroquine	69-87	prolyl endopeptidase	Homo sapiens	59-62
32305587-4	2020	After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative.	Hydroxychloroquine	89-92	prolyl endopeptidase	Homo sapiens	59-62
32546977-1	2020	Purpose: To evaluate, in a proof-of-concept study, a decision aid that incorporates hypothetical choices in the form of a discrete-choice experiment (DCE), to help patients with early rheumatoid arthritis (RA) understand their values and nudge them towards a value-centric decision between methotrexate and triple therapy (a combination of methotrexate, sulphasalazine and hydroxychloroquine).	Hydroxychloroquine	373-391	activation induced cytidine deaminase	Homo sapiens	62-65
31865445-18	2020	Both chloroquine and HCQ may induce PAI in SLE patients.	Hydroxychloroquine	21-24	serpin family E member 1	Homo sapiens	36-39
32088265-4	2020	Chloroquine and hydroxychloroquine increased IL-1beta-induced CXCL8 secretion in macrophages which was critically dependent on the lysosomotropic character and inhibition of macroautophagy but independent from the NLRP3 inflammasome.	Hydroxychloroquine	16-34	interleukin 1 alpha	Homo sapiens	45-53
32088265-4	2020	Chloroquine and hydroxychloroquine increased IL-1beta-induced CXCL8 secretion in macrophages which was critically dependent on the lysosomotropic character and inhibition of macroautophagy but independent from the NLRP3 inflammasome.	Hydroxychloroquine	16-34	C-X-C motif chemokine ligand 8	Homo sapiens	62-67
32088265-4	2020	Chloroquine and hydroxychloroquine increased IL-1beta-induced CXCL8 secretion in macrophages which was critically dependent on the lysosomotropic character and inhibition of macroautophagy but independent from the NLRP3 inflammasome.	Hydroxychloroquine	16-34	NLR family pyrin domain containing 3	Homo sapiens	214-219
32141953-6	2020	The pathophysiology of lesions may be similar among the lesional subtypes, and patients with a more TLR9-driven disease mechanism may have more benefit from hydroxychloroquine.	Hydroxychloroquine	157-175	toll like receptor 9	Homo sapiens	100-104
32216836-3	2020	METHODS: In this study, CD146+cells were enriched from the human bone marrow aspirates and trans-differentiated into mature endothelial cells, pericytes, and cardiomyocytes after exposure to autophagy stimulator (50-muM Met)/inhibitor (15-muM HCQ).	Hydroxychloroquine	243-246	melanoma cell adhesion molecule	Homo sapiens	24-29
32322397-5	2020	Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Hydroxychloroquine	0-18	importin	None	106-114
32322397-5	2020	Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import.	Hydroxychloroquine	0-18	inositol monophosphatase 1	Homo sapiens	116-130
33144910-3	2020	Here, we describe the case of a 17-year-old male patient exhibiting both systemic LE and EM lesions together with ANA and anti-Ro/SSA positivity who was successfully treated with systemic corticosteroids and hydroxychloroquine.	Hydroxychloroquine	208-226	tripartite motif containing 21	Homo sapiens	127-133
32399404-7	2020	CONCLUSION: The PKA pathway plays an important role in the protective effects of beta2-adrenergic agonist on the RPE cells against HCQ toxicity.	Hydroxychloroquine	131-134	G protein-coupled receptor 162	Homo sapiens	81-86
32260307-7	2020	However, hydroxychloroquine mitigated TNF-alpha-induced HUVEC production of 8-isoprostane and Nicotinanamide adenine dinucleotide phosphate (NADPH) oxidase expression.	Hydroxychloroquine	9-27	tumor necrosis factor	Homo sapiens	38-47
32260307-8	2020	Hydroxychloroquine also mitigated TNF-alpha and preeclamptic serum-induced HUVEC monolayer permeability and rescued the loss of zona occludens protein zona occludens 1 (ZO-1).	Hydroxychloroquine	0-18	tumor necrosis factor	Homo sapiens	34-43
32260307-8	2020	Hydroxychloroquine also mitigated TNF-alpha and preeclamptic serum-induced HUVEC monolayer permeability and rescued the loss of zona occludens protein zona occludens 1 (ZO-1).	Hydroxychloroquine	0-18	tight junction protein 1	Homo sapiens	169-173
32001266-0	2020	Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation.	Hydroxychloroquine	0-18	forkhead box O3	Homo sapiens	62-68
32001266-0	2020	Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation.	Hydroxychloroquine	0-18	signal transducer and activator of transcription 3	Homo sapiens	99-104
32216836-10	2020	RESULT: Data revealed the modulation of autophagy factors, Beclin-1, P62, and LC3 II/I ratio in differentiating CD146+ cells after exposure to Met and HCQ (p < 0.05).	Hydroxychloroquine	151-154	beclin 1	Homo sapiens	59-67
32216836-10	2020	RESULT: Data revealed the modulation of autophagy factors, Beclin-1, P62, and LC3 II/I ratio in differentiating CD146+ cells after exposure to Met and HCQ (p < 0.05).	Hydroxychloroquine	151-154	nucleoporin 62	Homo sapiens	69-72
32216836-10	2020	RESULT: Data revealed the modulation of autophagy factors, Beclin-1, P62, and LC3 II/I ratio in differentiating CD146+ cells after exposure to Met and HCQ (p < 0.05).	Hydroxychloroquine	151-154	melanoma cell adhesion molecule	Homo sapiens	112-117
32216836-16	2020	The treatment of cells with HCQ increased the levels of TNF-alpha and IL-6 compared to the Met-treated cells.	Hydroxychloroquine	28-31	tumor necrosis factor	Homo sapiens	56-65
32216836-16	2020	The treatment of cells with HCQ increased the levels of TNF-alpha and IL-6 compared to the Met-treated cells.	Hydroxychloroquine	28-31	interleukin 6	Homo sapiens	70-74
31951366-8	2020	The autophagy induced by CA4 can be effectively inhibited by HCQ to achieve synergistic treatment of tumors.	Hydroxychloroquine	61-64	carbonic anhydrase 4	Homo sapiens	25-28
32190699-15	2020	Reduction in lysosomal degradation of the internal insulin-insulin receptor complex and enhancement in insulin sensitivity and adiponectin levels are some of the hypothesized mechanisms for the antidiabetic effect of hydroxychloroquine.	Hydroxychloroquine	217-235	insulin	Homo sapiens	51-58
32190699-15	2020	Reduction in lysosomal degradation of the internal insulin-insulin receptor complex and enhancement in insulin sensitivity and adiponectin levels are some of the hypothesized mechanisms for the antidiabetic effect of hydroxychloroquine.	Hydroxychloroquine	217-235	insulin	Homo sapiens	59-66
32190699-15	2020	Reduction in lysosomal degradation of the internal insulin-insulin receptor complex and enhancement in insulin sensitivity and adiponectin levels are some of the hypothesized mechanisms for the antidiabetic effect of hydroxychloroquine.	Hydroxychloroquine	217-235	insulin	Homo sapiens	59-66
32190699-15	2020	Reduction in lysosomal degradation of the internal insulin-insulin receptor complex and enhancement in insulin sensitivity and adiponectin levels are some of the hypothesized mechanisms for the antidiabetic effect of hydroxychloroquine.	Hydroxychloroquine	217-235	adiponectin, C1Q and collagen domain containing	Homo sapiens	127-138
31951366-10	2020	The in vivo pharmacodynamic result revealed that CA4-FeAlg/HCQ showed the greatest therapeutic effect, with the final V/V0 of 0.40 +- 0.10.	Hydroxychloroquine	59-62	carbonic anhydrase 4	Homo sapiens	49-52
33292107-7	2020	Hydroxychloroquine also inhibited P450 2D6 and the transporter OATP1A2.	Hydroxychloroquine	0-18	solute carrier organic anion transporter family member 1A2	Homo sapiens	63-70
31918061-8	2020	In vitro, HCQ suppresses LL37-induced MCs activation in vitro, including the release of inflammatory factors, chemotaxis, degranulation and calcium influx.	Hydroxychloroquine	10-13	cathelicidin antimicrobial peptide	Homo sapiens	25-29
31918061-9	2020	Moreover, HCQ attenuated LL37-mediated MCs activation partly via inhibiting KCa3.1-mediated calcium signaling.	Hydroxychloroquine	10-13	cathelicidin antimicrobial peptide	Homo sapiens	25-29
31918061-9	2020	Moreover, HCQ attenuated LL37-mediated MCs activation partly via inhibiting KCa3.1-mediated calcium signaling.	Hydroxychloroquine	10-13	potassium calcium-activated channel subfamily N member 4	Homo sapiens	76-82
31843528-6	2020	Hydroxychloroquine (HCQ), antagonist of autophagy, was found to dramatically inhibit COL1A2 mRNA expression and cell proliferation in a dose-dependent manner.	Hydroxychloroquine	0-18	collagen, type I, alpha 2	Mus musculus	85-91
31843528-6	2020	Hydroxychloroquine (HCQ), antagonist of autophagy, was found to dramatically inhibit COL1A2 mRNA expression and cell proliferation in a dose-dependent manner.	Hydroxychloroquine	20-23	collagen, type I, alpha 2	Mus musculus	85-91
32937616-10	2020	Immunohistochemistry showed that the protein of Beclin-1 increased in the castration group compared to the control group, while decreased in the HCQ group compared to the castration group.	Hydroxychloroquine	145-148	beclin 1	Rattus norvegicus	48-56
33052313-6	2020	Moreover, the docking on mucin as well as various receptors including Angiotensin-converting enzyme 2 (ACE-2), heparin sulphate proteoglycan and Phosphatidylinositol binding clathrin assembly protein (PICALM), which are expressed in the lung and intranasal tissues and represent initial sites of attachment of the viral particles to the surface of respiratory cells, has shown good binding of CQ and HCQ to these receptors.	Hydroxychloroquine	400-403	phosphatidylinositol binding clathrin assembly protein	Homo sapiens	145-199
31769590-7	2020	Hydroxychloroquine (CQ), an autophagy inhibitor, enhanced the increase of LC3B-II but not Beclin1 in CSE or rHMGB1-treated MH-S cells, and inhibition of autophagy by CQ and 3-methyladenine (3-MA) abrogated the migration and p65 phosphorylation of CSE-treated cells.	Hydroxychloroquine	0-18	high mobility group box 1	Rattus norvegicus	108-114
31769590-7	2020	Hydroxychloroquine (CQ), an autophagy inhibitor, enhanced the increase of LC3B-II but not Beclin1 in CSE or rHMGB1-treated MH-S cells, and inhibition of autophagy by CQ and 3-methyladenine (3-MA) abrogated the migration and p65 phosphorylation of CSE-treated cells.	Hydroxychloroquine	0-18	RELA proto-oncogene, NF-kB subunit	Homo sapiens	224-227
31520587-11	2020	Treatment of the patient with hydroxychloroquine conferred prolonged beneficial clinical effects, including stabilization of trismus and reduction of corticosteroid dose, C-reactive protein, and size of masses.	Hydroxychloroquine	30-48	C-reactive protein	Homo sapiens	171-189
32923679-0	2020	C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis.	Hydroxychloroquine	72-90	C-C motif chemokine receptor 5	Homo sapiens	0-29
32937616-11	2020	While P62 protein moderately dyed in the control group and weakly dyed in the castration group, it strongly dyed in the HCQ group.	Hydroxychloroquine	120-123	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	6-9
32937616-12	2020	Caspase-3 and Bax protein were weakly dyed in the control group but moderately dyed in the castration group and strongly dyed in the HCQ group.	Hydroxychloroquine	133-136	caspase 3	Rattus norvegicus	0-9
32937616-12	2020	Caspase-3 and Bax protein were weakly dyed in the control group but moderately dyed in the castration group and strongly dyed in the HCQ group.	Hydroxychloroquine	133-136	BCL2 associated X, apoptosis regulator	Rattus norvegicus	14-17
32937616-13	2020	The expressions of apoptosis suppressor Bcl-2 were reduced in the castration group and further reduced in the HCQ group compared to the castration group.	Hydroxychloroquine	110-113	BCL2, apoptosis regulator	Rattus norvegicus	40-45
32937616-14	2020	RT-PCR revealed that the mRNA of LC3 and Atg5 in the castration group increased compared to the control group, while decreased after treated with HCQ.	Hydroxychloroquine	146-149	autophagy related 5	Rattus norvegicus	41-45
32314717-18	2020	HCQ alleviated the destruction in small intestinal epithelium and inhibited the expression levels of TLR9, NF-kappaB and IL-1beta in the serum.	Hydroxychloroquine	0-3	toll like receptor 9	Homo sapiens	101-105
32314717-18	2020	HCQ alleviated the destruction in small intestinal epithelium and inhibited the expression levels of TLR9, NF-kappaB and IL-1beta in the serum.	Hydroxychloroquine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	107-116
32314717-18	2020	HCQ alleviated the destruction in small intestinal epithelium and inhibited the expression levels of TLR9, NF-kappaB and IL-1beta in the serum.	Hydroxychloroquine	0-3	interleukin 1 alpha	Homo sapiens	121-129
32314717-21	2020	Conclusion HCQ alleviates 5-FU-induced enteritis in mice and inhibit TLR9 and NF-kappaB-dependent DNA sensing pathways and the secretion of IL-1beta in dendritic cells.	Hydroxychloroquine	11-14	toll-like receptor 9	Mus musculus	69-73
32314717-21	2020	Conclusion HCQ alleviates 5-FU-induced enteritis in mice and inhibit TLR9 and NF-kappaB-dependent DNA sensing pathways and the secretion of IL-1beta in dendritic cells.	Hydroxychloroquine	11-14	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87
32314717-21	2020	Conclusion HCQ alleviates 5-FU-induced enteritis in mice and inhibit TLR9 and NF-kappaB-dependent DNA sensing pathways and the secretion of IL-1beta in dendritic cells.	Hydroxychloroquine	11-14	interleukin 1 alpha	Mus musculus	140-148
31299246-3	2019	Based on the hypothesis that simultaneous inhibition of mTORC1 and autophagy would limit the availability of critical nutrients and inhibit LAM cells, we conducted a phase 1 clinical trial of sirolimus and hydroxychloroquine for LAM.	Hydroxychloroquine	206-224	CREB regulated transcription coactivator 1	Mus musculus	56-62
31477360-2	2019	CASE REPORT: A 20-year-old woman (60 kg) presented 1 h after ingesting 36 g of hydroxychloroquine.	Hydroxychloroquine	79-97	immunoglobulin kappa variable 1-27	Homo sapiens	13-17
31586865-3	2019	Here we designed a novel biocompatible cartilage-targeting and MMP-13/pH-responsive ferritin nanocages (CMFn) loaded with an anti-inflammatory drug (Hydroxychloroquine, HCQ), termed CMFn@HCQ, for OA imaging and therapy.	Hydroxychloroquine	149-167	matrix metallopeptidase 13	Homo sapiens	39-69
31586865-3	2019	Here we designed a novel biocompatible cartilage-targeting and MMP-13/pH-responsive ferritin nanocages (CMFn) loaded with an anti-inflammatory drug (Hydroxychloroquine, HCQ), termed CMFn@HCQ, for OA imaging and therapy.	Hydroxychloroquine	169-172	matrix metallopeptidase 13	Homo sapiens	39-69
31586865-3	2019	Here we designed a novel biocompatible cartilage-targeting and MMP-13/pH-responsive ferritin nanocages (CMFn) loaded with an anti-inflammatory drug (Hydroxychloroquine, HCQ), termed CMFn@HCQ, for OA imaging and therapy.	Hydroxychloroquine	187-190	matrix metallopeptidase 13	Homo sapiens	39-69
31780678-5	2019	Remarkably, silencing AK2 exerted the greater tumor suppression roles when combined with hydroxychloroquine, an effective autophagy inhibitor, in vitro and in xenografts mouse models.	Hydroxychloroquine	89-107	adenylate kinase 2	Mus musculus	22-25
31801334-22	2019	However, hydroxychloroquine (HCQ), a broad anti-inflammatory agent has been shown to reduce HbA1c by 0.87%.	Hydroxychloroquine	9-27	hemoglobin subunit alpha 1	Homo sapiens	92-96
31801334-22	2019	However, hydroxychloroquine (HCQ), a broad anti-inflammatory agent has been shown to reduce HbA1c by 0.87%.	Hydroxychloroquine	29-32	hemoglobin subunit alpha 1	Homo sapiens	92-96
31550663-5	2019	By structural studies, we demonstrate that HCQ inhibits the allosteric binding of PRC2 to EED within the H3K27me3-binding pocket, thus antagonizing the PRC2 catalytic activity.	Hydroxychloroquine	43-46	embryonic ectoderm development	Homo sapiens	90-93
31775905-0	2019	Hydroxychloroquine inhibits IL-1beta production from amyloid-stimulated human neutrophils.	Hydroxychloroquine	0-18	interleukin 1 beta	Homo sapiens	28-36
31775905-2	2019	We tested the hypothesis that HCQ affects the NLRP3 inflammasome, which is involved in autoinflammation.	Hydroxychloroquine	30-33	NLR family pyrin domain containing 3	Homo sapiens	46-51
31775905-7	2019	HCQ pretreatment significantly inhibited the SAA-induced IL-1beta production in human neutrophils, but did not affect the SAA-induced NF-kappaB activation, pro-IL-1beta mRNA expression, and NLRP3 protein expression.	Hydroxychloroquine	0-3	serum amyloid A1 cluster	Homo sapiens	45-48
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Hydroxychloroquine	225-243	coagulation factor II thrombin receptor	Homo sapiens	143-145
31775905-7	2019	HCQ pretreatment significantly inhibited the SAA-induced IL-1beta production in human neutrophils, but did not affect the SAA-induced NF-kappaB activation, pro-IL-1beta mRNA expression, and NLRP3 protein expression.	Hydroxychloroquine	0-3	interleukin 1 beta	Homo sapiens	57-65
31775905-7	2019	HCQ pretreatment significantly inhibited the SAA-induced IL-1beta production in human neutrophils, but did not affect the SAA-induced NF-kappaB activation, pro-IL-1beta mRNA expression, and NLRP3 protein expression.	Hydroxychloroquine	0-3	NLR family pyrin domain containing 3	Homo sapiens	190-195
31775905-8	2019	Furthermore, SAA stimulation induced cleaved caspase-1 (p20) secretion from human neutrophils, and this release was suppressed by HCQ pretreatment.	Hydroxychloroquine	130-133	serum amyloid A1 cluster	Homo sapiens	13-16
31775905-8	2019	Furthermore, SAA stimulation induced cleaved caspase-1 (p20) secretion from human neutrophils, and this release was suppressed by HCQ pretreatment.	Hydroxychloroquine	130-133	caspase 1	Homo sapiens	45-54
31775905-8	2019	Furthermore, SAA stimulation induced cleaved caspase-1 (p20) secretion from human neutrophils, and this release was suppressed by HCQ pretreatment.	Hydroxychloroquine	130-133	tubulin polymerization promoting protein family member 3	Homo sapiens	56-59
31775905-9	2019	CONCLUSIONS: Treatment with HCQ was associated with impaired production of IL-1beta in SAA-stimulated human neutrophils without affecting the priming process of the NLRP3 inflammasome such as pro-IL-1beta or NLRP3 induction.	Hydroxychloroquine	28-31	interleukin 1 beta	Homo sapiens	75-83
31775905-9	2019	CONCLUSIONS: Treatment with HCQ was associated with impaired production of IL-1beta in SAA-stimulated human neutrophils without affecting the priming process of the NLRP3 inflammasome such as pro-IL-1beta or NLRP3 induction.	Hydroxychloroquine	28-31	serum amyloid A1 cluster	Homo sapiens	87-90
31775905-9	2019	CONCLUSIONS: Treatment with HCQ was associated with impaired production of IL-1beta in SAA-stimulated human neutrophils without affecting the priming process of the NLRP3 inflammasome such as pro-IL-1beta or NLRP3 induction.	Hydroxychloroquine	28-31	interleukin 1 beta	Homo sapiens	196-204
31775905-9	2019	CONCLUSIONS: Treatment with HCQ was associated with impaired production of IL-1beta in SAA-stimulated human neutrophils without affecting the priming process of the NLRP3 inflammasome such as pro-IL-1beta or NLRP3 induction.	Hydroxychloroquine	28-31	NLR family pyrin domain containing 3	Homo sapiens	208-213
31775905-10	2019	These findings suggest that HCQ affects the NLRP3 activation process, resulting in the impaired IL-1beta production in human neutrophils, as representative innate immune cells.	Hydroxychloroquine	28-31	NLR family pyrin domain containing 3	Homo sapiens	44-49
31775905-10	2019	These findings suggest that HCQ affects the NLRP3 activation process, resulting in the impaired IL-1beta production in human neutrophils, as representative innate immune cells.	Hydroxychloroquine	28-31	interleukin 1 beta	Homo sapiens	96-104
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Hydroxychloroquine	245-248	coagulation factor II thrombin receptor	Homo sapiens	143-145
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Hydroxychloroquine	304-307	coagulation factor II thrombin receptor	Homo sapiens	143-145
31499197-8	2019	In this study, we designed integrin alphavbeta3 targeting, acid environmental sensitive liposomal platforms to co-loaded paclitaxel and the autophagy inhibitor hydroxychloroquine.	Hydroxychloroquine	160-178	integrin subunit alpha V	Homo sapiens	27-47
31517637-13	2019	Moreover, inhibition of autophagy with molecules such as hydroxychloroquine (20 muMu) and 3-methyladenine (5 mM) was identified by the accumulation of p62 and LC3B.	Hydroxychloroquine	57-75	nucleoporin 62	Homo sapiens	151-154
31465776-0	2019	Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-kappaB signaling and NLRP3 inflammasome activation by exosomes in rats.	Hydroxychloroquine	42-60	nuclear factor kappa B subunit 1	Homo sapiens	116-125
31465776-0	2019	Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-kappaB signaling and NLRP3 inflammasome activation by exosomes in rats.	Hydroxychloroquine	42-60	NLR family, pyrin domain containing 3	Rattus norvegicus	140-145
31517637-13	2019	Moreover, inhibition of autophagy with molecules such as hydroxychloroquine (20 muMu) and 3-methyladenine (5 mM) was identified by the accumulation of p62 and LC3B.	Hydroxychloroquine	57-75	microtubule associated protein 1 light chain 3 beta	Homo sapiens	159-163
31485616-6	2019	In addition, more typical morphological changes associated with apoptosis emerged, and the ratio of Bax/Bcl-2 and activity of caspase-3 were markedly increased in K562/ADM cells treated with HCQ.	Hydroxychloroquine	191-194	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
31545270-6	2019	However, BEV (100 mug/ml) did not influence the autophagy of the LN18 and LN229 cells, and HCQ at less than 5 mug/ml significantly accumulated LC3B-II and p62 proteins and blocked the autophagy process.	Hydroxychloroquine	91-94	nucleoporin 62	Homo sapiens	155-158
31485616-6	2019	In addition, more typical morphological changes associated with apoptosis emerged, and the ratio of Bax/Bcl-2 and activity of caspase-3 were markedly increased in K562/ADM cells treated with HCQ.	Hydroxychloroquine	191-194	BCL2 apoptosis regulator	Homo sapiens	104-109
31485616-6	2019	In addition, more typical morphological changes associated with apoptosis emerged, and the ratio of Bax/Bcl-2 and activity of caspase-3 were markedly increased in K562/ADM cells treated with HCQ.	Hydroxychloroquine	191-194	caspase 3	Homo sapiens	126-135
31485616-8	2019	Furthermore, HCQ significantly reduced the increase in P-gp expression by inhibiting autophagic activity.	Hydroxychloroquine	13-16	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
31488317-8	2019	Furthermore, HCQ inhibited cell autophagy in breast cancer cells by regulating levels of p62, LC3-I and LC3-II.	Hydroxychloroquine	13-16	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	94-97
31488317-8	2019	Furthermore, HCQ inhibited cell autophagy in breast cancer cells by regulating levels of p62, LC3-I and LC3-II.	Hydroxychloroquine	13-16	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	104-107
31488317-10	2019	HCQ treatment markedly inhibited the activation of Ras/Raf/ERK signaling in SUM190 cells.	Hydroxychloroquine	0-3	mitogen-activated protein kinase 1	Homo sapiens	59-62
31488317-11	2019	CONCLUSION: To conclude, basal-like breast cancer represented by SUM-190 cells may be most sensitive to HCQ induced autophagy inhibition and the mechanism might be relative to Ras/Raf/ERK signaling pathway.	Hydroxychloroquine	104-107	mitogen-activated protein kinase 1	Homo sapiens	184-187
31382914-0	2019	Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.	Hydroxychloroquine	29-47	IGAN1	Homo sapiens	95-110
32821717-8	2019	In addition, CQ and HCQ inhibit Smad3 phosphorylation and VSMC proliferation induced by transforming growth factor-beta1.	Hydroxychloroquine	20-23	SMAD family member 3	Mus musculus	32-37
32821717-8	2019	In addition, CQ and HCQ inhibit Smad3 phosphorylation and VSMC proliferation induced by transforming growth factor-beta1.	Hydroxychloroquine	20-23	transforming growth factor, beta 1	Mus musculus	88-120
31382914-1	2019	BACKGROUND: Hydroxychloroquine (HCQ), a well-known immunomodulator, has recently been found to be a promising and safe anti-proteinuric agent for treating IgA nephropathy (IgAN).	Hydroxychloroquine	12-30	IGAN1	Homo sapiens	155-170
31382914-1	2019	BACKGROUND: Hydroxychloroquine (HCQ), a well-known immunomodulator, has recently been found to be a promising and safe anti-proteinuric agent for treating IgA nephropathy (IgAN).	Hydroxychloroquine	12-30	IGAN1	Homo sapiens	172-176
31382914-1	2019	BACKGROUND: Hydroxychloroquine (HCQ), a well-known immunomodulator, has recently been found to be a promising and safe anti-proteinuric agent for treating IgA nephropathy (IgAN).	Hydroxychloroquine	32-35	IGAN1	Homo sapiens	155-170
31382914-1	2019	BACKGROUND: Hydroxychloroquine (HCQ), a well-known immunomodulator, has recently been found to be a promising and safe anti-proteinuric agent for treating IgA nephropathy (IgAN).	Hydroxychloroquine	32-35	IGAN1	Homo sapiens	172-176
31382914-2	2019	We aimed to compare the efficacy and safety of HCQ and corticosteroid treatment in patients with IgAN.	Hydroxychloroquine	47-50	IGAN1	Homo sapiens	97-101
31382914-4	2019	Ninety-two patients with IgAN who received HCQ in addition to routine renin-angiotensin-aldosterone system inhibitors (RAASi) therapy were included.	Hydroxychloroquine	43-46	IGAN1	Homo sapiens	25-29
31382914-12	2019	CONCLUSIONS: The antiproteinuric effect of HCQ might be slightly inferior to that of corticosteroids over 6 months in patients with IgAN who were deemed to be candidates for HCQ and not corticosteroids treatment.	Hydroxychloroquine	43-46	IGAN1	Homo sapiens	132-136
30980399-13	2019	Furthermore, the combination of hydroxychloroquine and sorafenib enhances the antiproliferative and proapoptotic effects in S45F-mutated DT cells, suggesting that profiling beta-catenin status could guide clinical management of desmoid patients who are considering sorafenib treatment.	Hydroxychloroquine	32-50	catenin beta 1	Homo sapiens	173-185
31427967-0	2019	Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism.	Hydroxychloroquine	0-18	insulin	Homo sapiens	47-54
31427967-4	2019	Hydroxychloroquine has been suggested to have beneficial effects on lipids and insulin sensitivity, which may contribute in lowering high cardiovascular risk in SLE patients.	Hydroxychloroquine	0-18	insulin	Homo sapiens	79-86
31427967-9	2019	The present results revealed that hydroxychloroquine reduced weight, hepatic steatosis, glucose, and insulin resistance.	Hydroxychloroquine	34-52	insulin	Homo sapiens	101-108
31427967-10	2019	Furthermore, hydroxychloroquine downregulated the expression of peroxisome proliferator-activated receptor gamma in the liver.	Hydroxychloroquine	13-31	peroxisome proliferator activated receptor gamma	Mus musculus	64-112
31427967-12	2019	Hydroxychloroquine shows potential in ameliorating obesity-induced pathology, which acts though PPARgamma to facilitate the healthy function of hepatic tissues.	Hydroxychloroquine	0-18	peroxisome proliferator activated receptor gamma	Mus musculus	96-105
31427967-13	2019	This evidence shows that hydroxychloroquine plays a role in improving obesity-induced lipotoxicity and insulin resistance though the peroxisome proliferator-activated receptor gamma pathway.	Hydroxychloroquine	25-43	peroxisome proliferator activated receptor gamma	Mus musculus	133-181
31068068-0	2019	Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.	Hydroxychloroquine	0-18	S100 calcium binding protein A1	Homo sapiens	52-56
30922594-12	2019	CONCLUSIONS: HCQ in addition to optimized RAAS inhibition significantly reduced proteinuria in patients with IgAN over 6 months without evidence of adverse events.	Hydroxychloroquine	13-16	IGAN1	Homo sapiens	109-113
31192747-8	2019	LEF dose-dependently inhibited all measured parameters, where HCQ potently and dose-dependently decreased B cell proliferation, CXCL13, IFN-alpha, IgG and IgM production.	Hydroxychloroquine	62-65	C-X-C motif chemokine ligand 13	Homo sapiens	128-134
31192747-8	2019	LEF dose-dependently inhibited all measured parameters, where HCQ potently and dose-dependently decreased B cell proliferation, CXCL13, IFN-alpha, IgG and IgM production.	Hydroxychloroquine	62-65	interferon alpha 1	Homo sapiens	136-145
30862487-6	2019	Furthermore, IFNalpha and autophagy inhibitors (hydroxychloroquine and wortmannin) show clear synergistic effects on inhibiting growth and promoting apoptosis in HNSCC cells and xenograft models.	Hydroxychloroquine	48-66	interferon alpha 1	Homo sapiens	13-21
31268153-7	2019	Importantly, HCQ was determined to affect multiple pathways, including "negative regulation of endothelial cell proliferation", "blood vessel remodeling", "cell surface receptor signaling pathways" and "notch receptor processing" associated with "signal transduction", "cancers" and "immune system", through regulating C-X-C motif chemokine ligand 8, TNF, IL6, intercellular adhesion molecule 1 and FOS genes.	Hydroxychloroquine	13-16	tumor necrosis factor	Homo sapiens	351-354
31268153-7	2019	Importantly, HCQ was determined to affect multiple pathways, including "negative regulation of endothelial cell proliferation", "blood vessel remodeling", "cell surface receptor signaling pathways" and "notch receptor processing" associated with "signal transduction", "cancers" and "immune system", through regulating C-X-C motif chemokine ligand 8, TNF, IL6, intercellular adhesion molecule 1 and FOS genes.	Hydroxychloroquine	13-16	interleukin 6	Homo sapiens	356-359
31268153-7	2019	Importantly, HCQ was determined to affect multiple pathways, including "negative regulation of endothelial cell proliferation", "blood vessel remodeling", "cell surface receptor signaling pathways" and "notch receptor processing" associated with "signal transduction", "cancers" and "immune system", through regulating C-X-C motif chemokine ligand 8, TNF, IL6, intercellular adhesion molecule 1 and FOS genes.	Hydroxychloroquine	13-16	intercellular adhesion molecule 1	Homo sapiens	361-394
31268153-7	2019	Importantly, HCQ was determined to affect multiple pathways, including "negative regulation of endothelial cell proliferation", "blood vessel remodeling", "cell surface receptor signaling pathways" and "notch receptor processing" associated with "signal transduction", "cancers" and "immune system", through regulating C-X-C motif chemokine ligand 8, TNF, IL6, intercellular adhesion molecule 1 and FOS genes.	Hydroxychloroquine	13-16	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	399-402
30879061-0	2019	Hydroxychloroquine significantly reduces serum markers of endothelial injury and NEMO videocapillaroscopy score in systemic sclerosis.	Hydroxychloroquine	0-18	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	81-85
30797853-0	2019	Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition.	Hydroxychloroquine	0-18	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	47-52
30797853-4	2019	The neuroprotective potential of hydroxychloroquine and chloroquine remained controversial until recently a study showed that chloroquine exhibited an antiparkinsonian activity through Nurr1 modulation.	Hydroxychloroquine	33-51	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	185-190
30797853-6	2019	In rat rotenone model, hydroxychloroquine effectively boosted Nurr-1 expression, exhibited an anti-inflammatory effect as verified by hindering certain pro-inflammatory cytokines and successfully reduced GSK-3beta activity.	Hydroxychloroquine	23-41	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	62-68
30797853-6	2019	In rat rotenone model, hydroxychloroquine effectively boosted Nurr-1 expression, exhibited an anti-inflammatory effect as verified by hindering certain pro-inflammatory cytokines and successfully reduced GSK-3beta activity.	Hydroxychloroquine	23-41	glycogen synthase kinase 3 alpha	Rattus norvegicus	204-213
30797853-8	2019	However, this improvement was opposed by hydroxychloroquine induced autophagic inhibition as manifested by enhancing both LC3-II and P62 levels possibly through the prominent decline in sirtuin 1 level and elevated apoptotic biomarkers.	Hydroxychloroquine	41-59	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	133-136
30797853-8	2019	However, this improvement was opposed by hydroxychloroquine induced autophagic inhibition as manifested by enhancing both LC3-II and P62 levels possibly through the prominent decline in sirtuin 1 level and elevated apoptotic biomarkers.	Hydroxychloroquine	41-59	sirtuin 1	Rattus norvegicus	186-195
30797853-9	2019	In conclusion, hydroxychloroquine successfully ameliorated PD motor dysfunction in spite of the fact that both autophagy and apoptosis were deregulated through Nurr1 modulation.	Hydroxychloroquine	15-33	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	160-165
31556748-7	2019	Results: In vitro studies demonstrated that HCQ attenuated activation of the NLRP3 inflammasome and blocked LMP.	Hydroxychloroquine	44-47	NLR family, pyrin domain containing 3	Mus musculus	77-82
31556748-9	2019	Ex vivo culture of alveolar macrophages collected from cSiO2-treated mice showed significantly less NLRP3 inflammasome activation after in vivo exposure to HCQ.	Hydroxychloroquine	156-159	NLR family, pyrin domain containing 3	Mus musculus	100-105
31068068-1	2019	OBJECTIVES: We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.	Hydroxychloroquine	42-60	S100 calcium binding protein A8	Homo sapiens	70-76
31068068-1	2019	OBJECTIVES: We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.	Hydroxychloroquine	42-60	S100 calcium binding protein A9	Homo sapiens	81-87
31068068-1	2019	OBJECTIVES: We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.	Hydroxychloroquine	62-65	S100 calcium binding protein A8	Homo sapiens	70-76
31068068-1	2019	OBJECTIVES: We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.	Hydroxychloroquine	62-65	S100 calcium binding protein A9	Homo sapiens	81-87
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A8	Homo sapiens	9-15
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A9	Homo sapiens	20-26
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A8	Homo sapiens	233-239
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A9	Homo sapiens	252-258
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A8	Homo sapiens	233-239
31068068-4	2019	RESULTS: S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023).	Hydroxychloroquine	134-137	S100 calcium binding protein A9	Homo sapiens	252-258
31068068-7	2019	CONCLUSION: HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement.	Hydroxychloroquine	12-15	S100 calcium binding protein A1	Homo sapiens	67-71
31631597-1	2019	Objective: To determine the effects of autophagy inhibitor hydroxychloroquine (HCQ) on chemosensitivity of castration-resistant prostate cancer 22RV1 cell line in vitro and in vivo, and changes in its mRNA expressions of autophagy gene Bcelin-1, autophagy specific substrate P62 gene, pro-apoptotic gene Bax.	Hydroxychloroquine	59-77	nucleoporin 62	Homo sapiens	275-278
30767212-8	2019	Furthermore, in SLE patients increased circulating levels of OPN were associated with the use of hydroxychloroquine and the positivity for the anti-dsDNA autoantibodies.	Hydroxychloroquine	97-115	secreted phosphoprotein 1	Homo sapiens	61-64
31208693-4	2019	Importantly, they demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a rational basis for future clinical evaluation of this combination therapy.	Hydroxychloroquine	79-97	mitogen-activated protein kinase kinase 7	Homo sapiens	129-132
31208693-4	2019	Importantly, they demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a rational basis for future clinical evaluation of this combination therapy.	Hydroxychloroquine	79-97	mitogen-activated protein kinase 1	Homo sapiens	133-136
31208693-4	2019	Importantly, they demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a rational basis for future clinical evaluation of this combination therapy.	Hydroxychloroquine	99-102	mitogen-activated protein kinase kinase 7	Homo sapiens	129-132
31208693-4	2019	Importantly, they demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a rational basis for future clinical evaluation of this combination therapy.	Hydroxychloroquine	99-102	mitogen-activated protein kinase 1	Homo sapiens	133-136
30760865-7	2019	Furthermore, either LPS or hydroxychloroquine (HCQ), an autophagy inhibitor, could promote mouse lung fibroblast proliferation, which could be reversed by RAPA application.	Hydroxychloroquine	27-45	transcriptional regulating factor 1	Mus musculus	155-159
30760865-7	2019	Furthermore, either LPS or hydroxychloroquine (HCQ), an autophagy inhibitor, could promote mouse lung fibroblast proliferation, which could be reversed by RAPA application.	Hydroxychloroquine	47-50	transcriptional regulating factor 1	Mus musculus	155-159
31631597-1	2019	Objective: To determine the effects of autophagy inhibitor hydroxychloroquine (HCQ) on chemosensitivity of castration-resistant prostate cancer 22RV1 cell line in vitro and in vivo, and changes in its mRNA expressions of autophagy gene Bcelin-1, autophagy specific substrate P62 gene, pro-apoptotic gene Bax.	Hydroxychloroquine	59-77	BCL2 associated X, apoptosis regulator	Homo sapiens	304-307
31631597-13	2019	In vitro and in vivo, HCQ+DOC upregulated the mRNA and protein expressions of Beclin-1, P62 and Bax ( P<0.05).	Hydroxychloroquine	22-26	beclin 1	Homo sapiens	78-86
31631597-13	2019	In vitro and in vivo, HCQ+DOC upregulated the mRNA and protein expressions of Beclin-1, P62 and Bax ( P<0.05).	Hydroxychloroquine	22-26	nucleoporin 62	Mus musculus	88-91
31631597-13	2019	In vitro and in vivo, HCQ+DOC upregulated the mRNA and protein expressions of Beclin-1, P62 and Bax ( P<0.05).	Hydroxychloroquine	22-26	BCL2-associated X protein	Mus musculus	96-99
31392302-7	2019	Addition of HCQ to HFD decreased the serum levels of LDL-C, TCHO, and TG, increased serum levels of HDL-C, and decreased the atherosclerotic lesions in the aortic root.	Hydroxychloroquine	12-15	component of oligomeric golgi complex 2	Mus musculus	53-58
30341573-8	2019	Interestingly, pretreating cells with chloroquine, and also hydroxychloroquine, but not dexamethasone, attenuated poly IC-induced PAI-1 expression in GECs.	Hydroxychloroquine	60-78	serpin family E member 1	Homo sapiens	130-135
30381299-8	2019	Inhibition of autophagy by hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in both ETV6-RUNX1-positive cell lines and primary acute lymphoblastic leukemia samples, and selectively sensitized primary ETV6-RUNX1-positive leukemia samples to L asparaginase.	Hydroxychloroquine	27-45	ETS variant transcription factor 6	Homo sapiens	116-120
30381299-8	2019	Inhibition of autophagy by hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in both ETV6-RUNX1-positive cell lines and primary acute lymphoblastic leukemia samples, and selectively sensitized primary ETV6-RUNX1-positive leukemia samples to L asparaginase.	Hydroxychloroquine	27-45	RUNX family transcription factor 1	Homo sapiens	121-126
30381299-8	2019	Inhibition of autophagy by hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in both ETV6-RUNX1-positive cell lines and primary acute lymphoblastic leukemia samples, and selectively sensitized primary ETV6-RUNX1-positive leukemia samples to L asparaginase.	Hydroxychloroquine	27-45	ETS variant transcription factor 6	Homo sapiens	232-236
30381299-8	2019	Inhibition of autophagy by hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in both ETV6-RUNX1-positive cell lines and primary acute lymphoblastic leukemia samples, and selectively sensitized primary ETV6-RUNX1-positive leukemia samples to L asparaginase.	Hydroxychloroquine	27-45	RUNX family transcription factor 1	Homo sapiens	237-242
30381299-8	2019	Inhibition of autophagy by hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in both ETV6-RUNX1-positive cell lines and primary acute lymphoblastic leukemia samples, and selectively sensitized primary ETV6-RUNX1-positive leukemia samples to L asparaginase.	Hydroxychloroquine	27-45	asparaginase and isoaspartyl peptidase 1	Homo sapiens	272-286
30582995-0	2019	Evaluating results of an interferon-gamma release assay in patients with autoimmune disease who are taking hydroxychloroquine.	Hydroxychloroquine	107-125	interferon gamma	Homo sapiens	25-41
30846987-9	2019	Conclusion: Our findings reveal that clinically-relevant HCQ concentrations partially inhibit the pDC response to TLR9 and weakly affect the response to TLR7/8 stimulation.	Hydroxychloroquine	57-60	toll like receptor 9	Homo sapiens	114-118
29324592-0	2019	FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.	Hydroxychloroquine	84-102	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
29324592-0	2019	FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.	Hydroxychloroquine	84-102	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	49-53
30846987-9	2019	Conclusion: Our findings reveal that clinically-relevant HCQ concentrations partially inhibit the pDC response to TLR9 and weakly affect the response to TLR7/8 stimulation.	Hydroxychloroquine	57-60	toll like receptor 7	Homo sapiens	153-157
31713476-9	2019	RESULTS: After 48 weeks of add-on treatment with HCQ, almost all SGLT-2 inhibitors were withdrawn; metformin dose was reduced to 1000 mg, glimepiride reduced to 1 mg and sitagliptin reduced to 50 mg OD.	Hydroxychloroquine	49-52	solute carrier family 5 member 2	Homo sapiens	65-71
30227141-0	2019	Increased Myeloid Dendritic Cells and TNF-alpha Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.	Hydroxychloroquine	85-103	tumor necrosis factor	Homo sapiens	38-47
30227141-6	2019	QC was more effective than HCQ at inhibiting the toll receptor-mediated production of TNF-alpha and IL-6 in the peripheral blood mononuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and HCQ inhibited IFN-alpha equally.	Hydroxychloroquine	27-30	tumor necrosis factor	Homo sapiens	86-95
30227141-6	2019	QC was more effective than HCQ at inhibiting the toll receptor-mediated production of TNF-alpha and IL-6 in the peripheral blood mononuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and HCQ inhibited IFN-alpha equally.	Hydroxychloroquine	27-30	interleukin 6	Homo sapiens	100-104
31521049-4	2019	PATIENTS AND METHODS: We treated patients with untreated metastatic NSCLC with carboplatin, paclitaxel (and bevacizumab if criteria met) and hydroxychloroquine 200 mg BID.	Hydroxychloroquine	141-159	BH3 interacting domain death agonist	Homo sapiens	167-170
31241661-9	2019	Low MX1 levels were shown to be associated with both a low disease activity score based on the European League Against Rheumatism (EULAR) Sjogren"s Syndrome Disease Activity Index (ESSDAI) and hydroxychloroquine use in all patients.	Hydroxychloroquine	193-211	MX dynamin like GTPase 1	Homo sapiens	4-7
30563869-12	2019	Autophagy-mediated release of TF-bearing and IL-17A-bearing NETs provides a link between thromboinflammation and fibrosis in SLE and may account for the salutary effects of hydroxychloroquine.	Hydroxychloroquine	173-191	interleukin 17A	Homo sapiens	45-51
30442709-4	2019	HCQ and Lys05 also bound to and inhibited PPT1 activity, but only DC661 maintained activity in acidic media.	Hydroxychloroquine	0-3	palmitoyl-protein thioesterase 1	Homo sapiens	42-46
30571257-0	2018	Dysregulated IL-1beta-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine.	Hydroxychloroquine	78-96	interleukin 1 beta	Homo sapiens	13-21
30571257-0	2018	Dysregulated IL-1beta-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine.	Hydroxychloroquine	78-96	colony stimulating factor 2	Homo sapiens	22-28
30571257-9	2018	We provide evidence that interleukin-1beta amplifies the expansion of GM-CSF-expressing CD4 T cells, which is effectively suppressed by hydroxychloroquine.	Hydroxychloroquine	136-154	interleukin 1 beta	Homo sapiens	25-42
30571257-9	2018	We provide evidence that interleukin-1beta amplifies the expansion of GM-CSF-expressing CD4 T cells, which is effectively suppressed by hydroxychloroquine.	Hydroxychloroquine	136-154	colony stimulating factor 2	Homo sapiens	70-76
30571257-11	2018	CONCLUSIONS: Given the safety profile of hydroxychloroquine and its clinical pedigree in treating autoimmune diseases such as rheumatoid arthritis, where GM-CSF plays a pivotal role, we propose that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart disease after ARF.	Hydroxychloroquine	41-59	colony stimulating factor 2	Homo sapiens	154-160
30571257-11	2018	CONCLUSIONS: Given the safety profile of hydroxychloroquine and its clinical pedigree in treating autoimmune diseases such as rheumatoid arthritis, where GM-CSF plays a pivotal role, we propose that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart disease after ARF.	Hydroxychloroquine	199-217	colony stimulating factor 2	Homo sapiens	154-160
30603640-9	2018	Effects on PCSK9 concentrations by monotherapy with hydroxychloroquine (HCQ), which is thought having protective effects against AS in SLE, were investigated by follow-up analysis in 15 SLE patients.	Hydroxychloroquine	52-70	proprotein convertase subtilisin/kexin type 9	Homo sapiens	11-16
30603640-9	2018	Effects on PCSK9 concentrations by monotherapy with hydroxychloroquine (HCQ), which is thought having protective effects against AS in SLE, were investigated by follow-up analysis in 15 SLE patients.	Hydroxychloroquine	72-75	proprotein convertase subtilisin/kexin type 9	Homo sapiens	11-16
30603640-13	2018	Interestingly, monotherapy with HCQ for three months significantly reduced PCSK9 and CRP levels in inactive SLE patients.	Hydroxychloroquine	32-35	proprotein convertase subtilisin/kexin type 9	Homo sapiens	75-80
30603640-13	2018	Interestingly, monotherapy with HCQ for three months significantly reduced PCSK9 and CRP levels in inactive SLE patients.	Hydroxychloroquine	32-35	C-reactive protein	Homo sapiens	85-88
30603640-15	2018	HCQ, which is thought having protective effects against AS in SLE, can effectively reduce PCSK9 levels in SLE patients.	Hydroxychloroquine	0-3	proprotein convertase subtilisin/kexin type 9	Homo sapiens	90-95
30399161-0	2018	Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome.	Hydroxychloroquine	0-18	apolipoprotein H	Mus musculus	78-88
30549469-1	2018	PURPOSE: To evaluate changes in the peripapillary retinal nerve fiber layer (RNFL) thicknesses using spectral-domain optical coherence tomography (SD-OCT) in hydroxychloroquine (HCQ) users.	Hydroxychloroquine	158-176	plexin A2	Homo sapiens	150-153
30549469-1	2018	PURPOSE: To evaluate changes in the peripapillary retinal nerve fiber layer (RNFL) thicknesses using spectral-domain optical coherence tomography (SD-OCT) in hydroxychloroquine (HCQ) users.	Hydroxychloroquine	178-181	plexin A2	Homo sapiens	150-153
30399161-9	2018	Hydroxychloroquine improved acetylcholine-dependent dilation, on pKd (p = 0.02) but not maximal capacity compared to untreated mice.	Hydroxychloroquine	0-18	protein kinase D1	Mus musculus	65-68
30399161-11	2018	CONCLUSIONS: We demonstrated that endothelial dysfunction in mouse resistance arteries persisted at 3 weeks after a single injection of monoclonal anti-beta-2-GPI antibodies, and that hydroxychloroquine improved endothelium-dependent dilation at 3 weeks, through improvement of NO synthase coupling and oxidative stress reduction.	Hydroxychloroquine	184-202	apolipoprotein H	Mus musculus	152-162
30257342-0	2018	Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure.	Hydroxychloroquine	28-46	negative elongation factor complex member C/D	Homo sapiens	50-53
29781188-9	2018	Of note, X6 was also more effective than HCQ in reducing ISG expression in vitro (P &lt; 0.05 for IFI27 and MX1, and P &lt; 0.01 for IFI44L and PKR) in human peripheral blood mononuclear cells from patients with SLE.	Hydroxychloroquine	41-44	interferon alpha inducible protein 27	Homo sapiens	98-103
30257342-9	2018	CONCLUSION: Hydroxychloroquine administration in women with RIF With a high TNF-alpha/IL-10 ratio during the implantation window can decrease this ratio and seems to be an effective therapeutic strategy in RIF caused by cellular immune abnormalities through a shift in Th2 responses.	Hydroxychloroquine	12-30	interleukin 10	Homo sapiens	86-91
30257342-6	2018	RESULTS: Hydroxychloroquine treatment significantly decreased (p &lt; 0.0001) serum level of TNF-alpha and significantly increased serum level of IL-10 (p &lt; 0.0001).	Hydroxychloroquine	9-27	tumor necrosis factor	Homo sapiens	93-102
30257342-6	2018	RESULTS: Hydroxychloroquine treatment significantly decreased (p &lt; 0.0001) serum level of TNF-alpha and significantly increased serum level of IL-10 (p &lt; 0.0001).	Hydroxychloroquine	9-27	interleukin 10	Homo sapiens	146-151
30257342-9	2018	CONCLUSION: Hydroxychloroquine administration in women with RIF With a high TNF-alpha/IL-10 ratio during the implantation window can decrease this ratio and seems to be an effective therapeutic strategy in RIF caused by cellular immune abnormalities through a shift in Th2 responses.	Hydroxychloroquine	12-30	tumor necrosis factor	Homo sapiens	76-85
30336752-9	2018	Diverse changes between CD4+CD25-Foxp3+ T cells and Treg cells when faced with different medications, especially HCQ and MMF.	Hydroxychloroquine	113-116	CD4 molecule	Homo sapiens	24-27
30336752-9	2018	Diverse changes between CD4+CD25-Foxp3+ T cells and Treg cells when faced with different medications, especially HCQ and MMF.	Hydroxychloroquine	113-116	interleukin 2 receptor subunit alpha	Homo sapiens	28-32
30336752-9	2018	Diverse changes between CD4+CD25-Foxp3+ T cells and Treg cells when faced with different medications, especially HCQ and MMF.	Hydroxychloroquine	113-116	forkhead box P3	Homo sapiens	33-38
30099017-7	2018	Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2.	Hydroxychloroquine	135-138	matrix metallopeptidase 9	Mus musculus	205-209
30099017-7	2018	Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2.	Hydroxychloroquine	135-138	matrix metallopeptidase 2	Mus musculus	214-218
30099017-8	2018	Moreover, HCQ disturbed the CXCR4/CXCL12 axis which could induce invasion and metastasis of malignant melanoma in an autophagy-independent way.	Hydroxychloroquine	10-13	chemokine (C-X-C motif) receptor 4	Mus musculus	28-33
30099017-8	2018	Moreover, HCQ disturbed the CXCR4/CXCL12 axis which could induce invasion and metastasis of malignant melanoma in an autophagy-independent way.	Hydroxychloroquine	10-13	chemokine (C-X-C motif) ligand 12	Mus musculus	34-40
29987550-8	2018	Two-month treatment with HCQ resulted in significant decrease in SLEDAI-2K (p &lt; 0.001), anti-dsDNA (p &lt; 0.001), IL-1beta (p = 0.003), IL-6 (p &lt; 0.001) and TNF-alpha (p &lt; 0.001) and a significant increase in CH50 levels (p = 0.012).	Hydroxychloroquine	25-28	interleukin 1 beta	Homo sapiens	118-126
29981383-0	2018	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.	Hydroxychloroquine	0-18	toll like receptor 9	Homo sapiens	108-128
29981383-4	2018	Hydroxychloroquine efficiently inhibited the mammalian target of rapamycin complex 1, differentiation of CD19+IgD-CD27+ class-switched memory B cells to plasmablasts and their IgG production, under stimulation with CpG, a Toll-like receptor (TLR)-9 ligand.	Hydroxychloroquine	0-18	toll like receptor 9	Homo sapiens	222-248
29981383-5	2018	Hydroxychloroquine also inhibited CpG-induced production of interleukin-6 and tumor necrosis factor-alpha in B cell subsets.	Hydroxychloroquine	0-18	interleukin 6	Homo sapiens	60-105
29981383-6	2018	Taken together, hydroxychloroquine markedly suppresses the TLR9-mediated human B cell functions during inflammatory processes.	Hydroxychloroquine	16-34	toll like receptor 9	Homo sapiens	59-63
29987550-8	2018	Two-month treatment with HCQ resulted in significant decrease in SLEDAI-2K (p &lt; 0.001), anti-dsDNA (p &lt; 0.001), IL-1beta (p = 0.003), IL-6 (p &lt; 0.001) and TNF-alpha (p &lt; 0.001) and a significant increase in CH50 levels (p = 0.012).	Hydroxychloroquine	25-28	interleukin 6	Homo sapiens	140-144
29987550-8	2018	Two-month treatment with HCQ resulted in significant decrease in SLEDAI-2K (p &lt; 0.001), anti-dsDNA (p &lt; 0.001), IL-1beta (p = 0.003), IL-6 (p &lt; 0.001) and TNF-alpha (p &lt; 0.001) and a significant increase in CH50 levels (p = 0.012).	Hydroxychloroquine	25-28	tumor necrosis factor	Homo sapiens	164-173
29696437-0	2018	Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.	Hydroxychloroquine	17-35	spen family transcriptional repressor	Homo sapiens	0-5
30121047-0	2018	Attenuation of antimalarial agent hydroxychloroquine on TNF-alpha-induced endothelial inflammation.	Hydroxychloroquine	34-52	tumor necrosis factor	Homo sapiens	56-65
30121047-7	2018	RESULTS: TNF-alpha-induced endothelial-leukocyte adhesion and the leukocyte transmigration were profoundly reduced by HCQ treatment.	Hydroxychloroquine	118-121	tumor necrosis factor	Homo sapiens	9-18
30121047-8	2018	HCQ treatment dramatically inhibited the expression of TNF-alpha-induced endothelial ICAM-1 and VCAM-1.	Hydroxychloroquine	0-3	tumor necrosis factor	Homo sapiens	55-64
30121047-8	2018	HCQ treatment dramatically inhibited the expression of TNF-alpha-induced endothelial ICAM-1 and VCAM-1.	Hydroxychloroquine	0-3	intercellular adhesion molecule 1	Homo sapiens	85-91
30094155-6	2018	Although hydroxychloroquine has been hypothesized to interfere with mutated SP-C accumulation, data on long term outcome remains limited.	Hydroxychloroquine	9-27	surfactant protein C	Homo sapiens	76-80
30121047-8	2018	HCQ treatment dramatically inhibited the expression of TNF-alpha-induced endothelial ICAM-1 and VCAM-1.	Hydroxychloroquine	0-3	vascular cell adhesion molecule 1	Homo sapiens	96-102
30121047-9	2018	Furthermore, treatment with HCQ prevented the TNF-alpha-induced translocation of NF-kappaB p65 into the nucleus and the phosphorylation of the p65 subunit in HUVECs.	Hydroxychloroquine	28-31	tumor necrosis factor	Homo sapiens	46-55
30121047-9	2018	Furthermore, treatment with HCQ prevented the TNF-alpha-induced translocation of NF-kappaB p65 into the nucleus and the phosphorylation of the p65 subunit in HUVECs.	Hydroxychloroquine	28-31	nuclear factor kappa B subunit 1	Homo sapiens	81-90
30121047-9	2018	Furthermore, treatment with HCQ prevented the TNF-alpha-induced translocation of NF-kappaB p65 into the nucleus and the phosphorylation of the p65 subunit in HUVECs.	Hydroxychloroquine	28-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	91-94
30121047-9	2018	Furthermore, treatment with HCQ prevented the TNF-alpha-induced translocation of NF-kappaB p65 into the nucleus and the phosphorylation of the p65 subunit in HUVECs.	Hydroxychloroquine	28-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	143-146
30121047-10	2018	HCQ inhibited the expression of phosphorylated p38 and JNK protein but not ERK.	Hydroxychloroquine	0-3	mitogen-activated protein kinase 14	Homo sapiens	47-50
30121047-10	2018	HCQ inhibited the expression of phosphorylated p38 and JNK protein but not ERK.	Hydroxychloroquine	0-3	mitogen-activated protein kinase 8	Homo sapiens	55-58
30121047-12	2018	HCQ administration also suppressed TNF-alpha induced lung injury in mice by reducing neutrophil infiltration in pulmonary interstitial tissue.	Hydroxychloroquine	0-3	tumor necrosis factor	Mus musculus	35-44
30121047-13	2018	CONCLUSIONS: This work shows the inhibitory effect of HCQ on endothelial inflammatory response through, at least in part, blocking NF-kappaB, p38 and JNK pathways.	Hydroxychloroquine	54-57	nuclear factor kappa B subunit 1	Homo sapiens	131-140
30121047-13	2018	CONCLUSIONS: This work shows the inhibitory effect of HCQ on endothelial inflammatory response through, at least in part, blocking NF-kappaB, p38 and JNK pathways.	Hydroxychloroquine	54-57	mitogen-activated protein kinase 14	Homo sapiens	142-145
30121047-13	2018	CONCLUSIONS: This work shows the inhibitory effect of HCQ on endothelial inflammatory response through, at least in part, blocking NF-kappaB, p38 and JNK pathways.	Hydroxychloroquine	54-57	mitogen-activated protein kinase 8	Homo sapiens	150-153
30323820-7	2018	Chloroquine and hydroxychloroquine, anti-inflammatory drugs used to treat rheumatoid arthritis, prevent TRAF3 degradation in osteoclast precursors and inhibit osteoclast formation in vitro.	Hydroxychloroquine	16-34	TNF receptor-associated factor 3	Mus musculus	104-109
29901098-8	2018	Notably, pharmacological blockade of autophagy activation using hydroxychloroquine markedly enhanced ART-induced apoptosis and increased the protein levels of cleaved caspase 3 and PARP, while decreasing the levels of LC3 and beclin-1.	Hydroxychloroquine	64-82	poly(ADP-ribose) polymerase 1	Homo sapiens	181-185
29901098-8	2018	Notably, pharmacological blockade of autophagy activation using hydroxychloroquine markedly enhanced ART-induced apoptosis and increased the protein levels of cleaved caspase 3 and PARP, while decreasing the levels of LC3 and beclin-1.	Hydroxychloroquine	64-82	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	218-221
29901098-8	2018	Notably, pharmacological blockade of autophagy activation using hydroxychloroquine markedly enhanced ART-induced apoptosis and increased the protein levels of cleaved caspase 3 and PARP, while decreasing the levels of LC3 and beclin-1.	Hydroxychloroquine	64-82	beclin 1	Homo sapiens	226-234
29696437-7	2018	There has been a sharp decline in HCQ dosing following ophthalmology weight-based guidelines in recent years.	Hydroxychloroquine	34-37	spen family transcriptional repressor	Homo sapiens	17-22
29950226-11	2018	HCQ inhibited the expression of LC3-II/LC3-I and BCL-2, but increased the expression of caspase-3 and PARP.	Hydroxychloroquine	0-3	BCL2 apoptosis regulator	Homo sapiens	49-54
29605419-2	2018	The aim of this study was to determine the effects of atazanavir on myocardial infarction (MI)-induced cardiac fibrosis in rats and used a TLR 9 antagonist, hydroxychloroquine (HCQ) to elucidate the potential mechanism in vitro.	Hydroxychloroquine	177-180	toll-like receptor 9	Rattus norvegicus	139-144
30047573-8	2018	RESULTS: The results showed that HCQ use was associated with a significant reduction in the proportion of systemic T cells that were CCR5+CD4+ (p = 0.01) and Th17 (p = 0.01).	Hydroxychloroquine	33-36	C-C motif chemokine receptor 5	Homo sapiens	133-137
29545450-10	2018	RESULTS: In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation.	Hydroxychloroquine	22-25	interleukin 17A	Homo sapiens	62-67
29545450-14	2018	Moreover, miR-590 was increased in patients treated with HCQ plus prednisone.	Hydroxychloroquine	57-60	microRNA 590	Homo sapiens	10-17
29545450-15	2018	CONCLUSION: HCQ inhibited Th17 cell differentiation and IL-17 production both in vitro and in patients with SLE.	Hydroxychloroquine	12-15	interleukin 17A	Homo sapiens	56-61
29950226-11	2018	HCQ inhibited the expression of LC3-II/LC3-I and BCL-2, but increased the expression of caspase-3 and PARP.	Hydroxychloroquine	0-3	caspase 3	Homo sapiens	88-97
29668284-4	2018	Surprisingly, although the treatment of both HCQ and UC-MSCs could ameliorate renal damage separately, the presence of HCQ decreased unexpectedly the therapeutic effects of UC-MSCs through interfering expression of IFN-gamma.	Hydroxychloroquine	119-122	interferon gamma	Homo sapiens	215-224
29668284-7	2018	Results showed that after administration of UC-MSCs pretreated by HCQ, CXCR3 expression in renal tissues, serum IL-2, and IgM levels decreased significantly, and serum IL-10 level increased significantly.	Hydroxychloroquine	66-69	interleukin 2	Homo sapiens	112-116
29668284-7	2018	Results showed that after administration of UC-MSCs pretreated by HCQ, CXCR3 expression in renal tissues, serum IL-2, and IgM levels decreased significantly, and serum IL-10 level increased significantly.	Hydroxychloroquine	66-69	interleukin 10	Homo sapiens	168-173
29668284-8	2018	HCQ pretreatment caused a significant decrease of TNF-alpha and MCP-1 secretion and an increase of IL-1beta and CXCL10 release from UC-MSCs.	Hydroxychloroquine	0-3	tumor necrosis factor	Homo sapiens	50-59
29668284-8	2018	HCQ pretreatment caused a significant decrease of TNF-alpha and MCP-1 secretion and an increase of IL-1beta and CXCL10 release from UC-MSCs.	Hydroxychloroquine	0-3	C-C motif chemokine ligand 2	Homo sapiens	64-69
29668284-8	2018	HCQ pretreatment caused a significant decrease of TNF-alpha and MCP-1 secretion and an increase of IL-1beta and CXCL10 release from UC-MSCs.	Hydroxychloroquine	0-3	interleukin 1 beta	Homo sapiens	99-107
29668284-8	2018	HCQ pretreatment caused a significant decrease of TNF-alpha and MCP-1 secretion and an increase of IL-1beta and CXCL10 release from UC-MSCs.	Hydroxychloroquine	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	112-118
29524884-11	2018	Moreover, a proteasome inhibitor, MG-132, and the lysosomotropic agent, hydroxychloroquine (HCQ) were found to abolish the inhibitory effect of steviol in Pkd1-/- cells.	Hydroxychloroquine	72-90	polycystin 1, transient receptor potential channel interacting	Canis lupus familiaris	155-159
29681086-0	2018	A novel homozygous mutation in the SLCO2A1 gene causing pachydermoperiostosis: Efficacy of hydroxychloroquine treatment.	Hydroxychloroquine	91-109	solute carrier organic anion transporter family member 2A1	Homo sapiens	35-42
29524884-11	2018	Moreover, a proteasome inhibitor, MG-132, and the lysosomotropic agent, hydroxychloroquine (HCQ) were found to abolish the inhibitory effect of steviol in Pkd1-/- cells.	Hydroxychloroquine	92-95	polycystin 1, transient receptor potential channel interacting	Canis lupus familiaris	155-159
29502121-1	2018	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that is useful as in the treatment for lupus because of its inhibitory effect on toll-like receptors and cytokines, which are speculated to play a role in the pathogenesis of Immunoglobulin A (IgA) nephropathy (IgAN).	Hydroxychloroquine	12-30	IGAN1	Homo sapiens	280-284
29515028-3	2018	We found that SLE B cells from patients without hydroxychloroquine treatment displayed defective in vitro TLR9 responses, as illustrated by the impaired upregulation of B cell activation molecules and the diminished production of various cytokines including antiinflammatory IL-10.	Hydroxychloroquine	48-66	toll like receptor 9	Homo sapiens	106-110
29515028-3	2018	We found that SLE B cells from patients without hydroxychloroquine treatment displayed defective in vitro TLR9 responses, as illustrated by the impaired upregulation of B cell activation molecules and the diminished production of various cytokines including antiinflammatory IL-10.	Hydroxychloroquine	48-66	interleukin 10	Homo sapiens	275-280
29500339-0	2018	Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation.	Hydroxychloroquine	0-18	NLR family pyrin domain containing 3	Homo sapiens	97-102
29500339-8	2018	Mechanistic studies showed that HCQ could inhibit the priming of the NLRP3 inflammasome by down-regulating I/R or H/R-induced NF-kappaB signaling.	Hydroxychloroquine	32-35	NLR family pyrin domain containing 3	Homo sapiens	69-74
29500339-8	2018	Mechanistic studies showed that HCQ could inhibit the priming of the NLRP3 inflammasome by down-regulating I/R or H/R-induced NF-kappaB signaling.	Hydroxychloroquine	32-35	nuclear factor kappa B subunit 1	Homo sapiens	126-135
29500339-9	2018	Moreover, HCQ reduced cathepsin (CTS) B, CTSD and CTSL activity, and their redistribution from lysosomes to cytoplasm.	Hydroxychloroquine	10-13	cathepsin B	Homo sapiens	22-39
29500339-9	2018	Moreover, HCQ reduced cathepsin (CTS) B, CTSD and CTSL activity, and their redistribution from lysosomes to cytoplasm.	Hydroxychloroquine	10-13	cathepsin D	Homo sapiens	41-45
29500339-9	2018	Moreover, HCQ reduced cathepsin (CTS) B, CTSD and CTSL activity, and their redistribution from lysosomes to cytoplasm.	Hydroxychloroquine	10-13	cathepsin L	Homo sapiens	50-54
29500339-11	2018	Notably, we found that HCQ attenuated renal injury through downregulation of CTSB and CTSL-mediated NLRP3 inflammasome activation.	Hydroxychloroquine	23-26	cathepsin B	Homo sapiens	77-81
29500339-11	2018	Notably, we found that HCQ attenuated renal injury through downregulation of CTSB and CTSL-mediated NLRP3 inflammasome activation.	Hydroxychloroquine	23-26	cathepsin L	Homo sapiens	86-90
29500339-11	2018	Notably, we found that HCQ attenuated renal injury through downregulation of CTSB and CTSL-mediated NLRP3 inflammasome activation.	Hydroxychloroquine	23-26	NLR family pyrin domain containing 3	Homo sapiens	100-105
29349515-11	2018	Interestingly, in hydroxychloroquine or topical corticosteroid-treated patients, MMP-2/-9 activity levels were found to be higher compared to untreated patients.	Hydroxychloroquine	18-36	matrix metallopeptidase 2	Homo sapiens	81-89
29456648-0	2018	Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-kappaB signaling pathway in lupus nephritis mice.	Hydroxychloroquine	29-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-113
29456648-6	2018	It was observed that L-HCQ + ART and H-HCQ ameliorated the LN-induced body weight decrease, and significantly decreased the levels of anti-double stranded DNA, antinuclear antibodies, immunoglobulin G, interferon gamma, tumor necrosis factor-alpha and transforming growth factor-beta1, as well as improved the kidney and spleen pathology, when compared with the model group.	Hydroxychloroquine	23-26	interferon gamma	Mus musculus	202-284
29502121-1	2018	BACKGROUND: Hydroxychloroquine (HCQ) is a well-known immunomodulator that is useful as in the treatment for lupus because of its inhibitory effect on toll-like receptors and cytokines, which are speculated to play a role in the pathogenesis of Immunoglobulin A (IgA) nephropathy (IgAN).	Hydroxychloroquine	32-35	IGAN1	Homo sapiens	280-284
29502121-2	2018	However, there was only one study that investigated the effect of HCQ on proteinuria in patients with IgAN.	Hydroxychloroquine	66-69	IGAN1	Homo sapiens	102-106
29502121-9	2018	CONCLUSION: The addition of HCQ to RAASi resulted in a significant and safe reduction in proteinuria in patients with IgAN.	Hydroxychloroquine	28-31	IGAN1	Homo sapiens	118-122
30603055-0	2018	Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors.	Hydroxychloroquine	30-48	Prader Willi/Angelman region RNA 4	Homo sapiens	92-97
30603055-1	2018	Chloroquine and hydroxychloroquine (HCQ) are robust inducers of the tumor suppressor Par-4 secretion from normal cells.	Hydroxychloroquine	16-34	Prader Willi/Angelman region RNA 4	Homo sapiens	85-90
30603055-1	2018	Chloroquine and hydroxychloroquine (HCQ) are robust inducers of the tumor suppressor Par-4 secretion from normal cells.	Hydroxychloroquine	36-39	Prader Willi/Angelman region RNA 4	Homo sapiens	85-90
30603055-6	2018	Eight of the nine patients treated with HCQ showed elevation in plasma Par-4 levels over basal levels.	Hydroxychloroquine	40-43	Prader Willi/Angelman region RNA 4	Homo sapiens	71-76
30603055-8	2018	The resected tumors from the eight HCQ-treated patients with elevated plasma Par-4 levels, but not the resected tumor from the patient who failed to induce plasma Par-4 levels, exhibited TUNEL-positivity indicative of apoptosis.	Hydroxychloroquine	35-38	Prader Willi/Angelman region RNA 4	Homo sapiens	77-82
30603055-8	2018	The resected tumors from the eight HCQ-treated patients with elevated plasma Par-4 levels, but not the resected tumor from the patient who failed to induce plasma Par-4 levels, exhibited TUNEL-positivity indicative of apoptosis.	Hydroxychloroquine	35-38	Prader Willi/Angelman region RNA 4	Homo sapiens	163-168
30603055-9	2018	Resected tumors from all nine HCQ-treated patients showed p62/sequestosome-1 induction indicative of autophagy-inhibition by HCQ.	Hydroxychloroquine	30-33	sequestosome 1	Homo sapiens	58-61
30603055-9	2018	Resected tumors from all nine HCQ-treated patients showed p62/sequestosome-1 induction indicative of autophagy-inhibition by HCQ.	Hydroxychloroquine	30-33	sequestosome 1	Homo sapiens	62-76
29724987-6	2018	PRP protocol was started after the failure of conventional therapies based on the use of topical and systemic corticosteroids, hydroxychloroquine, and low-level laser therapy applications.	Hydroxychloroquine	127-145	complement component 4 binding protein alpha	Homo sapiens	0-3
28887220-4	2018	Here we coencapsulated ZD6474 and hydroxychloroquine into R6dGR peptide-modified liposomes (R6dGR-Lip) which can specifically recognize both integrin alphavbeta3 and neuropilin-1 receptors that are highly expressed on the endothelial cells and glioma cells.	Hydroxychloroquine	34-52	neuropilin 1	Mus musculus	166-178
29288196-0	2018	Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis.	Hydroxychloroquine	0-18	transthyretin	Homo sapiens	110-123
29130361-8	2018	Knockdown of ATG7 or cotreatment with hydroxychloroquine, an autophagy inhibitor, restored sensitivity to 4OHT in both the MCF7/MTA1 and tamoxifen resistant cells.	Hydroxychloroquine	38-56	metastasis associated 1	Homo sapiens	128-132
29136759-8	2018	Further research demonstrated that HCQ inhibited the generation of Tfh cells stimulated by IL-12 and IL-21.	Hydroxychloroquine	35-38	interleukin 21	Homo sapiens	101-106
29136759-9	2018	In conclusion, our study indicates a previously unrecognized mechanism of HCQ in RA, that HCQ directly suppresses the generation of Tfh cells by blocking IL-12 and IL-21 signaling pathways probably.	Hydroxychloroquine	90-93	interleukin 21	Homo sapiens	164-169
30041771-7	2018	Studies in vitro have shown that HCQ is able to restore the placental expression of Annexin V, which has an anticoagulant effect and to prevent the placental injury induced by APL.	Hydroxychloroquine	33-36	annexin A5	Homo sapiens	84-93
29045759-5	2018	Results: Soluble TF levels were significantly reduced comparing baseline and 3 months after HCQ commencement [401.8 (152.8) vs 300.9 (108) pg/ml (P = 0.010)].	Hydroxychloroquine	92-95	coagulation factor III, tissue factor	Homo sapiens	17-19
29045759-9	2018	Conclusion: HCQ significantly reduced soluble TF levels in patients with aPL.	Hydroxychloroquine	12-15	coagulation factor III, tissue factor	Homo sapiens	46-48
28793932-0	2017	Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling.	Hydroxychloroquine	0-18	CD40 ligand	Homo sapiens	28-33
28802235-9	2017	Interestingly, hydroxychloroquine (a lysosome inhibitor) treatment abolished steviol"s effect in reducing CFTR and beta-catenin protein expression.	Hydroxychloroquine	15-33	CF transmembrane conductance regulator	Homo sapiens	106-110
28802235-9	2017	Interestingly, hydroxychloroquine (a lysosome inhibitor) treatment abolished steviol"s effect in reducing CFTR and beta-catenin protein expression.	Hydroxychloroquine	15-33	catenin beta 1	Homo sapiens	115-127
28883515-7	2017	Treatment with a specific FXa inhibitor, hydroxychloroquine or fluvastatin significantly reduced FXa-induced and IgG-potentiated Ca2+ release.	Hydroxychloroquine	41-59	coagulation factor X	Homo sapiens	97-100
28708385-9	2017	The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation.	Hydroxychloroquine	54-57	mitogen-activated protein kinase 1	Homo sapiens	117-120
28708385-9	2017	The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation.	Hydroxychloroquine	54-57	AKT serine/threonine kinase 1	Homo sapiens	125-128
28941496-3	2017	To quantify the effects of HCQ versus QC in suppressing secretion of tumor necrosis factor-alpha (TNF-alpha) and IFN-alpha from the peripheral blood mononuclear cells of DM and CLE patients, lipopolysaccharide-stimulated and control peripheral blood mononuclear cells from DM and CLE patients and control subjects were analyzed for the effect of HCQ and QC on TNF-alpha and IFN-alpha production using ELISA testing.	Hydroxychloroquine	27-30	tumor necrosis factor	Homo sapiens	69-96
28941496-3	2017	To quantify the effects of HCQ versus QC in suppressing secretion of tumor necrosis factor-alpha (TNF-alpha) and IFN-alpha from the peripheral blood mononuclear cells of DM and CLE patients, lipopolysaccharide-stimulated and control peripheral blood mononuclear cells from DM and CLE patients and control subjects were analyzed for the effect of HCQ and QC on TNF-alpha and IFN-alpha production using ELISA testing.	Hydroxychloroquine	27-30	tumor necrosis factor	Homo sapiens	98-107
28941496-3	2017	To quantify the effects of HCQ versus QC in suppressing secretion of tumor necrosis factor-alpha (TNF-alpha) and IFN-alpha from the peripheral blood mononuclear cells of DM and CLE patients, lipopolysaccharide-stimulated and control peripheral blood mononuclear cells from DM and CLE patients and control subjects were analyzed for the effect of HCQ and QC on TNF-alpha and IFN-alpha production using ELISA testing.	Hydroxychloroquine	27-30	interferon alpha 1	Homo sapiens	113-122
28793932-2	2017	Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism.	Hydroxychloroquine	8-26	CD40 ligand	Homo sapiens	129-134
28793932-2	2017	Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism.	Hydroxychloroquine	122-125	CD40 ligand	Homo sapiens	129-134
28793932-5	2017	RESULTS: HCQ treatment had significant dose-dependent suppressive effects on membranous CD154 expression in ionomycin-activated T cells from lupus patients.	Hydroxychloroquine	9-12	CD40 ligand	Homo sapiens	88-93
28793932-6	2017	Furthermore, HCQ inhibited intracellular sustained calcium storage release, and attenuated the nuclear translocation of NFATc2 and the expression of NFATc1.	Hydroxychloroquine	13-16	nuclear factor of activated T cells 2	Homo sapiens	120-126
28793932-6	2017	Furthermore, HCQ inhibited intracellular sustained calcium storage release, and attenuated the nuclear translocation of NFATc2 and the expression of NFATc1.	Hydroxychloroquine	13-16	nuclear factor of activated T cells 1	Homo sapiens	149-155
28793932-8	2017	CONCLUSIONS: HCQ inhibited NFAT signaling in activated T cells and blocked the expression of membranous CD154, but not STAT5 signaling.	Hydroxychloroquine	13-16	CD40 ligand	Homo sapiens	104-109
28501799-7	2017	SIGLEC1 and IFN-alpha expression were reduced by hydroxychloroquine and oral glucocorticoids.	Hydroxychloroquine	49-67	sialic acid binding Ig like lectin 1	Homo sapiens	0-7
28501799-7	2017	SIGLEC1 and IFN-alpha expression were reduced by hydroxychloroquine and oral glucocorticoids.	Hydroxychloroquine	49-67	interferon alpha 1	Homo sapiens	12-21
28501799-8	2017	CONCLUSIONS: High expression of SIGLEC1 in pregnant women with autoantibodies against Ro/SS-A indicates an enhanced risk for CHB development, and these women may benefit especially from IFN-alpha directed therapy, for example with hydroxychloroquine.	Hydroxychloroquine	231-249	sialic acid binding Ig like lectin 1	Homo sapiens	32-39
28501799-8	2017	CONCLUSIONS: High expression of SIGLEC1 in pregnant women with autoantibodies against Ro/SS-A indicates an enhanced risk for CHB development, and these women may benefit especially from IFN-alpha directed therapy, for example with hydroxychloroquine.	Hydroxychloroquine	231-249	tripartite motif containing 21	Homo sapiens	86-93
28501799-8	2017	CONCLUSIONS: High expression of SIGLEC1 in pregnant women with autoantibodies against Ro/SS-A indicates an enhanced risk for CHB development, and these women may benefit especially from IFN-alpha directed therapy, for example with hydroxychloroquine.	Hydroxychloroquine	231-249	interferon alpha 1	Homo sapiens	186-195
28349446-0	2017	Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.	Hydroxychloroquine	0-18	IGAN1	Homo sapiens	56-71
28703806-5	2017	AML CD34+ cells were more sensitive to the autophagy inhibitor hydroxychloroquine (HCQ) than normal bone marrow CD34+ cells.	Hydroxychloroquine	63-81	CD34 molecule	Homo sapiens	4-8
28703806-5	2017	AML CD34+ cells were more sensitive to the autophagy inhibitor hydroxychloroquine (HCQ) than normal bone marrow CD34+ cells.	Hydroxychloroquine	83-86	CD34 molecule	Homo sapiens	4-8
28703806-9	2017	The immature AML CD34+-enriched ROSlow cells maintained higher basal autophagy and showed reduced survival upon HCQ treatment compared with ROShigh cells.	Hydroxychloroquine	112-115	CD34 molecule	Homo sapiens	17-21
28339096-5	2017	Consequently, although anticoagulation remains the standard treatment for thrombotic APS and during pregnancy, the realisation that these additional pathways are involved in the pathogenesis of APS has significant implications for treatment: agents acting outside the coagulation system, such as hydroxychloroquine for pregnancy complications and sirolimus as an inhibitor of the mammalian target of rapamycin (mTOR) pathway, are now under evaluation and represent a radical change in thinking for haematologists.	Hydroxychloroquine	296-314	mechanistic target of rapamycin kinase	Homo sapiens	380-409
28339096-5	2017	Consequently, although anticoagulation remains the standard treatment for thrombotic APS and during pregnancy, the realisation that these additional pathways are involved in the pathogenesis of APS has significant implications for treatment: agents acting outside the coagulation system, such as hydroxychloroquine for pregnancy complications and sirolimus as an inhibitor of the mammalian target of rapamycin (mTOR) pathway, are now under evaluation and represent a radical change in thinking for haematologists.	Hydroxychloroquine	296-314	mechanistic target of rapamycin kinase	Homo sapiens	411-415
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	0-18	interferon alpha 1	Homo sapiens	267-276
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	0-18	interleukin 6	Homo sapiens	277-281
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	0-18	tumor necrosis factor	Homo sapiens	286-295
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	20-23	interferon alpha 1	Homo sapiens	267-276
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	20-23	interleukin 6	Homo sapiens	277-281
28349446-2	2017	Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-alpha,IL-6 and TNF-alpha.	Hydroxychloroquine	20-23	tumor necrosis factor	Homo sapiens	286-295
28349446-3	2017	We evaluated the efficacy of HCQ in reducing proteinuria in patients with IgAN.	Hydroxychloroquine	29-32	IGAN1	Homo sapiens	74-78
28349446-9	2017	CONCLUSIONS: In selected patients with IgAN, HCQ is effective in ameliorating proteinuria.	Hydroxychloroquine	45-48	IGAN1	Homo sapiens	39-43
28402954-8	2017	Interestingly, inhibition of lysosomal degradation using hydroxychloroquine (HCQ) induced expression of the tumor suppressor p53, promoted apoptosis, and inhibited HCC growth, whereas activation of autophagy using an mTOR inhibitor (Torin1) promoted HCC growth.	Hydroxychloroquine	57-75	tumor protein p53	Homo sapiens	125-128
28701864-11	2017	Blockade of autophagy by hydroxychloroquine dramatically potentiated KG-135-induced FOXO3a and its downstream (FasL) ligand accompanied by the cleavage of caspase-8.	Hydroxychloroquine	25-43	forkhead box O3	Homo sapiens	84-90
28701864-11	2017	Blockade of autophagy by hydroxychloroquine dramatically potentiated KG-135-induced FOXO3a and its downstream (FasL) ligand accompanied by the cleavage of caspase-8.	Hydroxychloroquine	25-43	Fas ligand	Homo sapiens	111-115
28701864-11	2017	Blockade of autophagy by hydroxychloroquine dramatically potentiated KG-135-induced FOXO3a and its downstream (FasL) ligand accompanied by the cleavage of caspase-8.	Hydroxychloroquine	25-43	caspase 8	Homo sapiens	155-164
28402954-8	2017	Interestingly, inhibition of lysosomal degradation using hydroxychloroquine (HCQ) induced expression of the tumor suppressor p53, promoted apoptosis, and inhibited HCC growth, whereas activation of autophagy using an mTOR inhibitor (Torin1) promoted HCC growth.	Hydroxychloroquine	77-80	tumor protein p53	Homo sapiens	125-128
28500073-6	2017	Hydroxychloroquine used for treating systemic lupus erythematosus and a Syk inhibitor blocked NA-TLR localization with FcgammaRIIIa.	Hydroxychloroquine	0-18	Fc gamma receptor IIIa	Homo sapiens	119-131
28496328-6	2017	CONCLUSION: The aHR for DM was lowest for patients with RA and PS/PSA who initiated treatment with an anti-TNF agent with concomitant HCQ, followed by HCQ users.	Hydroxychloroquine	134-137	aryl hydrocarbon receptor	Homo sapiens	16-19
28318681-4	2017	This review can hopefully serve as an aid to dermatologists and help ensure they continue using hydroxychloroquine safely and effectively.	Hydroxychloroquine	96-114	activation induced cytidine deaminase	Homo sapiens	38-41
28507328-10	2017	In vitro, HCQ inhibited IL-1beta and caspase 1 activation induced by ATP in a dose-dependent manner.	Hydroxychloroquine	10-13	interleukin 1 beta	Homo sapiens	24-32
28507328-10	2017	In vitro, HCQ inhibited IL-1beta and caspase 1 activation induced by ATP in a dose-dependent manner.	Hydroxychloroquine	10-13	caspase 1	Homo sapiens	37-46
28507328-12	2017	In vivo, HCQ inhibited caspase 1-dependent ATP-induced neutrophil recruitment.	Hydroxychloroquine	9-12	caspase 1	Homo sapiens	23-32
28507328-5	2017	Electrophysiology experiments demonstrated that HCQ inhibited Ca++-activated K+ conductance in THP-1 macrophages in a dose-dependent manner.	Hydroxychloroquine	48-51	GLI family zinc finger 2	Homo sapiens	95-100
28496328-6	2017	CONCLUSION: The aHR for DM was lowest for patients with RA and PS/PSA who initiated treatment with an anti-TNF agent with concomitant HCQ, followed by HCQ users.	Hydroxychloroquine	134-137	tumor necrosis factor	Homo sapiens	107-110
28496328-6	2017	CONCLUSION: The aHR for DM was lowest for patients with RA and PS/PSA who initiated treatment with an anti-TNF agent with concomitant HCQ, followed by HCQ users.	Hydroxychloroquine	151-154	aryl hydrocarbon receptor	Homo sapiens	16-19
28557788-4	2017	Hydroxychloroquine sulfate is stable for at least 90 days in Medisca Oral Mix or Oral Mix SF suspension media at 25 C and 4 C.	Hydroxychloroquine	0-26	Mix paired-like homeobox	Homo sapiens	74-77
27903507-7	2017	RESULTS: HCQ strongly reduces or completely prevents the induction of endosomal NOX by TNFalpha, IL-1beta and aPL in human monocytes and MonoMac1 cells.	Hydroxychloroquine	9-12	tumor necrosis factor	Homo sapiens	87-95
27903507-7	2017	RESULTS: HCQ strongly reduces or completely prevents the induction of endosomal NOX by TNFalpha, IL-1beta and aPL in human monocytes and MonoMac1 cells.	Hydroxychloroquine	9-12	interleukin 1 beta	Homo sapiens	97-105
27903507-9	2017	This effect of HCQ is not mediated by direct interference with the agonists but by inhibiting the translocation of the catalytic subunit of NOX2 (gp91phox) into the endosome.	Hydroxychloroquine	15-18	cytochrome b-245 beta chain	Homo sapiens	140-144
27903507-9	2017	This effect of HCQ is not mediated by direct interference with the agonists but by inhibiting the translocation of the catalytic subunit of NOX2 (gp91phox) into the endosome.	Hydroxychloroquine	15-18	cytochrome b-245 beta chain	Homo sapiens	146-154
27903507-10	2017	In vivo, HCQ protects mice from aPL-induced and NOX2-mediated thrombus formation.	Hydroxychloroquine	9-12	cytochrome b-245, beta polypeptide	Mus musculus	48-52
27903507-11	2017	CONCLUSIONS: We describe here a novel mechanism of action of HCQ, that is, interference with the assembly of endosomal NOX2.	Hydroxychloroquine	61-64	cytochrome b-245 beta chain	Homo sapiens	119-123
27903507-12	2017	Since endosomal NOX2 is involved in many inflammatory and prothrombotic signalling pathways, this activity of HCQ might explain many of its beneficial effects in rheumatic diseases including the APS.	Hydroxychloroquine	110-113	cytochrome b-245 beta chain	Homo sapiens	16-20
28339029-6	2017	We revealed that in a time-dependent manner HCQ induced the expression of NKG2D ligand ULBP4 on the surface of CML cells.	Hydroxychloroquine	44-47	killer cell lectin like receptor K1	Homo sapiens	74-79
28339029-6	2017	We revealed that in a time-dependent manner HCQ induced the expression of NKG2D ligand ULBP4 on the surface of CML cells.	Hydroxychloroquine	44-47	retinoic acid early transcript 1E	Homo sapiens	87-92
28339029-8	2017	Blocking the interaction of NKG2D with its ligands deleted the sensitizing effects of HCQ.	Hydroxychloroquine	86-89	killer cell lectin like receptor K1	Homo sapiens	28-33
28339029-9	2017	In addition, we showed that HCQ did not affect the synthesis or degradation of ULBP4, but induced the translocation of ULBP4 from the cytoplasm to the cell membrane.	Hydroxychloroquine	28-31	retinoic acid early transcript 1E	Homo sapiens	119-124
28557788-4	2017	Hydroxychloroquine sulfate is stable for at least 90 days in Medisca Oral Mix or Oral Mix SF suspension media at 25 C and 4 C.	Hydroxychloroquine	0-26	Mix paired-like homeobox	Homo sapiens	86-89
28433067-6	2017	Moreover, bladder cancer cells treated with CQ and HCQ underwent apoptosis, resulting in increased caspase 3/7 activities, increased level of cleaved poly(ADP-ribose) polymerase (PARP), caspase 3, and DNA fragmentation.	Hydroxychloroquine	51-54	caspase 3	Homo sapiens	99-108
28382796-7	2017	Inhibition of autophagy protein LC3A using hydroxychloroquine (HCQ) increased sensitivity to cisplatin in CCC cells in vitro.	Hydroxychloroquine	43-61	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	32-36
28382796-7	2017	Inhibition of autophagy protein LC3A using hydroxychloroquine (HCQ) increased sensitivity to cisplatin in CCC cells in vitro.	Hydroxychloroquine	63-66	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	32-36
28433067-6	2017	Moreover, bladder cancer cells treated with CQ and HCQ underwent apoptosis, resulting in increased caspase 3/7 activities, increased level of cleaved poly(ADP-ribose) polymerase (PARP), caspase 3, and DNA fragmentation.	Hydroxychloroquine	51-54	poly(ADP-ribose) polymerase 1	Homo sapiens	150-177
28433067-6	2017	Moreover, bladder cancer cells treated with CQ and HCQ underwent apoptosis, resulting in increased caspase 3/7 activities, increased level of cleaved poly(ADP-ribose) polymerase (PARP), caspase 3, and DNA fragmentation.	Hydroxychloroquine	51-54	poly(ADP-ribose) polymerase 1	Homo sapiens	179-183
28433067-6	2017	Moreover, bladder cancer cells treated with CQ and HCQ underwent apoptosis, resulting in increased caspase 3/7 activities, increased level of cleaved poly(ADP-ribose) polymerase (PARP), caspase 3, and DNA fragmentation.	Hydroxychloroquine	51-54	caspase 3	Homo sapiens	186-195
27632587-1	2017	PURPOSE: To report a case of bilateral panretinal degeneration in a patient with long-term hydroxychloroquine exposure and positive for a heterozygous mutation in the USH2A gene.	Hydroxychloroquine	91-109	usherin	Homo sapiens	167-172
28145658-12	2017	Screening of HCQ retinopathy by the recommended guidelines that include SD-OCT seems useful and should be done to detect retinal damage earlier in patients with chronic exposure to HCQ.	Hydroxychloroquine	13-16	plexin A2	Homo sapiens	75-78
27939801-7	2017	Case #2: this 79-year-old woman had a history of CPDD was on glucocorticoid and hydroxychloroquine therapy for lupus.	Hydroxychloroquine	80-98	CCAL1	Homo sapiens	49-53
27406736-5	2017	Both the levels of IgG anti-cardiolipin and IgG/IgM anti-beta2-glycoprotein I (anti-beta2GPI) were significantly reduced at end of follow-up compared to the baseline in HCQ-exposed patients, while there were no differences in the other group.	Hydroxychloroquine	169-172	apolipoprotein H	Homo sapiens	84-92
28036259-6	2017	BKM120 treatment led to the nuclear accumulation of forkhead box O3 (FOXO3a) in Caski and T47D cells, which showed a synergistic effect of BKM120 and HCQ and the strong induction of autophagy.	Hydroxychloroquine	150-153	forkhead box O3	Homo sapiens	69-75
28036259-8	2017	These data suggest that BKM120-induced nuclear translocation of FOXO3a might elicit autophagy and be a critical factor determining the synergistic activity of BKM120 and HCQ in PIK3CA-mutant cancer cells.	Hydroxychloroquine	170-173	forkhead box O3	Homo sapiens	64-70
28036259-8	2017	These data suggest that BKM120-induced nuclear translocation of FOXO3a might elicit autophagy and be a critical factor determining the synergistic activity of BKM120 and HCQ in PIK3CA-mutant cancer cells.	Hydroxychloroquine	170-173	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	177-183
28036259-9	2017	The release of FOXO3a from 14-3-3 by BV02 or 14-3-3 knockdown induced autophagy by BKM120 in C33A cells and sensitized the cells to the combined BKM120 and HCQ treatment, suggesting that cytoplasmic retention of FOXO3a by 14-3-3 even in the presence of BKM120 inhibit autophagy induction and synergistic effect of BKM120 and HCQ combination.	Hydroxychloroquine	156-159	forkhead box O3	Homo sapiens	15-21
28036259-9	2017	The release of FOXO3a from 14-3-3 by BV02 or 14-3-3 knockdown induced autophagy by BKM120 in C33A cells and sensitized the cells to the combined BKM120 and HCQ treatment, suggesting that cytoplasmic retention of FOXO3a by 14-3-3 even in the presence of BKM120 inhibit autophagy induction and synergistic effect of BKM120 and HCQ combination.	Hydroxychloroquine	325-328	forkhead box O3	Homo sapiens	15-21
28123046-13	2017	Insulin-like growth factor-1 (IGF-1) levels were also elevated by TAD + HCQ (343 +- 14 vs. 262 +- 22 ng/ml, P &lt; 0.05).	Hydroxychloroquine	72-75	insulin-like growth factor 1	Mus musculus	0-28
28123046-13	2017	Insulin-like growth factor-1 (IGF-1) levels were also elevated by TAD + HCQ (343 +- 14 vs. 262 +- 22 ng/ml, P &lt; 0.05).	Hydroxychloroquine	72-75	insulin-like growth factor 1	Mus musculus	30-35
28981387-7	2017	Expression of HLTF allows repair of DNA damage caused by LAI-induced reactive oxygen species, leading to HCQ resistance.	Hydroxychloroquine	105-108	helicase like transcription factor	Homo sapiens	14-18
28981387-8	2017	Sensitivity to HCQ is increased in cells where HLTF is silenced by promoter methylation.	Hydroxychloroquine	15-18	helicase like transcription factor	Homo sapiens	47-51
28916403-10	2017	Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy.	Hydroxychloroquine	119-137	lipoprotein lipase	Homo sapiens	18-21
27632587-9	2017	CONCLUSION: We report a case of panretinal degeneration but with features characteristic of hydroxychloroquine retinopathy in a patient who was found to be a heterozygous carrier of the USH2A gene, a cause of recessive retinitis pigmentosa without hearing loss.	Hydroxychloroquine	92-110	usherin	Homo sapiens	186-191
27629805-9	2016	At the behavioral level, further inhibition of the autophagic flux by hydroxychloroquine intensified cold and heat nociception after sciatic nerve injury and offset the pain protection provided by progranulin.	Hydroxychloroquine	70-88	granulin	Mus musculus	197-208
27955694-7	2016	This analysis revealed lower IFN scores in patients using hydroxychloroquine, prednisone, and/or sulfasalazine, but it did not show significant associations between the other parameters and the IFN score.	Hydroxychloroquine	58-76	interferon alpha 1	Homo sapiens	29-32
27743378-6	2016	Moreover, results from in vitro clonogenic survival assays showed that RAD51 depletion greatly enabled EC cells to resist the autophagy inhibitors 3MA and hydroxychloroquine (HCQ) treatments.	Hydroxychloroquine	155-173	RAD51 recombinase	Homo sapiens	71-76
27743378-6	2016	Moreover, results from in vitro clonogenic survival assays showed that RAD51 depletion greatly enabled EC cells to resist the autophagy inhibitors 3MA and hydroxychloroquine (HCQ) treatments.	Hydroxychloroquine	175-178	RAD51 recombinase	Homo sapiens	71-76
27939463-3	2016	In this study, we aimed to investigate whether hydroxychloroquine was endothelial protective in an in vitro model of TNF-alpha and preeclamptic serum induced dysfunction.	Hydroxychloroquine	47-65	tumor necrosis factor	Homo sapiens	117-126
27939463-4	2016	We showed that hydroxychloroquine significantly reduced the production of TNF-alpha and preeclamptic serum induced endothelin-1 (ET-1).	Hydroxychloroquine	15-33	tumor necrosis factor	Homo sapiens	74-83
27939463-4	2016	We showed that hydroxychloroquine significantly reduced the production of TNF-alpha and preeclamptic serum induced endothelin-1 (ET-1).	Hydroxychloroquine	15-33	endothelin 1	Homo sapiens	115-127
27939463-4	2016	We showed that hydroxychloroquine significantly reduced the production of TNF-alpha and preeclamptic serum induced endothelin-1 (ET-1).	Hydroxychloroquine	15-33	endothelin 1	Homo sapiens	129-133
27939463-5	2016	Hydroxychloroquine also significantly mitigated TNF-alpha induced impairment of angiogenesis.	Hydroxychloroquine	0-18	tumor necrosis factor	Homo sapiens	48-57
27288548-6	2016	Furthermore, we found that HCQ inhibited the production of inflammatory cytokines and ROS in response to toll-like receptor 4 (TLR4) activation in macrophages.	Hydroxychloroquine	27-30	toll-like receptor 4	Mus musculus	105-125
27005921-4	2016	DISCUSSION: SD-OCT could be used as a test in order to reveal HCQ toxicity in the event of retinal detachment.	Hydroxychloroquine	62-65	plexin A2	Homo sapiens	15-18
27288548-6	2016	Furthermore, we found that HCQ inhibited the production of inflammatory cytokines and ROS in response to toll-like receptor 4 (TLR4) activation in macrophages.	Hydroxychloroquine	27-30	toll-like receptor 4	Mus musculus	127-131
27656614-5	2016	RESULTS: In both groups of patients receiving hydroxychloroquine and placebo, except for serum level of insulin that was significantly elevated after treatment by hydroxychloroquine, the changes in other parameters remained insignificant.	Hydroxychloroquine	46-64	insulin	Homo sapiens	104-111
27656614-5	2016	RESULTS: In both groups of patients receiving hydroxychloroquine and placebo, except for serum level of insulin that was significantly elevated after treatment by hydroxychloroquine, the changes in other parameters remained insignificant.	Hydroxychloroquine	163-181	insulin	Homo sapiens	104-111
27656614-6	2016	Both groups experienced increase of insulin level, but this change was considerably higher in those groups receiving hydroxychloroquine.	Hydroxychloroquine	117-135	insulin	Homo sapiens	36-43
27656614-8	2016	CONCLUSION: The use of hydroxychloroquine may increase the serum insulin level in patients with prediabetic states who are at risk of developing diabetes mellitus.	Hydroxychloroquine	23-41	insulin	Homo sapiens	65-72
26727968-7	2016	Cox time-varying regression models were used to estimate the association between hydroxychloroquine exposure and development of CVD, after adjusting for propensity score and relevant confounders, including demographics, CVD-related comorbidities, RA severity, and activity indicators and medications.	Hydroxychloroquine	81-99	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
26953155-7	2016	The TLR7 to TLR9 blocker hydroxychloroquine has been in use in patients with lupus for more than 50 years, but oligonucleotide-based inhibitors of TLR7 to TLR9, despite showing promise in animal models of lupus, have not reached the primary end point in a recent phase 1 trial.	Hydroxychloroquine	25-43	toll like receptor 7	Homo sapiens	4-8
26953155-7	2016	The TLR7 to TLR9 blocker hydroxychloroquine has been in use in patients with lupus for more than 50 years, but oligonucleotide-based inhibitors of TLR7 to TLR9, despite showing promise in animal models of lupus, have not reached the primary end point in a recent phase 1 trial.	Hydroxychloroquine	25-43	toll like receptor 9	Homo sapiens	12-16
26587870-1	2016	BACKGROUND: Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations.	Hydroxychloroquine	12-30	RNA transcription, translation and transport factor	Homo sapiens	112-115
26587870-1	2016	BACKGROUND: Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations.	Hydroxychloroquine	32-35	RNA transcription, translation and transport factor	Homo sapiens	112-115
26587870-3	2016	To establish an appropriate therapeutic regimen and to clarify the pharmacokinetics (PK) of HCQ in Japanese patients with CLE with or without SLE (CLE/SLE), a population pharmacokinetic (PopPK) analysis was performed.	Hydroxychloroquine	92-95	RNA transcription, translation and transport factor	Homo sapiens	122-125
26587870-7	2016	RESULTS: The PopPKs of HCQ in the blood and plasma of 90 Japanese patients with CLE/SLE were well described by a 1-compartment model with first-order absorption and absorption lag time.	Hydroxychloroquine	23-26	RNA transcription, translation and transport factor	Homo sapiens	80-87
26587870-10	2016	Simulations based on the final model suggested that the recommended daily doses of HCQ sulfate (200-400 mg) based on the ideal body weight in Japanese patients with CLE/SLE were in the similar concentration ranges.	Hydroxychloroquine	83-94	RNA transcription, translation and transport factor	Homo sapiens	165-172
26587870-11	2016	CONCLUSIONS: The PopPK models derived from both blood and plasma HCQ concentrations of Japanese patients with CLE/SLE were developed and validated.	Hydroxychloroquine	65-68	RNA transcription, translation and transport factor	Homo sapiens	110-117
26587870-12	2016	Based on this study, the dosage regimens of HCQ sulfate for Japanese patients with CLE/SLE should be calculated using the individual ideal body weight.	Hydroxychloroquine	44-55	RNA transcription, translation and transport factor	Homo sapiens	83-90
26775710-4	2016	We also identified that HCQ could decrease lesion numbers and disrupt lesion histopathology, as well as increase the levels of peritoneal macrophages and the IP-10 (10 kDa interferon-gamma-induced protein) chemokine in a mouse model of endometriosis.	Hydroxychloroquine	24-27	chemokine (C-X-C motif) ligand 10	Mus musculus	158-215
27847636-0	2016	Expanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation.	Hydroxychloroquine	64-82	plexin A2	Homo sapiens	25-28
26876692-8	2016	Mean (SD, median, IQR) HCQ concentrations in the blood at V1 were 660 (314, 615, 424) ng/ml and increased to 1020 (632, 906, 781) ng/ml at V2 (mean difference 366 units, 95% confidence interval -472 to -260, p &lt; 0.001).	Hydroxychloroquine	23-26	nibrin	Homo sapiens	55-60
26311262-1	2016	PURPOSE: To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT).	Hydroxychloroquine	120-138	ATP binding cassette subfamily A member 4	Homo sapiens	66-71
26311262-1	2016	PURPOSE: To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT).	Hydroxychloroquine	140-143	ATP binding cassette subfamily A member 4	Homo sapiens	66-71
26432597-3	2016	Based on microarray, TNF and IL6 were among the most highly upregulated genes in both stimulated conditions, each of which was significantly inhibited by preincubation with hydroxychloroquine (HCQ).	Hydroxychloroquine	173-191	tumor necrosis factor	Homo sapiens	21-24
26432597-3	2016	Based on microarray, TNF and IL6 were among the most highly upregulated genes in both stimulated conditions, each of which was significantly inhibited by preincubation with hydroxychloroquine (HCQ).	Hydroxychloroquine	173-191	interleukin 6	Homo sapiens	29-32
26432597-3	2016	Based on microarray, TNF and IL6 were among the most highly upregulated genes in both stimulated conditions, each of which was significantly inhibited by preincubation with hydroxychloroquine (HCQ).	Hydroxychloroquine	193-196	tumor necrosis factor	Homo sapiens	21-24
26432597-3	2016	Based on microarray, TNF and IL6 were among the most highly upregulated genes in both stimulated conditions, each of which was significantly inhibited by preincubation with hydroxychloroquine (HCQ).	Hydroxychloroquine	193-196	interleukin 6	Homo sapiens	29-32
26432597-4	2016	In contrast, following stimulation of macrophages with either TNF-alpha or IFN-alpha, which do not signal through TLR, the resultant gene expression was refractory to HCQ.	Hydroxychloroquine	167-170	tumor necrosis factor	Homo sapiens	62-71
26432597-4	2016	In contrast, following stimulation of macrophages with either TNF-alpha or IFN-alpha, which do not signal through TLR, the resultant gene expression was refractory to HCQ.	Hydroxychloroquine	167-170	interferon alpha 1	Homo sapiens	75-84
26432597-6	2016	In summary, these results support that the HCQ-sensitive phenotype of hY3 stimulated macrophages reflects the bifurcation of TLR downstream signals involving NF-kappaB and STAT 1 pathways and for the former dimethylation of H3K4.	Hydroxychloroquine	43-46	RNA, Ro60-associated Y3	Homo sapiens	70-73
26432597-6	2016	In summary, these results support that the HCQ-sensitive phenotype of hY3 stimulated macrophages reflects the bifurcation of TLR downstream signals involving NF-kappaB and STAT 1 pathways and for the former dimethylation of H3K4.	Hydroxychloroquine	43-46	signal transducer and activator of transcription 1	Homo sapiens	172-178
26432597-7	2016	Accordingly, HCQ may act more as a preventive measure in downregulating the initial production of IFN-alpha or TNF-alpha and not affect the resultant autocoid stimulation reflected in TNF-alpha and IFN-alpha responsive genes.	Hydroxychloroquine	13-16	interferon alpha 1	Homo sapiens	98-107
26432597-7	2016	Accordingly, HCQ may act more as a preventive measure in downregulating the initial production of IFN-alpha or TNF-alpha and not affect the resultant autocoid stimulation reflected in TNF-alpha and IFN-alpha responsive genes.	Hydroxychloroquine	13-16	tumor necrosis factor	Homo sapiens	111-120
26429523-0	2016	Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2.	Hydroxychloroquine	16-34	solute carrier organic anion transporter family member 1A2	Homo sapiens	65-107
26429523-5	2016	Our data revealed that both CQ and HCQ potently inhibit the uptake activity of organic anion transporting polypeptide 1A2 (OATP1A2).	Hydroxychloroquine	35-38	solute carrier organic anion transporter family member 1A2	Homo sapiens	79-121
26429523-5	2016	Our data revealed that both CQ and HCQ potently inhibit the uptake activity of organic anion transporting polypeptide 1A2 (OATP1A2).	Hydroxychloroquine	35-38	solute carrier organic anion transporter family member 1A2	Homo sapiens	123-130
26429523-7	2016	In this study, we demonstrate that CQ and HCQ could markedly impair atROL uptake in OATP1A2-expressing HEK293 cells and more importantly, in primary human RPE cells.	Hydroxychloroquine	42-45	solute carrier organic anion transporter family member 1A2	Homo sapiens	84-91
26429523-8	2016	Our study shows that CQ and HCQ are novel inhibitors of OATP1A2 and significantly impair OATP1A2-mediated substrate uptake, particularly transport of atROL into the RPE.	Hydroxychloroquine	28-31	solute carrier organic anion transporter family member 1A2	Homo sapiens	56-63
26429523-8	2016	Our study shows that CQ and HCQ are novel inhibitors of OATP1A2 and significantly impair OATP1A2-mediated substrate uptake, particularly transport of atROL into the RPE.	Hydroxychloroquine	28-31	solute carrier organic anion transporter family member 1A2	Homo sapiens	89-96
26727968-10	2016	The fully adjusted Cox model showed a hazard ratio of 0.28 (95% CI 0.12-0.63, P=0.002) for incident CVD and 0.30 (95% CI 0.13-0.68, P=0.004) for incident composite coronary artery disease, stroke, and transient ischemic attack for hydroxychloroquine users versus nonusers, respectively.	Hydroxychloroquine	231-249	cytochrome c oxidase subunit 8A	Homo sapiens	19-22
26316040-0	2016	Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.	Hydroxychloroquine	63-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-51
26316040-5	2016	CYP2D6*10 polymorphisms (rs1065852 and rs1135840) were significantly associated with the [DHCQ]:[HCQ] ratio after adjustment for age, sex, dose per weight per day, and SLE Disease Activity Index score (P = 0.03 and P &lt; 0.01, respectively).	Hydroxychloroquine	91-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	142-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-6	2016	In adjusted models, the [DHCQ]:[HCQ] ratio was highest in patients with the G/G genotype of the CYP2D6*10 (rs1065852) polymorphism and lowest in those with the A/A genotype (P = 0.03).	Hydroxychloroquine	26-29	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	96-102
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	142-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
26316040-7	2016	Similarly, the [DHCQ]:[HCQ] ratio was highest in patients with the C/C genotype of the CYP2D6*10 (rs1135840) polymorphism and lowest in those with the G/G genotype (P &lt; 0.01).	Hydroxychloroquine	17-20	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79
26316040-10	2016	CONCLUSION: Our study showed that the [DHCQ]:[HCQ] ratio was related to CYP2D6 polymorphisms in Korean lupus patients taking oral HCQ.	Hydroxychloroquine	40-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	72-78
26316040-1	2016	OBJECTIVE: To evaluate associations of genetic polymorphisms in cytochrome P450 (CYP) isoforms 2D6, 3A5, and 3A4 with blood concentrations of hydroxychloroquine (HCQ) and its metabolite, N-desethyl HCQ (DHCQ), in patients with systemic lupus erythematosus (SLE).	Hydroxychloroquine	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
26316040-10	2016	CONCLUSION: Our study showed that the [DHCQ]:[HCQ] ratio was related to CYP2D6 polymorphisms in Korean lupus patients taking oral HCQ.	Hydroxychloroquine	46-49	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	72-78
26316040-11	2016	CYP polymorphisms may explain why there is wide variation in blood HCQ concentrations.	Hydroxychloroquine	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-3
26197707-0	2015	Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.	Hydroxychloroquine	28-46	insulin	Homo sapiens	50-57
26316040-12	2016	The role of an individual"s CYP polymorphisms should be considered when prescribing oral HCQ.	Hydroxychloroquine	89-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-31
26636577-0	2015	Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation.	Hydroxychloroquine	0-18	mitogen activated protein kinase 3	Rattus norvegicus	100-106
26636577-4	2015	It was found that HCQ was protective in neonatal rat cardiomyocytes through inhibition of apoptosis, measured by TUNEL and cleaved caspase-3.	Hydroxychloroquine	18-21	caspase 3	Rattus norvegicus	131-140
26636577-5	2015	This protection in vitro was mediated through enhancement of ERK1/2 phosphorylation mediated by HCQ in a dose-dependent fashion.	Hydroxychloroquine	96-99	mitogen activated protein kinase 3	Rattus norvegicus	61-67
26636577-6	2015	A decrease in infarct size was observed in an in vivo model of myocardial I/R injury in HCQ treated animals and furthermore this protection was blocked in the presence of the ERK1/2 inhibitor U0126.	Hydroxychloroquine	88-91	mitogen activated protein kinase 3	Rattus norvegicus	175-181
26636577-8	2015	Moreover, it was shown that HCQ is protective via enhanced phosphorylation of the pro-survival kinase ERK1/2.	Hydroxychloroquine	28-31	mitogen activated protein kinase 3	Rattus norvegicus	102-108
26344560-5	2015	RESULTS: HCQ pretreatment reduced the production of pro-inflammatory (TNF-alpha, IL-6, and IL-12) and anti-inflammatory (IL-10 and IL-1 receptor antagonist) cytokines in LPS-stimulated human microglia.	Hydroxychloroquine	9-12	tumor necrosis factor	Homo sapiens	70-79
26344560-5	2015	RESULTS: HCQ pretreatment reduced the production of pro-inflammatory (TNF-alpha, IL-6, and IL-12) and anti-inflammatory (IL-10 and IL-1 receptor antagonist) cytokines in LPS-stimulated human microglia.	Hydroxychloroquine	9-12	interleukin 6	Homo sapiens	81-85
26344560-5	2015	RESULTS: HCQ pretreatment reduced the production of pro-inflammatory (TNF-alpha, IL-6, and IL-12) and anti-inflammatory (IL-10 and IL-1 receptor antagonist) cytokines in LPS-stimulated human microglia.	Hydroxychloroquine	9-12	interleukin 10	Homo sapiens	121-126
26344560-5	2015	RESULTS: HCQ pretreatment reduced the production of pro-inflammatory (TNF-alpha, IL-6, and IL-12) and anti-inflammatory (IL-10 and IL-1 receptor antagonist) cytokines in LPS-stimulated human microglia.	Hydroxychloroquine	9-12	interleukin 1 receptor antagonist	Homo sapiens	131-155
26344560-6	2015	HCQ pretreatment delayed the onset of EAE, and reduced the number of Iba-1 positive microglia/macrophages and signs of demyelination in the spinal cords of HCQ treated animals.	Hydroxychloroquine	0-3	allograft inflammatory factor 1	Homo sapiens	69-74
26344560-6	2015	HCQ pretreatment delayed the onset of EAE, and reduced the number of Iba-1 positive microglia/macrophages and signs of demyelination in the spinal cords of HCQ treated animals.	Hydroxychloroquine	156-159	allograft inflammatory factor 1	Homo sapiens	69-74
26375670-11	2015	CONCLUSIONS: The results of reduced SUVmax without tumor volume reduction after two weeks of Rapa and HCQ treatment may indicate that non-proliferative glycolysis occurred mainly in the cancer associated fibroblast compartment, and decreased glycolytic activity was evident from Rapa + HCQ double autophagy modulator treatment.	Hydroxychloroquine	102-105	transcriptional regulating factor 1	Homo sapiens	279-283
26375670-11	2015	CONCLUSIONS: The results of reduced SUVmax without tumor volume reduction after two weeks of Rapa and HCQ treatment may indicate that non-proliferative glycolysis occurred mainly in the cancer associated fibroblast compartment, and decreased glycolytic activity was evident from Rapa + HCQ double autophagy modulator treatment.	Hydroxychloroquine	286-289	transcriptional regulating factor 1	Homo sapiens	93-97
26197707-4	2015	We hypothesised that HCQ may have favourable effects on insulin sensitivity and/or beta cell function.	Hydroxychloroquine	21-24	insulin	Homo sapiens	56-63
26197707-11	2015	RESULTS: There was a positive change in insulin sensitivity with HCQ but not placebo (mean +- SEM: +20.0% +- 7.1% vs -18.4% +- 7.9%, respectively; p &lt; 0.01; difference: 38.3% +- 10.6%; 95% CI: 17%, 60%).	Hydroxychloroquine	65-68	insulin	Homo sapiens	40-47
26197707-14	2015	In contrast, adiponectin levels increased after HCQ treatment but not after placebo (+18.7% vs +0.7%, respectively; p &lt; 0.001).	Hydroxychloroquine	48-51	adiponectin, C1Q and collagen domain containing	Homo sapiens	13-24
26197707-17	2015	CONCLUSIONS/INTERPRETATION: HCQ improves both beta cell function and insulin sensitivity in non-diabetic individuals.	Hydroxychloroquine	28-31	insulin	Homo sapiens	69-76
26197707-19	2015	An additional novel observation is that HCQ improves adiponectin levels, possibly being a mediator of the favourable effects on glucose metabolism.	Hydroxychloroquine	40-43	adiponectin, C1Q and collagen domain containing	Homo sapiens	53-64
25443193-6	2015	SD-OCT findings in the retina can identify hydroxychloroquine retinopathy in asymptomatic patients.	Hydroxychloroquine	43-61	plexin A2	Homo sapiens	3-6
26233237-3	2015	Here we report a child with a novel mutation in PRKCD gene who presented with CMV infection and an early onset SLE-like disorder which was successfully treated with hydroxychloroquine.	Hydroxychloroquine	165-183	protein kinase C delta	Homo sapiens	48-53
26082314-0	2015	15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes.	Hydroxychloroquine	56-74	carbonyl reductase 1	Homo sapiens	0-37
26082314-6	2015	The effect of the most popular DMARDs, hydroxychloroquine, on the expression of HPGD in RA-FLS was also investigated.	Hydroxychloroquine	39-57	carbonyl reductase 1	Homo sapiens	80-84
26082314-8	2015	In RA-FLS, the expression of HPGD was increased following treatment with several DMARDs, including sulfasalazine, methotrexate, and hydroxychloroquine.	Hydroxychloroquine	132-150	carbonyl reductase 1	Homo sapiens	29-33
26082314-9	2015	Hydroxychloroquine (10 microM) treatment induced the phosphorylation of ERK, SAPK/JNK and p38.	Hydroxychloroquine	0-18	mitogen-activated protein kinase 14	Homo sapiens	90-93
26082314-11	2015	Hydroxychloroquine may therefore, affect the pathogenesis of RA through the MAP kinase pathway by regulating the expression of HPGD.	Hydroxychloroquine	0-18	carbonyl reductase 1	Homo sapiens	127-131
26211587-4	2015	The extent of cell death and features of HCQ-induced autophagic markers including increase in microtubule-associated protein light chain 3 (LC3) I conversion to LC3-II, beclin-1, ATG5, as well as green fluorescent protein-LC3 positive puncta and autophagosome were remarkably greater in U937/AR cells.	Hydroxychloroquine	41-44	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	140-143
26211587-4	2015	The extent of cell death and features of HCQ-induced autophagic markers including increase in microtubule-associated protein light chain 3 (LC3) I conversion to LC3-II, beclin-1, ATG5, as well as green fluorescent protein-LC3 positive puncta and autophagosome were remarkably greater in U937/AR cells.	Hydroxychloroquine	41-44	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	161-164
26211587-4	2015	The extent of cell death and features of HCQ-induced autophagic markers including increase in microtubule-associated protein light chain 3 (LC3) I conversion to LC3-II, beclin-1, ATG5, as well as green fluorescent protein-LC3 positive puncta and autophagosome were remarkably greater in U937/AR cells.	Hydroxychloroquine	41-44	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	161-164
26211587-5	2015	Also, p62/SQSTM1 was increased in response to HCQ.	Hydroxychloroquine	46-49	sequestosome 1	Homo sapiens	6-9
26211587-5	2015	Also, p62/SQSTM1 was increased in response to HCQ.	Hydroxychloroquine	46-49	sequestosome 1	Homo sapiens	10-16
26211587-7	2015	Therefore, a reduction of p62/SQSTM1 indicates increased autophagic degradation, whereas an increase of p62/SQSTM1 by HCQ indicates inhibited autophagic degradation.	Hydroxychloroquine	118-121	sequestosome 1	Homo sapiens	104-107
26211587-7	2015	Therefore, a reduction of p62/SQSTM1 indicates increased autophagic degradation, whereas an increase of p62/SQSTM1 by HCQ indicates inhibited autophagic degradation.	Hydroxychloroquine	118-121	sequestosome 1	Homo sapiens	108-114
26211587-8	2015	Knock down of p62/SQSTM1 using siRNA were prevented the HCQ-induced LC3-II protein level as well as significantly reduced the HCQ-induced cell death in U937/AR cells.	Hydroxychloroquine	56-59	sequestosome 1	Homo sapiens	14-17
26211587-8	2015	Knock down of p62/SQSTM1 using siRNA were prevented the HCQ-induced LC3-II protein level as well as significantly reduced the HCQ-induced cell death in U937/AR cells.	Hydroxychloroquine	56-59	sequestosome 1	Homo sapiens	18-24
26211587-8	2015	Knock down of p62/SQSTM1 using siRNA were prevented the HCQ-induced LC3-II protein level as well as significantly reduced the HCQ-induced cell death in U937/AR cells.	Hydroxychloroquine	56-59	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	68-71
26211587-8	2015	Knock down of p62/SQSTM1 using siRNA were prevented the HCQ-induced LC3-II protein level as well as significantly reduced the HCQ-induced cell death in U937/AR cells.	Hydroxychloroquine	126-129	sequestosome 1	Homo sapiens	14-17
26211587-8	2015	Knock down of p62/SQSTM1 using siRNA were prevented the HCQ-induced LC3-II protein level as well as significantly reduced the HCQ-induced cell death in U937/AR cells.	Hydroxychloroquine	126-129	sequestosome 1	Homo sapiens	18-24
25752684-5	2015	CQ and HCQ significantly increased ARPE-19 monolayer permeability after 3 and 18 h, respectively, and enhanced mRNA levels for claudin-1 and occludin.	Hydroxychloroquine	7-10	claudin 1	Homo sapiens	127-136
25752684-5	2015	CQ and HCQ significantly increased ARPE-19 monolayer permeability after 3 and 18 h, respectively, and enhanced mRNA levels for claudin-1 and occludin.	Hydroxychloroquine	7-10	occludin	Homo sapiens	141-149
25890187-7	2015	RESULTS: In the longitudinal study, IgG anti-apoA-1 levels were significantly higher in patients with persistently active disease, those on high dose corticosteroid and those not taking hydroxychloroquine.	Hydroxychloroquine	186-204	apolipoprotein A1	Homo sapiens	45-51
25366134-0	2015	Disseminated Primary Cutaneous CD8+ Small/Medium-sized Pleomorphic T-cell Lymphoma Responding to Hydroxychloroquine.	Hydroxychloroquine	97-115	CD8a molecule	Homo sapiens	31-34
25913441-4	2015	RESULTS: There was a significant correlation (P&lt;0.05) between cumulative HCQ dose and positive results on SD-OCT and 10.2 visual field.	Hydroxychloroquine	76-79	plexin A2	Homo sapiens	112-115
25913441-12	2015	CONCLUSION: The significant correlation between cumulative HCQ dose, considered as the main risk factor for maculopathy, and positive SD-OCT and 10.2 visual field results render the combination of these two tests the basis of the screening strategy for plaquenil maculopathy.	Hydroxychloroquine	59-62	plexin A2	Homo sapiens	137-140
25913441-12	2015	CONCLUSION: The significant correlation between cumulative HCQ dose, considered as the main risk factor for maculopathy, and positive SD-OCT and 10.2 visual field results render the combination of these two tests the basis of the screening strategy for plaquenil maculopathy.	Hydroxychloroquine	253-262	plexin A2	Homo sapiens	137-140
26125760-5	2015	Flow cytometry was applied to detect changes in apoptosis of RPMI8226/DOX cells (stained with annexin-V/propidium iodide) caused by inhibition by hydroxychloroquine and 3-methyladenine on autophagy.	Hydroxychloroquine	146-164	annexin A5	Homo sapiens	94-103
25556310-3	2015	In preliminary studies, hydroxychloroquine, which has multiple anti-inflammatory properties, preserved vascular compliance for the aorta and major vessels, as well as reduced the extent of severity of atherosclerosis in ApoE-/- mice.	Hydroxychloroquine	24-42	apolipoprotein E	Mus musculus	220-224
25890187-11	2015	However, levels of IgG anti-apoA-1 vary over time and are associated with disease activity, treatment with high dose corticosteroid and not taking hydroxychloroquine.	Hydroxychloroquine	147-165	apolipoprotein A1	Homo sapiens	28-34
24347114-10	2014	Furthermore, treatment with hydroxychloroquine should be considered in children with SFTPC mutations.	Hydroxychloroquine	28-46	surfactant protein C	Homo sapiens	85-90
25635992-8	2015	AQP-5 mRNA expression level of the model group was lower than other groups (p &lt; 0.05); the expression levels in the TGP group and the combination group were higher than the hydroxychloroquine group (p &lt; 0.05).	Hydroxychloroquine	176-194	aquaporin 5	Mus musculus	0-5
25339775-6	2015	In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity.	Hydroxychloroquine	38-56	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	125-129
25339775-6	2015	In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity.	Hydroxychloroquine	58-61	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	125-129
25187658-3	2014	Using high-throughput screening, we identified certain statins and antimalarial agents including chloroquine, hydroxychloroquine, and quinacrine as strong ERK5 activators.	Hydroxychloroquine	110-128	mitogen-activated protein kinase 7	Mus musculus	155-159
25187658-5	2014	Chloroquine and hydroxychloroquine upregulated ERK5 kinase activity and inhibited VCAM-1 expression in an ERK5-dependent but MAPK/ERK kinase 5- and Kruppel-like factor 2/4-independent manner.	Hydroxychloroquine	16-34	mitogen-activated protein kinase 7	Mus musculus	47-51
25187658-5	2014	Chloroquine and hydroxychloroquine upregulated ERK5 kinase activity and inhibited VCAM-1 expression in an ERK5-dependent but MAPK/ERK kinase 5- and Kruppel-like factor 2/4-independent manner.	Hydroxychloroquine	16-34	vascular cell adhesion molecule 1	Mus musculus	82-88
25187658-5	2014	Chloroquine and hydroxychloroquine upregulated ERK5 kinase activity and inhibited VCAM-1 expression in an ERK5-dependent but MAPK/ERK kinase 5- and Kruppel-like factor 2/4-independent manner.	Hydroxychloroquine	16-34	mitogen-activated protein kinase 7	Mus musculus	106-110
24470436-2	2014	We examined the effect of HCQ on insulin resistance in subjects without diabetes mellitus with stable RA.	Hydroxychloroquine	26-29	insulin	Homo sapiens	33-40
24928945-11	2014	Consistent with these observations, TAM+HCQ treatment increased tumor CD68(+) cells infiltration, whereas ICI and ICI+HCQ reduced peripheral tumor macrophage content.	Hydroxychloroquine	40-43	CD68 antigen	Mus musculus	70-74
24842914-10	2014	Vascular reactive oxygen species content and mRNA levels of nicotinamide adenine dinucleotide phosphate oxidase subunits NOX-1 and p47(phox) were increased in lupus mice and reduced by hydroxychloroquine or antioxidants.	Hydroxychloroquine	185-203	NADPH oxidase 1	Mus musculus	121-126
24842914-10	2014	Vascular reactive oxygen species content and mRNA levels of nicotinamide adenine dinucleotide phosphate oxidase subunits NOX-1 and p47(phox) were increased in lupus mice and reduced by hydroxychloroquine or antioxidants.	Hydroxychloroquine	185-203	NSFL1 (p97) cofactor (p47)	Mus musculus	131-134
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Hydroxychloroquine	175-193	interleukin 22	Homo sapiens	25-30
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Hydroxychloroquine	175-193	interleukin 22	Homo sapiens	80-85
24635166-5	2014	The frequencies of Th22, IL-22(+) Th17 and Th17 cells and the concentrations of IL-22 and IL-17 were reduced in response to the drugs methylprednisolone, cyclophosphamide and hydroxychloroquine for 4 weeks in the majority of SLE patients.	Hydroxychloroquine	175-193	interleukin 17A	Homo sapiens	90-95
24342772-7	2014	Our data also confirm an earlier report that this same mechanism may explain inhibition of TLR7 and 9 signaling by hydroxychloroquine (Plaquenil; Sanofi-Aventis, Bridgewater, NJ), a drug commonly prescribed to treat lupus.	Hydroxychloroquine	115-133	toll-like receptor 7	Mus musculus	91-95
23831963-9	2014	Interestingly, patients on hydroxychloroquine showed reduced MxA levels (EIA, p=0.04; FACS p=0.001).	Hydroxychloroquine	27-45	MX dynamin like GTPase 1	Homo sapiens	61-64
23831963-11	2014	MxA levels associate with features of active disease and are reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA in stratifying patients according to IFN positivity.	Hydroxychloroquine	72-90	MX dynamin like GTPase 1	Homo sapiens	0-3
23831963-11	2014	MxA levels associate with features of active disease and are reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA in stratifying patients according to IFN positivity.	Hydroxychloroquine	72-90	MX dynamin like GTPase 1	Homo sapiens	150-153
24656088-11	2014	HCQ treatment induced the same effect and decreased TLR4 mRNA (40% and 35%, respectively) and protein expressions (62% and 42%, respectively) in BeWo cells.	Hydroxychloroquine	0-3	toll like receptor 4	Homo sapiens	52-56
24855048-3	2014	By blocking the toll-like receptor 7 and 9 in plasmacytoid dendritic cells, HCQ inhibits interferon-alpha production which plays a crucial role in SLE pathogenesis.	Hydroxychloroquine	76-79	toll like receptor 7	Homo sapiens	16-42
24944668-8	2014	The results demonstrated that HCQ increased the expressions of LC3 mRNA and LC3II protein and GFP-LC3 signalling but reduced the expression of p62/STSQM1 in cervical cancer SiHa cells.	Hydroxychloroquine	30-33	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	63-66
24944668-8	2014	The results demonstrated that HCQ increased the expressions of LC3 mRNA and LC3II protein and GFP-LC3 signalling but reduced the expression of p62/STSQM1 in cervical cancer SiHa cells.	Hydroxychloroquine	30-33	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	76-79
24944668-8	2014	The results demonstrated that HCQ increased the expressions of LC3 mRNA and LC3II protein and GFP-LC3 signalling but reduced the expression of p62/STSQM1 in cervical cancer SiHa cells.	Hydroxychloroquine	30-33	sequestosome 1	Homo sapiens	143-146
24342772-7	2014	Our data also confirm an earlier report that this same mechanism may explain inhibition of TLR7 and 9 signaling by hydroxychloroquine (Plaquenil; Sanofi-Aventis, Bridgewater, NJ), a drug commonly prescribed to treat lupus.	Hydroxychloroquine	135-144	toll-like receptor 7	Mus musculus	91-95
24305049-9	2013	In this regard, we also show that treatment of mice with the autophagy inhibitor hydroxychloroquine, which is currently being used in several clinical trials, significantly accelerates tumour formation in mice containing oncogenic Kras but lacking p53.	Hydroxychloroquine	81-99	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	231-235
24325143-8	2014	aPL-induced inhibition of trophoblast migration was partially reversed by HCQ, even though HCQ significantly increased secretion of pro-migratory IL-6 to greater than baseline.	Hydroxychloroquine	91-94	interleukin 6	Homo sapiens	146-150
24325143-10	2014	CONCLUSION: Hydroxychloroquine reversed the aPL-inhibition of trophoblast IL-6 secretion and partially limited aPL-inhibition of cell migration.	Hydroxychloroquine	12-30	interleukin 6	Homo sapiens	74-78
24313261-6	2014	After treatment with prednisone and hydroxychloroquine, the levels of plasma IL-22 in new-onset SLE patients were obviously increased but still lower than healthy controls.	Hydroxychloroquine	36-54	interleukin 22	Homo sapiens	77-82
24460726-0	2014	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.	Hydroxychloroquine	134-152	C-C motif chemokine ligand 2	Homo sapiens	18-22
24460726-0	2014	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.	Hydroxychloroquine	134-152	C-X-C motif chemokine ligand 10	Homo sapiens	27-33
24305049-9	2013	In this regard, we also show that treatment of mice with the autophagy inhibitor hydroxychloroquine, which is currently being used in several clinical trials, significantly accelerates tumour formation in mice containing oncogenic Kras but lacking p53.	Hydroxychloroquine	81-99	transformation related protein 53, pseudogene	Mus musculus	248-251
23850938-0	2013	Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn and LC-MS-TOF studies.	Hydroxychloroquine	58-76	moesin	Homo sapiens	97-100
24121037-3	2013	B cell, PBMC, and urinary miR-let-7a expression were decreased with HCQ or PRED treatment.	Hydroxychloroquine	68-71	microRNA 615	Mus musculus	26-29
24121037-4	2013	HCQ or PRED treatment reduced miR-21 expression in mesangial cells, T cells, pDCs, PBMCs, and the urine.	Hydroxychloroquine	0-3	microRNA 21a	Mus musculus	30-36
24121037-5	2013	MiR-146a expression was reduced in mesangial cells with HCQ treatment and in pDCs with HCQ or PRED treatment.	Hydroxychloroquine	56-59	microRNA 146	Mus musculus	0-8
24121037-5	2013	MiR-146a expression was reduced in mesangial cells with HCQ treatment and in pDCs with HCQ or PRED treatment.	Hydroxychloroquine	87-90	microRNA 146	Mus musculus	0-8
24791507-7	2013	The expression level of FasL of the normal group was much lower than that in the hydroxychloroquine group (P &lt; 0.05).	Hydroxychloroquine	81-99	Fas ligand (TNF superfamily, member 6)	Mus musculus	24-28
24791507-11	2013	CONCLUSION: The nourishing Yin, strengthening Qi and activating blood decoction could down-regulate the expression level of Fas/FasL in salivary glands of NOD mice with Sjogren"s syndrome and their mRNA expression, and had a better efficacy after being combined with hydroxychloroquine.	Hydroxychloroquine	267-285	Fas ligand (TNF superfamily, member 6)	Mus musculus	128-132
23926286-6	2013	Administration of hydroxychloroquine (an inhibitor of pro-TGF-B processing) at the preimplantation stage was able to block the liberation of biologically active TGF-B1 from its latent complex at the postimplantation stage; as a consequence, the number of implantation sites was reduced at Day 5 (1000 h), as was the number of fetuses at Day 13.	Hydroxychloroquine	18-36	transforming growth factor, beta 1	Mus musculus	58-63
23926286-6	2013	Administration of hydroxychloroquine (an inhibitor of pro-TGF-B processing) at the preimplantation stage was able to block the liberation of biologically active TGF-B1 from its latent complex at the postimplantation stage; as a consequence, the number of implantation sites was reduced at Day 5 (1000 h), as was the number of fetuses at Day 13.	Hydroxychloroquine	18-36	transforming growth factor, beta 1	Mus musculus	161-167
23940455-0	2013	Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats.	Hydroxychloroquine	20-38	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
23711386-4	2013	Many commonly used DMARDs (e.g. methotrexate, sulfasalazine, leflunomide/teriflunomide, hydroxychloroquine) are ABCG2 substrates.	Hydroxychloroquine	88-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	112-117
23541328-0	2013	Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells.	Hydroxychloroquine	0-18	protein tyrosine phosphatase receptor type C	Homo sapiens	55-59
24098639-0	2013	New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.	Hydroxychloroquine	95-113	keratin 20	Homo sapiens	126-130
24098639-3	2013	In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody.	Hydroxychloroquine	96-114	keratin 20	Homo sapiens	197-201
24098639-8	2013	In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab.	Hydroxychloroquine	84-102	keratin 20	Homo sapiens	53-57
24098639-9	2013	These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.	Hydroxychloroquine	78-96	keratin 20	Homo sapiens	50-54
24448858-0	2013	[Effects of hydroxychloroquine on insulin sensitivity and lipid profile in patients with rheumatoid arthritis].	Hydroxychloroquine	12-30	insulin	Homo sapiens	34-41
23681079-3	2013	Recently, we have reported that immunohistochemistry for autophagic markers LC3 and p62 can replace electron microscopy in the diagnosis of HCQ-induced and colchicine-induced autophagic vacuolar skeletal myopathies.	Hydroxychloroquine	140-143	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	76-79
23681079-3	2013	Recently, we have reported that immunohistochemistry for autophagic markers LC3 and p62 can replace electron microscopy in the diagnosis of HCQ-induced and colchicine-induced autophagic vacuolar skeletal myopathies.	Hydroxychloroquine	140-143	nucleoporin 62	Homo sapiens	84-87
23778483-7	2013	RESULTS: We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and IL-22 supernatant levels after adding hydroxychloroquine.	Hydroxychloroquine	258-276	interleukin 6	Homo sapiens	204-208
23778483-8	2013	CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.	Hydroxychloroquine	51-69	interleukin 6	Homo sapiens	79-83
23778483-8	2013	CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.	Hydroxychloroquine	51-69	interleukin 17A	Homo sapiens	85-90
23778483-8	2013	CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.	Hydroxychloroquine	51-69	interleukin 22	Homo sapiens	95-100
23719253-0	2013	Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine.	Hydroxychloroquine	118-136	surfactant protein C	Homo sapiens	71-91
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	21-39	ATM serine/threonine kinase	Rattus norvegicus	336-339
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	21-39	AKT serine/threonine kinase 1	Rattus norvegicus	366-369
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	21-39	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	393-396
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	41-44	ATM serine/threonine kinase	Rattus norvegicus	336-339
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	41-44	AKT serine/threonine kinase 1	Rattus norvegicus	366-369
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	41-44	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	393-396
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	311-314	ATM serine/threonine kinase	Rattus norvegicus	50-79
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	311-314	ATM serine/threonine kinase	Rattus norvegicus	81-84
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	311-314	ATM serine/threonine kinase	Rattus norvegicus	336-339
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	311-314	AKT serine/threonine kinase 1	Rattus norvegicus	366-369
23940455-1	2013	BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.	Hydroxychloroquine	311-314	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	393-396
23940455-2	2013	OBJECTIVE: To explore the effects of low-dose HCQ on the expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium in a rat model.	Hydroxychloroquine	46-49	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
23940455-2	2013	OBJECTIVE: To explore the effects of low-dose HCQ on the expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium in a rat model.	Hydroxychloroquine	46-49	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	94-97
23940455-0	2013	Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats.	Hydroxychloroquine	20-38	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	79-82
23878841-0	2013	Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren"s syndrome.	Hydroxychloroquine	64-82	TNF superfamily member 13b	Homo sapiens	19-43
23940455-10	2013	CONCLUSION: Low-dose HCQ can significantly increase the expression of phosphorylated Akt protein without significantly impacting expression of phosphorylated p53 protein in the peri-infarct myocardium.	Hydroxychloroquine	21-24	AKT serine/threonine kinase 1	Rattus norvegicus	85-88
23668020-10	2013	IL-1beta in serum in the TCM group and the TCM WM group were lower than that of the hydroxychloroquine group (P &lt; 0.05), but without statistical significance compared with the normal group.	Hydroxychloroquine	84-102	interleukin 1 beta	Mus musculus	0-8
23668020-11	2013	TNF-alpha protein expression in the TCM group and the TCM WM group showed no significant difference compared with the normal group, whereas the TCM WM group were notably lower than that of the hydroxychloroquine group (P &lt; 0.05).	Hydroxychloroquine	193-211	tumor necrosis factor	Mus musculus	0-9
23577025-4	2013	The lysosomal modulator Bafilomycin A1 (Baf) rescued dog cells from cytotoxicity caused by 3 phospholipogenic 5HT1b antagonists and hydroxychloroquine, but not fluoxetine, and rescued rat cells from hydroxychloroquine and NMTMB, a 5HT1b antagonist.	Hydroxychloroquine	132-150	BAF nuclear assembly factor 1	Rattus norvegicus	24-27
23577025-4	2013	The lysosomal modulator Bafilomycin A1 (Baf) rescued dog cells from cytotoxicity caused by 3 phospholipogenic 5HT1b antagonists and hydroxychloroquine, but not fluoxetine, and rescued rat cells from hydroxychloroquine and NMTMB, a 5HT1b antagonist.	Hydroxychloroquine	199-217	BAF nuclear assembly factor 1	Rattus norvegicus	24-27
22820788-9	2012	Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/muL vs -23 cells/muL at week 48; difference, -62 cells/muL; 95% CI, -115 to -8; P = .03).	Hydroxychloroquine	45-63	tripartite motif containing 37	Homo sapiens	94-97
21309955-10	2012	NACP-Rep1 allele lengths correlated positively with HCQ total scores averaged across all time points (r = 0.420; P = 0.006) as well as with post-DAM HCQ total scores in the morning (r = 0.488, P = 0.001) and afternoon (r = 0.423, P = 0.005).	Hydroxychloroquine	52-55	synuclein alpha	Homo sapiens	0-4
21309955-10	2012	NACP-Rep1 allele lengths correlated positively with HCQ total scores averaged across all time points (r = 0.420; P = 0.006) as well as with post-DAM HCQ total scores in the morning (r = 0.488, P = 0.001) and afternoon (r = 0.423, P = 0.005).	Hydroxychloroquine	52-55	CHM Rab escort protein	Homo sapiens	5-9
21309955-10	2012	NACP-Rep1 allele lengths correlated positively with HCQ total scores averaged across all time points (r = 0.420; P = 0.006) as well as with post-DAM HCQ total scores in the morning (r = 0.488, P = 0.001) and afternoon (r = 0.423, P = 0.005).	Hydroxychloroquine	149-152	synuclein alpha	Homo sapiens	0-4
21309955-10	2012	NACP-Rep1 allele lengths correlated positively with HCQ total scores averaged across all time points (r = 0.420; P = 0.006) as well as with post-DAM HCQ total scores in the morning (r = 0.488, P = 0.001) and afternoon (r = 0.423, P = 0.005).	Hydroxychloroquine	149-152	CHM Rab escort protein	Homo sapiens	5-9
22879389-12	2012	Accordingly, selective triple knockdown of the autophagy genes ATG7, ATG5 and ATG3, and pretreatment with the autophagy inhibitor hydroxychloroquine, efficiently overcame the resistance to Akt/mTOR inhibitors, leading to the activation of the mitochondrial apoptotic pathway.	Hydroxychloroquine	130-148	autophagy related 7	Homo sapiens	63-67
22879389-12	2012	Accordingly, selective triple knockdown of the autophagy genes ATG7, ATG5 and ATG3, and pretreatment with the autophagy inhibitor hydroxychloroquine, efficiently overcame the resistance to Akt/mTOR inhibitors, leading to the activation of the mitochondrial apoptotic pathway.	Hydroxychloroquine	130-148	AKT serine/threonine kinase 1	Homo sapiens	189-192
22879389-12	2012	Accordingly, selective triple knockdown of the autophagy genes ATG7, ATG5 and ATG3, and pretreatment with the autophagy inhibitor hydroxychloroquine, efficiently overcame the resistance to Akt/mTOR inhibitors, leading to the activation of the mitochondrial apoptotic pathway.	Hydroxychloroquine	130-148	mechanistic target of rapamycin kinase	Homo sapiens	193-197
22820788-9	2012	Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/muL vs -23 cells/muL at week 48; difference, -62 cells/muL; 95% CI, -115 to -8; P = .03).	Hydroxychloroquine	45-63	tripartite motif containing 37	Homo sapiens	111-114
22820788-9	2012	Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/muL vs -23 cells/muL at week 48; difference, -62 cells/muL; 95% CI, -115 to -8; P = .03).	Hydroxychloroquine	45-63	tripartite motif containing 37	Homo sapiens	111-114
22343096-9	2012	Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p = 0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-alpha (p = 0.0087).	Hydroxychloroquine	0-18	signaling lymphocytic activation molecule family member 1	Homo sapiens	65-69
22626746-0	2012	Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.	Hydroxychloroquine	16-34	tripartite motif containing 21	Homo sapiens	87-90
22626746-1	2012	BACKGROUND: A recent case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac manifestations of neonatal lupus (cardiac-NL) in pregnancies of anti-SSA/Ro-positive patients with systemic lupus erythematosus.	Hydroxychloroquine	63-81	tripartite motif containing 21	Homo sapiens	189-192
22626746-1	2012	BACKGROUND: A recent case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac manifestations of neonatal lupus (cardiac-NL) in pregnancies of anti-SSA/Ro-positive patients with systemic lupus erythematosus.	Hydroxychloroquine	83-86	tripartite motif containing 21	Homo sapiens	189-192
22626746-7	2012	In a multivariable analysis that adjusted for database source, maternal race/ethnicity, and anti-SSB/La status, HCQ use remained significantly associated with a decreased risk of cardiac-NL (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; P=0.037).	Hydroxychloroquine	112-115	small RNA binding exonuclease protection factor La	Homo sapiens	97-100
22343096-9	2012	Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p = 0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-alpha (p = 0.0087).	Hydroxychloroquine	0-18	interferon alpha 2	Homo sapiens	191-200
22343096-9	2012	Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p = 0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-alpha (p = 0.0087).	Hydroxychloroquine	126-144	signaling lymphocytic activation molecule family member 1	Homo sapiens	113-117
22343096-9	2012	Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p = 0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-alpha (p = 0.0087).	Hydroxychloroquine	126-144	interferon alpha 2	Homo sapiens	191-200
22734582-0	2012	Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus.	Hydroxychloroquine	0-18	tumor necrosis factor	Homo sapiens	47-95
22343096-10	2012	CONCLUSIONS: Hydroxychloroquine therapy resulted in significant clinical improvement in SLE patients, which strongly correlated with reductions in IFN-alpha levels.	Hydroxychloroquine	13-31	interferon alpha 2	Homo sapiens	147-156
22734582-3	2012	METHODS: Peripheral blood mononuclear cells (PBMCs) from SLE subjects treated or not with HCQ and from healthy controls were stimulated with the TLR-9 agonist, CpG oligodeoxynucleotides (CpG-A ODN)-2216, and the TLR-7 agonist, imiquimod.	Hydroxychloroquine	90-93	toll like receptor 9	Homo sapiens	145-150
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	toll like receptor 9	Homo sapiens	90-95
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	interferon alpha 1	Homo sapiens	96-105
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	toll like receptor 7	Homo sapiens	128-133
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	interferon alpha 1	Homo sapiens	134-143
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	toll like receptor 9	Homo sapiens	164-169
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	tumor necrosis factor	Homo sapiens	170-179
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	toll like receptor 7	Homo sapiens	204-209
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	60-63	tumor necrosis factor	Homo sapiens	210-219
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 9	Homo sapiens	90-95
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	interferon alpha 1	Homo sapiens	96-105
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 7	Homo sapiens	128-133
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	interferon alpha 1	Homo sapiens	134-143
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 9	Homo sapiens	164-169
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	tumor necrosis factor	Homo sapiens	170-179
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 7	Homo sapiens	204-209
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	tumor necrosis factor	Homo sapiens	210-219
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 9	Homo sapiens	90-95
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	interferon alpha 1	Homo sapiens	96-105
22676348-0	2012	Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals.	Hydroxychloroquine	0-18	insulin	Homo sapiens	28-35
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 7	Homo sapiens	128-133
22676348-10	2012	CONCLUSION: HCQ use for 6 weeks in non diabetic obese subjects was associated with a significant increase in ISI and trends toward reduced insulin resistance and insulin secretion.	Hydroxychloroquine	12-15	insulin	Homo sapiens	139-146
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	interferon alpha 1	Homo sapiens	134-143
22676348-11	2012	These data suggest that HCQ, a common medication used to treat RA, possesses beneficial effects upon insulin sensitization.	Hydroxychloroquine	24-27	insulin	Homo sapiens	101-108
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 9	Homo sapiens	164-169
22676348-12	2012	Further study of the insulin sensitizing effects of HCQ in patients with RA is warranted.	Hydroxychloroquine	52-55	insulin	Homo sapiens	21-28
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	tumor necrosis factor	Homo sapiens	170-179
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	toll like receptor 7	Homo sapiens	204-209
22734582-8	2012	In almost all cases, these subjects were being treated with HCQ (HCQ vs. no HCQ: impaired TLR-9/IFN-alpha, P = 0.0003; impaired TLR-7/IFN-alpha, P = 0.07; impaired TLR-9/TNF-alpha, P &lt; 0.009; impaired TLR-7/TNF-alpha, P &lt; 0.01).	Hydroxychloroquine	65-68	tumor necrosis factor	Homo sapiens	210-219
22734582-9	2012	CONCLUSIONS: Treatment with HCQ is associated with impaired ability of pDCs from subjects with SLE to produce IFN-alpha and TNF-alpha upon stimulation with TLR-9 and TLR-7 agonists.	Hydroxychloroquine	28-31	interferon alpha 1	Homo sapiens	110-119
22734582-9	2012	CONCLUSIONS: Treatment with HCQ is associated with impaired ability of pDCs from subjects with SLE to produce IFN-alpha and TNF-alpha upon stimulation with TLR-9 and TLR-7 agonists.	Hydroxychloroquine	28-31	tumor necrosis factor	Homo sapiens	124-133
22734582-9	2012	CONCLUSIONS: Treatment with HCQ is associated with impaired ability of pDCs from subjects with SLE to produce IFN-alpha and TNF-alpha upon stimulation with TLR-9 and TLR-7 agonists.	Hydroxychloroquine	28-31	toll like receptor 9	Homo sapiens	156-161
22734582-9	2012	CONCLUSIONS: Treatment with HCQ is associated with impaired ability of pDCs from subjects with SLE to produce IFN-alpha and TNF-alpha upon stimulation with TLR-9 and TLR-7 agonists.	Hydroxychloroquine	28-31	toll like receptor 7	Homo sapiens	166-171
22319600-8	2012	Historically safe in humans, chloroquine and hydroxychloroquine appear to be promising agents to safely and effectively target CXCR4 in patients with pancreatic cancer.	Hydroxychloroquine	45-63	C-X-C motif chemokine receptor 4	Homo sapiens	127-132
22513098-11	2012	Independent explanatory variables associated with down-regulation of TLR7 level included HPV infection and a higher cumulative dose of prednisolone; while a higher cumulative dose of hydroxychloroquine and HPV infection were associated with down-regulation of TLR9 level.	Hydroxychloroquine	183-201	toll like receptor 9	Homo sapiens	260-264
22513098-14	2012	CONCLUSIONS: In conclusion, prednisolone and TLR antagonist (hydroxychloroquine) may down-regulate protein levels of TLR7 and TLR9 in lupus patients, thereby decreasing the innate immune response against HPV infection.	Hydroxychloroquine	61-79	toll like receptor 7	Homo sapiens	117-121
22513098-14	2012	CONCLUSIONS: In conclusion, prednisolone and TLR antagonist (hydroxychloroquine) may down-regulate protein levels of TLR7 and TLR9 in lupus patients, thereby decreasing the innate immune response against HPV infection.	Hydroxychloroquine	61-79	toll like receptor 9	Homo sapiens	126-130
22159170-13	2012	Hydroxychloroquine causes early parafoveal loss of the outer segment lines on SD-OCT, with the first changes often evident in the inferotemporal quadrant.	Hydroxychloroquine	0-18	plexin A2	Homo sapiens	81-84
21161534-10	2012	Incidence of ADR-related DMARD withdrawal was maximum with leflunomide 2/15 (13.33%) followed by methotrexate 9/116 (7.76%), sulphasalazine 6/185 (3.24%), chloroquine 3/131 (2.29%) and hydroxychloroquine 8/444 (1.8%).	Hydroxychloroquine	185-203	aldo-keto reductase family 1 member B	Homo sapiens	13-16
21871597-0	2011	Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.	Hydroxychloroquine	0-18	annexin A5	Homo sapiens	103-113
21871597-2	2011	We recently showed that the antimalarial drug, hydroxychloroquine, dissociates antiphospholipid immune complexes and restores annexin A5 binding to planar phospholipid bilayer.	Hydroxychloroquine	47-65	annexin A5	Homo sapiens	126-136
21871597-6	2011	RESULTS: Hydroxychloroquine reversed the effects of the antiphospholipid antibodies on the syncytiotrophoblasts by markedly reducing immunoglobulin-G binding and restoring annexin A5 expression.	Hydroxychloroquine	9-27	annexin A5	Homo sapiens	172-182
21757995-6	2011	Hydroxychloroquine (CQ), an anti-malarial agent that increases autophagosomal number, significantly increased the punctate LC3-GFP spectral signature, providing proof-of-principle for this approach.	Hydroxychloroquine	0-18	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	123-126
21576701-3	2011	Hydroxychloroquine (HCQ) reduces endosomal TLR signaling; thus, we verified whether HCQ could dampen immune activation and be associated with an increase in CD4(+) T cells.	Hydroxychloroquine	0-18	CD4 molecule	Homo sapiens	157-160
21576701-3	2011	Hydroxychloroquine (HCQ) reduces endosomal TLR signaling; thus, we verified whether HCQ could dampen immune activation and be associated with an increase in CD4(+) T cells.	Hydroxychloroquine	20-23	CD4 molecule	Homo sapiens	157-160
21576701-3	2011	Hydroxychloroquine (HCQ) reduces endosomal TLR signaling; thus, we verified whether HCQ could dampen immune activation and be associated with an increase in CD4(+) T cells.	Hydroxychloroquine	84-87	CD4 molecule	Homo sapiens	157-160
21576701-6	2011	HCQ-induced immune modulation was associated with increased percentages of circulating CD4(+) T cells and was mostly retained 2 months after therapy interruption.	Hydroxychloroquine	0-3	CD4 molecule	Homo sapiens	87-90
20309693-10	2011	The results of this study suggest that HCQ may alleviate symptoms and signs of dry eye in pSS and decreases tear fluid BAFF levels.	Hydroxychloroquine	39-42	TNF superfamily member 13b	Homo sapiens	119-123
20447951-0	2010	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.	Hydroxychloroquine	173-191	small RNA binding exonuclease protection factor La	Homo sapiens	38-41
21640055-6	2011	Hydroxychloroquine treatment correlated negatively with total cholesterol (r=-0.4867, p=0.0002), LDL-C (r=-0.4805, p=0.0002) and apolipoprotein B (r=-0.4443, p=0.0011).	Hydroxychloroquine	0-18	component of oligomeric golgi complex 2	Homo sapiens	97-102
21640055-6	2011	Hydroxychloroquine treatment correlated negatively with total cholesterol (r=-0.4867, p=0.0002), LDL-C (r=-0.4805, p=0.0002) and apolipoprotein B (r=-0.4443, p=0.0011).	Hydroxychloroquine	0-18	apolipoprotein B	Homo sapiens	129-145
21640055-7	2011	In multivariate analysis LDL-C correlated with cumulative prednisone dose and negatively with hydroxychloroquine treatment (R2=0.40, p&lt;0.001).	Hydroxychloroquine	94-112	component of oligomeric golgi complex 2	Homo sapiens	25-30
21092132-5	2010	Exposure of SP-CI73T cells to drugs currently used empirically in ILD therapy, cyclophosphamide, azathioprine, hydroxychloroquine or methylprednisolone, enhanced expression of the chaperones HSP90, HSP70, calreticulin and calnexin.	Hydroxychloroquine	111-129	heat shock protein 90 alpha family class A member 1	Homo sapiens	191-196
21281071-1	2011	We report a case of orbital sarcoidosis with extraocular muscle and orbital fat involvement that did not respond to oral corticosteroid treatment, but was successfully treated with oral hydroxychloroquine.	Hydroxychloroquine	186-204	FAT atypical cadherin 1	Homo sapiens	76-79
21060664-5	2010	RESULTS: Five patients were found to have SD OCT findings corresponding to HCQ toxicity and retinal damage as seen by clinical exam and/or HVF perimetry.	Hydroxychloroquine	75-78	plexin A2	Homo sapiens	45-48
21060664-9	2010	CONCLUSION: Outer retinal abnormalities including perifoveal photoreceptor IS/OS junction disruption can be identified by SD OCT in early HCQ toxicity, sometimes even before ophthalmoscopic fundus changes are apparent.	Hydroxychloroquine	138-141	plexin A2	Homo sapiens	125-128
20447951-1	2010	BACKGROUND: Based on the potential involvement of Toll-like receptor (TLR) signalling in the pathogenesis of neonatal lupus (NL), it was hypothesised that fetal exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-SSA/Ro/SSB/La antibody-associated cardiac manifestations of NL (cardiac-NL).	Hydroxychloroquine	173-191	small RNA binding exonuclease protection factor La	Homo sapiens	253-256
20447951-1	2010	BACKGROUND: Based on the potential involvement of Toll-like receptor (TLR) signalling in the pathogenesis of neonatal lupus (NL), it was hypothesised that fetal exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-SSA/Ro/SSB/La antibody-associated cardiac manifestations of NL (cardiac-NL).	Hydroxychloroquine	193-196	small RNA binding exonuclease protection factor La	Homo sapiens	253-256
20447951-7	2010	CONCLUSION: This case-control study suggests that, in mothers with SLE with anti-SSA/Ro/SSB/La antibodies, exposure to HCQ during pregnancy may decrease the risk of fetal development of cardiac-NL.	Hydroxychloroquine	119-122	small RNA binding exonuclease protection factor La	Homo sapiens	88-91
20353989-4	2010	Recently, we reported that hydroxychloroquine, a synthetic antimalarial drug, can reverse this antibody-mediated process through two mechanisms: (1) by inhibiting the formation of aPL IgG-beta2glycoprotein I complexes; and (2) by promoting the formation of a second layer of AnxA5 crystal "patches" over areas where the immune complexes had disrupted AnxA5 crystallization.	Hydroxychloroquine	27-45	annexin A5	Homo sapiens	275-280
20140691-7	2010	It is noticeable that serum IL-18 levels in the patients treated with glucocorticoids and cyclophosphamide was lower than those treated with glucocorticoids only or glucocorticoids and other immune inhibitors such as chloroquine/hydroxychloroquine and azathioprine.	Hydroxychloroquine	229-247	interleukin 18	Homo sapiens	28-33
20099229-1	2010	PURPOSE: To report fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT) findings in a patient with early hydroxychloroquine maculopathy.	Hydroxychloroquine	140-158	plexin A2	Homo sapiens	102-105
20099229-8	2010	CONCLUSIONS: Findings on SD-OCT and FAF imaging support the histopathologic findings described in cases of hydroxychloroquine maculopathy.	Hydroxychloroquine	107-125	plexin A2	Homo sapiens	28-31
20436082-1	2010	OBJECTIVE: To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).	Hydroxychloroquine	57-75	insulin	Homo sapiens	144-151
20353989-4	2010	Recently, we reported that hydroxychloroquine, a synthetic antimalarial drug, can reverse this antibody-mediated process through two mechanisms: (1) by inhibiting the formation of aPL IgG-beta2glycoprotein I complexes; and (2) by promoting the formation of a second layer of AnxA5 crystal "patches" over areas where the immune complexes had disrupted AnxA5 crystallization.	Hydroxychloroquine	27-45	annexin A5	Homo sapiens	351-356
18758509-6	2008	The alkalinizing lysosomotropic drugs chloroquine, hydroxychloroquine, amodiaquine, and azithromycin had a similar effect on the overall production of mature bioactive TGFbeta.	Hydroxychloroquine	51-69	transforming growth factor beta 1	Homo sapiens	168-175
19749781-6	2009	These observations are supported by the demonstration that HCQ upregulates Beclin-1, a key regulator of autophagy.	Hydroxychloroquine	59-62	beclin 1	Homo sapiens	75-83
19073155-9	2009	However, co-treatment of K562 cells with CQ or HCQ in the presence of inhibitors of sGC-PKG-pathways reduced Hb F stimulation, suggesting the possible involvement of the sGC-PKG pathway.	Hydroxychloroquine	47-50	sarcoglycan beta	Homo sapiens	170-173
19073155-9	2009	However, co-treatment of K562 cells with CQ or HCQ in the presence of inhibitors of sGC-PKG-pathways reduced Hb F stimulation, suggesting the possible involvement of the sGC-PKG pathway.	Hydroxychloroquine	47-50	protein kinase cGMP-dependent 1	Homo sapiens	174-177
18577708-0	2008	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.	Hydroxychloroquine	0-18	apolipoprotein H	Homo sapiens	77-97
18577708-3	2008	We therefore used the techniques of ellipsometry and atomic force microscopy (AFM) to investigate whether HCQ directly affects the formation of aPL IgG-beta2GPI complexes on phospholipid bilayers.	Hydroxychloroquine	106-109	apolipoprotein H	Homo sapiens	152-160
18577708-4	2008	HCQ, at concentrations of 1 mug/mL and greater, significantly reduced the binding of aPL-beta2GPI complexes to phospholipid surfaces and THP-1 (human acute monocytic leukemia cell line) monocytes.	Hydroxychloroquine	0-3	apolipoprotein H	Homo sapiens	89-97
18577708-4	2008	HCQ, at concentrations of 1 mug/mL and greater, significantly reduced the binding of aPL-beta2GPI complexes to phospholipid surfaces and THP-1 (human acute monocytic leukemia cell line) monocytes.	Hydroxychloroquine	0-3	GLI family zinc finger 2	Homo sapiens	137-142
18577708-8	2008	In conclusion, HCQ reduces the formation of aPL-beta2GPI complexes to phospholipid bilayers and cells.	Hydroxychloroquine	15-18	apolipoprotein H	Homo sapiens	48-56
19965621-0	2010	Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.	Hydroxychloroquine	0-18	annexin A5	Homo sapiens	32-42
19965621-8	2010	HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5 binding to PLBs, an effect corroborated by atomic force microscopy.	Hydroxychloroquine	0-3	annexin A5	Homo sapiens	58-63
19965621-8	2010	HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5 binding to PLBs, an effect corroborated by atomic force microscopy.	Hydroxychloroquine	0-3	annexin A5	Homo sapiens	77-82
19965621-9	2010	Similar reversals of antiphospholipid-induced abnormalities were measured on the surfaces of human umbilical vein endothelial cells and syncytialized trophoblast cell lines, wherein HCQ reduced the binding of antiphospholipid antibodies, increased cell-surface AnxA5 concentrations, and prolonged plasma coagulation to control levels.	Hydroxychloroquine	182-185	annexin A5	Homo sapiens	261-266
19965621-10	2010	In addition, HCQ increased the AnxA5 anticoagulant activities of APS patient plasmas.	Hydroxychloroquine	13-16	annexin A5	Homo sapiens	31-36
19965621-11	2010	In conclusion, HCQ reversed antiphospholipid-mediated disruptions of AnxA5 on PLBs and cultured cells, and in APS patient plasmas.	Hydroxychloroquine	15-18	annexin A5	Homo sapiens	69-74
19373270-1	2010	PURPOSE: To evaluate peripapillary retinal nerve fibre layer (RNFL) thickness and macular inner and outer retinal thickness using spectral domain optical coherence tomography (Sd-OCT) in patients with chronic exposure to hydroxychloroquine or chloroquine.	Hydroxychloroquine	221-239	plexin A2	Homo sapiens	179-182
20126479-3	2009	RESULTS: SD-OCT images demonstrated loss of photoreceptor inner segment/outer segment (IS/OS) junction and a downward "sink-hole" displacement of inner retinal structures in areas of hydroxychloroquine toxicity corresponding to HVF 10-2 defects and ophthalmoscopic clinical examination findings.	Hydroxychloroquine	183-201	plexin A2	Homo sapiens	12-15
20126479-7	2009	CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.	Hydroxychloroquine	109-127	plexin A2	Homo sapiens	16-19
19357706-5	2009	The antiproliferative effect of HCQ was associated with decreased activation of the extracellular signal-regulated kinases 1/2 but not with inhibition of the mammalian target of the rapamycin pathway or with dephosphorylation of Akt.	Hydroxychloroquine	32-35	mitogen-activated protein kinase 3	Homo sapiens	84-126
19357706-9	2009	Induction of autophagic cell death by HCQ was also paralleled by increased expression of Beclin-1, a key regulator of autophagy.	Hydroxychloroquine	38-41	beclin 1	Homo sapiens	89-97
19584707-6	2009	Growth inhibitory concentrations of HCQ and ATRA stimulated purified p300/CBP-associated factor, where CBP is the cAMP-response element binding protein, HAT activity.	Hydroxychloroquine	36-39	E1A binding protein p300	Homo sapiens	69-73
19584707-6	2009	Growth inhibitory concentrations of HCQ and ATRA stimulated purified p300/CBP-associated factor, where CBP is the cAMP-response element binding protein, HAT activity.	Hydroxychloroquine	36-39	CREB binding protein	Homo sapiens	74-77
19584707-6	2009	Growth inhibitory concentrations of HCQ and ATRA stimulated purified p300/CBP-associated factor, where CBP is the cAMP-response element binding protein, HAT activity.	Hydroxychloroquine	36-39	CREB binding protein	Homo sapiens	103-106
19433433-9	2009	A subanalysis revealed that particularly the alpha-fodrin-positive patients responded to HCQ (P = 0.017 alpha-fodrin positive vs P = 0.4 alpha-fodrin negative).	Hydroxychloroquine	89-92	spectrin alpha, non-erythrocytic 1	Homo sapiens	45-57
19433433-9	2009	A subanalysis revealed that particularly the alpha-fodrin-positive patients responded to HCQ (P = 0.017 alpha-fodrin positive vs P = 0.4 alpha-fodrin negative).	Hydroxychloroquine	89-92	spectrin alpha, non-erythrocytic 1	Homo sapiens	104-116
19433433-9	2009	A subanalysis revealed that particularly the alpha-fodrin-positive patients responded to HCQ (P = 0.017 alpha-fodrin positive vs P = 0.4 alpha-fodrin negative).	Hydroxychloroquine	89-92	spectrin alpha, non-erythrocytic 1	Homo sapiens	104-116
18555940-4	2008	CASE SUMMARIES: The first case involved a 36-year-old woman with a 10-year history of rheumatoid arthritis and Sjogren"s syndrome who had begun a 25-day course of HCQ 100 mg BID due to lack of response to a corticosteroid, with a skin reaction developing 21 days into the new treatment.	Hydroxychloroquine	163-166	BH3 interacting domain death agonist	Homo sapiens	174-177
18555940-5	2008	In the second case, a 70-year-old man with poorly controlled rheumatoid arthritis had begun a course of oral HCQ 100 mg BID 20 days before development of AGEP.	Hydroxychloroquine	109-112	BH3 interacting domain death agonist	Homo sapiens	120-123
18555940-6	2008	The final case involved a 79-year-old woman with polymyalgia rheumatica who had been receiving HCQ 100 mg BID as a steroid-sparing agent for 22 days, with rash developing 20 days after the initiation of HCQ.	Hydroxychloroquine	95-98	BH3 interacting domain death agonist	Homo sapiens	106-109
17574068-4	2007	Multifocal ERG may detect macular dysfunction earlier than the currently recommended screening guidelines in patients with potential for macular toxicity from hydroxychloroquine.	Hydroxychloroquine	159-177	ETS transcription factor ERG	Homo sapiens	11-14
18324764-0	2008	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Hydroxychloroquine	186-204	glycogen synthase kinase 3 beta	Homo sapiens	117-147
18078614-1	2007	OBJECTIVE: To study interleukin (IL)-1beta levels in recent onset RA patients treated either with combination DMARD therapy (sulfasalazine, methotrexate, hydroxychloroquine) or a single DMARD therapy.	Hydroxychloroquine	154-172	interleukin 1 beta	Homo sapiens	20-42
18220957-4	2007	TLR7/9 antagonists, such as the anti-malaria drugs chloroquine, hydroxychloroquine and quinacrine, have been used since the 1950s to treat immune-mediated inflammatory disorders (IMID) such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjogren"s syndrome.	Hydroxychloroquine	64-82	toll like receptor 7	Homo sapiens	0-4
16734620-6	2006	The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation.	Hydroxychloroquine	42-45	caspase 3	Homo sapiens	66-75
17893969-0	2007	Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.	Hydroxychloroquine	24-42	protein tyrosine phosphatase receptor type C	Homo sapiens	115-119
17893969-0	2007	Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.	Hydroxychloroquine	155-173	protein tyrosine phosphatase receptor type C	Homo sapiens	115-119
16964632-3	2006	A 47-year-old woman diagnosed with HLA B27 ankylosing spondylitis was treated with HXQ for 22 days and had to discontinue the drug due to gastric intolerance.	Hydroxychloroquine	83-86	major histocompatibility complex, class I, B	Homo sapiens	35-40
16734620-7	2006	A combined treatment of HCQ and anti-Fas mAb increased FLS apoptosis and caspase-3 activity synergistically, compared with either anti-Fas mAb or HCQ alone.	Hydroxychloroquine	24-27	caspase 3	Homo sapiens	73-82
16734620-10	2006	Taken together, HCQ increases the apoptosis of rheumatoid synoviocytes by activating caspase-3, and also sensitizes rheumatoid synoviocytes to Fas-mediated apoptosis.	Hydroxychloroquine	16-19	caspase 3	Homo sapiens	85-94
16393772-3	2005	RESULTS: Aurothiomalate, hydroxychloroquine, methotrexate and leflunomide inhibited IL-1beta-induced inducible NO synthase (iNOS) expression and NO production in immortalized H4 chondrocytes, while penicillamine and sulfasalazine had no effect.	Hydroxychloroquine	25-43	interleukin 1 beta	Homo sapiens	84-92
16722594-11	2006	Hydroxychloroquine and non-steroidal anti-inflammatory drugs are used for milder disease; corticosteroids and immunosuppressive therapies are generally reserved for major organ involvement; anti-CD20 monoclonal antibody is now used in patients with severe disease who has not responded to conventional treatments.	Hydroxychloroquine	0-18	keratin 20	Homo sapiens	195-199
16844666-3	2006	Co-administration of hydroxychloroquine (HCQ) was used to redirect the secretion of human growth hormone (hGH) from saliva into serum.	Hydroxychloroquine	21-39	growth hormone 1	Homo sapiens	90-104
16844666-3	2006	Co-administration of hydroxychloroquine (HCQ) was used to redirect the secretion of human growth hormone (hGH) from saliva into serum.	Hydroxychloroquine	41-44	growth hormone 1	Homo sapiens	90-104
16393772-3	2005	RESULTS: Aurothiomalate, hydroxychloroquine, methotrexate and leflunomide inhibited IL-1beta-induced inducible NO synthase (iNOS) expression and NO production in immortalized H4 chondrocytes, while penicillamine and sulfasalazine had no effect.	Hydroxychloroquine	25-43	nitric oxide synthase 2	Homo sapiens	101-122
16393772-3	2005	RESULTS: Aurothiomalate, hydroxychloroquine, methotrexate and leflunomide inhibited IL-1beta-induced inducible NO synthase (iNOS) expression and NO production in immortalized H4 chondrocytes, while penicillamine and sulfasalazine had no effect.	Hydroxychloroquine	25-43	nitric oxide synthase 2	Homo sapiens	124-128
16393772-5	2005	Aurothiomalate and hydroxychloroquine also inhibited IL-1beta-induced NO production in OA cartilage whereas methotrexate and leflunomide had no effect.	Hydroxychloroquine	19-37	interleukin 1 beta	Homo sapiens	53-61
16393772-6	2005	CONCLUSION: Aurothiomalate and hydroxychloroquine suppressed IL-1beta-induced NO production in chondrocyte cultures and in OA cartilage.	Hydroxychloroquine	31-49	interleukin 1 beta	Homo sapiens	61-69
12813466-2	2003	Here, we show that HCQ induces signs of lysosomal membrane permeabilization (LMP), such as the decrease in the lysosomal pH gradient and the release of cathepsin B from the lysosomal lumen, followed by signs of apoptosis including caspase activation, phosphatidylserine exposure, and chromatin condensation with DNA loss.	Hydroxychloroquine	19-22	cathepsin B	Mus musculus	152-163
16130848-7	2005	Immune modification using local steroids and disease-modifying antirheumatic drugs, such as hydroxychloroquine, are known to inhibit inflammatory cells and cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor, which are responsible for pain and tissue damage.	Hydroxychloroquine	92-110	interleukin 1 alpha	Homo sapiens	175-188
16130848-7	2005	Immune modification using local steroids and disease-modifying antirheumatic drugs, such as hydroxychloroquine, are known to inhibit inflammatory cells and cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor, which are responsible for pain and tissue damage.	Hydroxychloroquine	92-110	interleukin 6	Homo sapiens	190-203
16142732-3	2005	TLR-3 signaling was assessed by incubating RASFs with poly(I-C), lipopolysaccharide, palmitoyl-3-cysteine-serine-lysine-4, or necrotic synovial fluid cells from RA patients in the presence or absence of hydroxychloroquine or Benzonase.	Hydroxychloroquine	203-221	toll like receptor 3	Homo sapiens	0-5
14963695-0	2005	The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2.	Hydroxychloroquine	30-48	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	73-78
14963695-0	2005	The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2.	Hydroxychloroquine	30-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	83-88
15590764-0	2005	Hydroxychloroquine therapy in patients with primary Sjogren"s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.	Hydroxychloroquine	0-18	butyrylcholinesterase	Homo sapiens	138-152
15590764-1	2005	OBJECTIVE: To determine whether (i) cholinesterase activity is increased in the saliva of patients with primary Sjogren"s syndrome (pSS), (ii) increased levels of cholinesterase of lymphocyte origin could interfere with the secretory activity of submandibular acinar cells, and (iii) hydroxychloroquine at therapeutic doses could interfere with cholinesterase activity.	Hydroxychloroquine	284-302	butyrylcholinesterase	Homo sapiens	163-177
15590764-1	2005	OBJECTIVE: To determine whether (i) cholinesterase activity is increased in the saliva of patients with primary Sjogren"s syndrome (pSS), (ii) increased levels of cholinesterase of lymphocyte origin could interfere with the secretory activity of submandibular acinar cells, and (iii) hydroxychloroquine at therapeutic doses could interfere with cholinesterase activity.	Hydroxychloroquine	284-302	butyrylcholinesterase	Homo sapiens	163-177
15590764-2	2005	METHODS: The Ellman method was used to determine the levels of salivary cholinesterase activity and the K(i) of both chloroquine and hydroxychloroquine for serum cholinesterase.	Hydroxychloroquine	133-151	butyrylcholinesterase	Homo sapiens	162-176
15590764-6	2005	The in vitro K(i) for hydroxychloroquine inhibition of cholinesterase was 0.38 +/- 1.4 microM.	Hydroxychloroquine	22-40	butyrylcholinesterase	Homo sapiens	55-69
15590764-7	2005	CONCLUSION: These data suggest that increased levels of cholinesterase present in the salivary glands of patients with pSS may contribute to glandular hypofunction and provide evidence that the therapeutic enhancement of salivary secretion in patients with pSS by hydroxychloroquine may be mediated by inhibition of glandular cholinesterase activity, although further in vivo investigation is needed.	Hydroxychloroquine	264-282	butyrylcholinesterase	Homo sapiens	56-70
15507280-2	2004	A recent study showed a significant increase in the expression of GPIIb/IIIa on platelets treated with aPL antibodies and a thrombin receptor peptide agonist (TRAP), and these effects were abrogated by hydroxychloroquine (HQ).	Hydroxychloroquine	202-220	integrin alpha 2b	Mus musculus	66-71
12813466-3	2003	HCQ also induces mitochondrial membrane permeabilization (MMP), as indicated by the insertion of Bax into mitochondrial membranes, the conformational activation of Bax within mitochondria, the release of cytochrome c from mitochondria, and the loss of the mitochondrial transmembrane potential.	Hydroxychloroquine	0-3	BCL2-associated X protein	Mus musculus	97-100
12813466-3	2003	HCQ also induces mitochondrial membrane permeabilization (MMP), as indicated by the insertion of Bax into mitochondrial membranes, the conformational activation of Bax within mitochondria, the release of cytochrome c from mitochondria, and the loss of the mitochondrial transmembrane potential.	Hydroxychloroquine	0-3	BCL2-associated X protein	Mus musculus	164-167
12813466-6	2003	Mouse embryonic fibroblasts lacking the expression of both Bax and Bak are resistant against hydroxychloroquine-induced apoptosis.	Hydroxychloroquine	93-111	BCL2-associated X protein	Mus musculus	59-62
14989426-5	2002	Antimalarials (hydroxychloroquine and chloroquine) have been found to increase the monocyte production of IL-1Ra and these changes might explain at least some of their mechanisms of action.	Hydroxychloroquine	15-33	interleukin 1 receptor antagonist	Homo sapiens	106-112
12352275-4	2002	After 8 weeks of double-blind treatment, there was no significant interaction between treatment status and length of treatment for positive, negative, or general symptoms according to the Positive and Negative Syndrome Scale, despite a hydroxychloroquine-associated decrease in serum interferon-gamma levels.	Hydroxychloroquine	236-254	interferon gamma	Homo sapiens	284-300
11849318-8	2002	Other weak-base amines, including hydroxychloroquine, ammonium chloride and methylamine, also induced reduction of cell surface TNF receptors, whereas lysosomal proteinase inhibitor, leupeptin, and BB-3013 were without effect.	Hydroxychloroquine	34-52	tumor necrosis factor	Homo sapiens	128-131
12020529-2	2002	We treated 22 patients who were infected with HIV-1 (viral load &lt; 100000 copies/mL and CD4 count &gt;150 cells/microL) with hydroxychloroquine (200 mg), hydroxycarbamide (hydroxyurea) (500 mg), and didanosine (125-200 mg), taken twice daily.	Hydroxychloroquine	127-145	CD4 molecule	Homo sapiens	90-93
12148891-0	2002	Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.	Hydroxychloroquine	0-18	caspase 3	Homo sapiens	92-101
12148891-0	2002	Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.	Hydroxychloroquine	0-18	BCL2 apoptosis regulator	Homo sapiens	120-125
12148891-0	2002	Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.	Hydroxychloroquine	0-18	BCL2 associated X, apoptosis regulator	Homo sapiens	126-129
12148891-6	2002	HCQ had marked selective cytotoxicity when compared with normal blood mononuclear cells, in which the LC50 was &gt;100 microg/ml at 24 h. HCQ induced the proteolytic cleavage of poly(ADP(adenosine 5"-diphosphate)ribose) polymerase (PARP) and increased the activity of caspase-3.	Hydroxychloroquine	0-3	poly(ADP-ribose) polymerase 1	Homo sapiens	232-236
12148891-6	2002	HCQ had marked selective cytotoxicity when compared with normal blood mononuclear cells, in which the LC50 was &gt;100 microg/ml at 24 h. HCQ induced the proteolytic cleavage of poly(ADP(adenosine 5"-diphosphate)ribose) polymerase (PARP) and increased the activity of caspase-3.	Hydroxychloroquine	0-3	caspase 3	Homo sapiens	268-277
12148891-6	2002	HCQ had marked selective cytotoxicity when compared with normal blood mononuclear cells, in which the LC50 was &gt;100 microg/ml at 24 h. HCQ induced the proteolytic cleavage of poly(ADP(adenosine 5"-diphosphate)ribose) polymerase (PARP) and increased the activity of caspase-3.	Hydroxychloroquine	138-141	poly(ADP-ribose) polymerase 1	Homo sapiens	232-236
12148891-6	2002	HCQ had marked selective cytotoxicity when compared with normal blood mononuclear cells, in which the LC50 was &gt;100 microg/ml at 24 h. HCQ induced the proteolytic cleavage of poly(ADP(adenosine 5"-diphosphate)ribose) polymerase (PARP) and increased the activity of caspase-3.	Hydroxychloroquine	138-141	caspase 3	Homo sapiens	268-277
11440626-0	2001	Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo.	Hydroxychloroquine	0-18	gonadotropin releasing hormone receptor	Rattus norvegicus	75-89
11384574-0	2001	Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?	Hydroxychloroquine	106-124	ATP binding cassette subfamily A member 4	Homo sapiens	16-20
11384574-0	2001	Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?	Hydroxychloroquine	106-124	ATP binding cassette subfamily A member 4	Homo sapiens	22-27
11384574-1	2001	PURPOSE: To determine if mutations in ABCR (ABCA4) are associated with chloroquine/hydroxychloroquine retinopathy.	Hydroxychloroquine	83-101	ATP binding cassette subfamily A member 4	Homo sapiens	38-42
11384574-1	2001	PURPOSE: To determine if mutations in ABCR (ABCA4) are associated with chloroquine/hydroxychloroquine retinopathy.	Hydroxychloroquine	83-101	ATP binding cassette subfamily A member 4	Homo sapiens	44-49
11384574-10	2001	CONCLUSIONS: Some individuals who have ABCR mutations may be predisposed to develop retinal toxicity when exposed to chloroquine/hydroxychloroquine.	Hydroxychloroquine	129-147	ATP binding cassette subfamily A member 4	Homo sapiens	39-43
11167827-0	2001	Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors.	Hydroxychloroquine	73-91	caspase 3	Homo sapiens	107-116
11359853-7	2001	Moreover, we found that Tet- and Tripterygium wilfordii hook F-induced T cell DNA damage required caspase-3 activity, and hydroxychloroquine-induced T cell DNA damage was mediated through a caspase-3- and caspase-8-independent, but Z-Asp-Glu-Val-Asp-fluomethyl ketone-sensitive, signaling pathway.	Hydroxychloroquine	122-140	caspase 3	Homo sapiens	190-199
11167827-5	2001	The apoptosis was associated with caspase-3 activation because the cleavage and activity of caspase-3 were increased by HCQ.	Hydroxychloroquine	120-123	caspase 3	Homo sapiens	34-43
11167827-5	2001	The apoptosis was associated with caspase-3 activation because the cleavage and activity of caspase-3 were increased by HCQ.	Hydroxychloroquine	120-123	caspase 3	Homo sapiens	92-101
10848718-7	2000	While the DM-MR values were not significantly changed, the phenotypic classification of one individual, who was heterozygous for a mutant CYP2D6 allele, was converted to a poor metabolizer by HCQ administration.	Hydroxychloroquine	192-195	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	138-144
11166661-8	2001	Because CQ and HCQ appear to have a novel site of action (i.e. post-transcriptional inhibition of gp120), these drugs may be particularly useful in combination with other anti-retroviral agents (e.g. ZDV, ddI and HU).	Hydroxychloroquine	15-18	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	98-103
10828029-4	2000	In a concentration-dependent manner, HCQ inhibited anti-TCR-induced up-regulation of CD69 expression, a distal TCR signaling event.	Hydroxychloroquine	37-40	CD69 molecule	Homo sapiens	85-89
10848718-8	2000	CONCLUSIONS: HCQ inhibits metoprolol metabolism most probably by inhibiting its biotransformation by CYP2D6.	Hydroxychloroquine	13-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	101-107
10364906-5	1999	RESULTS: After hydroxychloroquine treatment, salivary IL6 concentrations decreased from 13.2 (1.2) to 7.3 (1.1) pg/ml (mean (SEM)) (p &lt; 0.0001).	Hydroxychloroquine	15-33	interleukin 6	Homo sapiens	54-57
11227493-6	2000	In contrast, apoptosis induced by hydroxychloroquine (HCQ) in HL-60 cells was caspase-3 independent and was fully inhibited by ATA.	Hydroxychloroquine	34-52	caspase 3	Homo sapiens	78-87
11227493-6	2000	In contrast, apoptosis induced by hydroxychloroquine (HCQ) in HL-60 cells was caspase-3 independent and was fully inhibited by ATA.	Hydroxychloroquine	54-57	caspase 3	Homo sapiens	78-87
9918262-5	1999	Hydroxychloroquine has been reported to reduce insulin requirements in refractory type II diabetes by an average of 30%.	Hydroxychloroquine	0-18	insulin	Homo sapiens	47-54
9918262-6	1999	When hydroxychloroquine is initiated for the treatment of polyarthritis in a type II diabetic requiring insulin or sulfonylurea treatment, blood glucose levels should be monitored closely and the insulin dose may need to be reduced.	Hydroxychloroquine	5-23	insulin	Homo sapiens	104-111
9381529-4	1997	RESULTS: We found that similar concentrations of chloroquine and hydroxychloroquine suppress the T-cell response to MiHC in mice (C57BL/6 anti-BALB.B) and that lysosomotropic amines in combination with cyclosporine result in synergistic suppression of a proliferative response to MiHC.	Hydroxychloroquine	65-83	baculoviral IAP repeat-containing 3	Mus musculus	116-120
9779838-11	1998	CONCLUSION: During treatment with either CyA or CyA plus hydroxychloroquine, IL-10 levels decreased significantly.	Hydroxychloroquine	57-75	interleukin 10	Homo sapiens	77-82
9723661-0	1998	Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma.	Hydroxychloroquine	0-18	immunoglobulin heavy constant epsilon	Homo sapiens	59-62
9662754-12	1998	In such cases, coadministration of a remittive agent such as HCQ may enable reinstitution of IFN therapy without recurrence of arthritis.	Hydroxychloroquine	61-64	interferon alpha 1	Homo sapiens	93-96
9416907-7	1997	CONCLUSIONS: Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.	Hydroxychloroquine	13-31	immunoglobulin heavy variable V1-62	Mus musculus	146-149
9002011-0	1997	Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.	Hydroxychloroquine	16-34	tumor necrosis factor	Homo sapiens	50-77
9385480-2	1997	An initial randomized, placebo-controlled clinical trial conducted in 38 asymptomatic HIV-1-infected patients who had CD4+ counts between 200 and 500 cells/mm3 demonstrated that the amount of recoverable virus declined significantly in the HCQ group compared with the placebo group over the 8-week study period.	Hydroxychloroquine	240-243	CD4 molecule	Homo sapiens	118-121
9385480-8	1997	Interleukin-6 and serum immunoglobulin G levels were significantly reduced in the HCQ group but not in the ZDV group.	Hydroxychloroquine	82-85	interleukin 6	Homo sapiens	0-13
9352417-10	1997	HCQS showed a concentration-dependent inhibition of TGase activity.	Hydroxychloroquine	0-4	transglutaminase 1	Homo sapiens	52-57
9352417-11	1997	CONCLUSIONS: We suggest that HCQS causes an initial break in the barrier function of the epidermis by inhibiting TGase activity; this is followed by a physiologic response of the epidermis aimed at barrier restoration.	Hydroxychloroquine	29-33	transglutaminase 1	Homo sapiens	113-118
9195122-0	1997	Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD.	Hydroxychloroquine	43-61	CCAL1	Homo sapiens	75-79
9002011-7	1997	RESULTS: We observed that chloroquine and hydroxychloroquine equally inhibit PHA induced TNF-alpha and IFN-gamma production, and LPS induced TNF-alpha and IL-6 production, while PHA induced IL-6 production was not affected.	Hydroxychloroquine	42-60	tumor necrosis factor	Homo sapiens	89-98
9002011-7	1997	RESULTS: We observed that chloroquine and hydroxychloroquine equally inhibit PHA induced TNF-alpha and IFN-gamma production, and LPS induced TNF-alpha and IL-6 production, while PHA induced IL-6 production was not affected.	Hydroxychloroquine	42-60	interferon gamma	Homo sapiens	103-112
9002011-7	1997	RESULTS: We observed that chloroquine and hydroxychloroquine equally inhibit PHA induced TNF-alpha and IFN-gamma production, and LPS induced TNF-alpha and IL-6 production, while PHA induced IL-6 production was not affected.	Hydroxychloroquine	42-60	interleukin 6	Homo sapiens	190-194
9002011-0	1997	Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.	Hydroxychloroquine	16-34	interleukin 6	Homo sapiens	79-92
9002011-0	1997	Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.	Hydroxychloroquine	16-34	interferon gamma	Homo sapiens	98-114
9001825-1	1996	We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes.	Hydroxychloroquine	118-136	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	208-224
9156650-2	1997	In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and major histocompatibility (MHC) antigens.	Hydroxychloroquine	53-71	major histocompatibility complex, class I, C	Homo sapiens	149-152
9001825-2	1996	The mechanism of inhibition of gp 120 production was presumed to be the ability of HCQ to increase endosomal pH and therefore alter enzymes required for gp120 production.	Hydroxychloroquine	83-86	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	31-37
9001825-1	1996	We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes.	Hydroxychloroquine	118-136	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	226-232
9001825-2	1996	The mechanism of inhibition of gp 120 production was presumed to be the ability of HCQ to increase endosomal pH and therefore alter enzymes required for gp120 production.	Hydroxychloroquine	83-86	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	153-158
9001825-4	1996	Pretreatment of cells with HCQ and the levo- and dextro-enantiomers at concentrations demonstrated to suppress anti-HIV-1 activity increased endosomal pH to levels similar to increases seen with chloroquine and ammonium chloride, two other weak bases, and decreased gp 120 production.	Hydroxychloroquine	27-30	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	266-272
9001825-1	1996	We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes.	Hydroxychloroquine	138-141	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	208-224
9001825-1	1996	We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes.	Hydroxychloroquine	138-141	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	226-232
8807116-5	1996	We have demonstrated that HCQ causes a dose-dependent reduction of the cytotoxicity, proliferation, and TNF alpha production resulting from allorecognition in mixed lymphocyte culture (MLC).	Hydroxychloroquine	26-29	tumor necrosis factor	Homo sapiens	104-113
8807116-9	1996	HCQ"s ability to reduce the cytotoxicity, proliferation, and TNF alpha production resulting from allorecognition suggests that it may be useful in the prevention and treatment of graft-versus-host disease (GVHD).	Hydroxychloroquine	0-3	tumor necrosis factor	Homo sapiens	61-70
33802811-10	2021	HCQ apparent blood clearance (CL/F) was dependent on patients" bodyweight and platelet count.	Hydroxychloroquine	0-3	crooked neck pre-mRNA splicing factor 1	Homo sapiens	30-34
8565026-10	1995	Lastly, serum interleukin 6 levels declined in the HCQ group (14.3 +/- 13.5 U/mL vs 12.0 +/- 16.7 U/mL; P = 0.023) but not in the placebo group (11.3 +/- 8.8 U/mL vs 7.0 +/- 11.7 U/mL); this was coincident with a decrease in serum immunoglobulin (Ig)G (2563 +/- 1352 mg/mL vs 2307 +/- 1372 mg/dL; P = 0.032), compared with the placebo group (2733 +/- 1473 mg/dL vs 2709 +/- 1501 mg/dL).	Hydroxychloroquine	51-54	interleukin 6	Homo sapiens	14-27
8336306-0	1993	Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.	Hydroxychloroquine	46-64	interleukin 1 alpha	Homo sapiens	80-99
8336306-0	1993	Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.	Hydroxychloroquine	46-64	interleukin 1 alpha	Homo sapiens	101-111
8336306-0	1993	Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.	Hydroxychloroquine	46-64	interleukin 6	Homo sapiens	117-121
8336306-3	1993	Hydroxychloroquine inhibited production of IL-1-alpha (monocytes) and IL-6 (T cells and monocytes).	Hydroxychloroquine	0-18	interleukin 1 alpha	Homo sapiens	43-53
8336306-3	1993	Hydroxychloroquine inhibited production of IL-1-alpha (monocytes) and IL-6 (T cells and monocytes).	Hydroxychloroquine	0-18	interleukin 6	Homo sapiens	70-74
8485565-7	1993	Serum levels of CD8 and sIL-2R decrease after 6 weeks of hydroxychloroquine treatment.	Hydroxychloroquine	57-75	CD8a molecule	Homo sapiens	16-19
33770833-0	2021	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.	Hydroxychloroquine	130-148	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
33770833-0	2021	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.	Hydroxychloroquine	130-148	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
33770833-7	2021	RESULTS: Variants in CYP2D6 significantly affected the grade of ground glass (CYP2D6*4 AA carriers showed the higher risk for grade 3) and the risk of positive anti-Covid-19 IgM (CYP2D6*2XN CC and CYP3A4*1B AA had the lowest risk), the duration of HCQ, the use of corticosteroids or gender did not affect the Covid-19 status significantly.	Hydroxychloroquine	248-251	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	21-27
33770833-7	2021	RESULTS: Variants in CYP2D6 significantly affected the grade of ground glass (CYP2D6*4 AA carriers showed the higher risk for grade 3) and the risk of positive anti-Covid-19 IgM (CYP2D6*2XN CC and CYP3A4*1B AA had the lowest risk), the duration of HCQ, the use of corticosteroids or gender did not affect the Covid-19 status significantly.	Hydroxychloroquine	248-251	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
33770833-7	2021	RESULTS: Variants in CYP2D6 significantly affected the grade of ground glass (CYP2D6*4 AA carriers showed the higher risk for grade 3) and the risk of positive anti-Covid-19 IgM (CYP2D6*2XN CC and CYP3A4*1B AA had the lowest risk), the duration of HCQ, the use of corticosteroids or gender did not affect the Covid-19 status significantly.	Hydroxychloroquine	248-251	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
7575694-7	1995	The decrease in SAA concentrations was also significantly greater at weeks 4 and 24 in the tenidap-treated group than in the hydroxychloroquine-plus-piroxicam-treated group.	Hydroxychloroquine	125-143	serum amyloid A1 cluster	Homo sapiens	16-19
7575694-8	1995	Significant reductions in plasma IL-6 levels were observed at weeks 4, 12, and 24 within the tenidap group, and at week 24 within the hydroxychloroquine-plus-piroxicam-treated group.	Hydroxychloroquine	134-152	interleukin 6	Homo sapiens	33-37
2110430-10	1990	The daily insulin dose in patients treated with the combined insulin and hydroxychloroquine therapy had to be reduced an average of 30%.	Hydroxychloroquine	73-91	insulin	Homo sapiens	10-17
33763494-0	2021	Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.	Hydroxychloroquine	0-18	tlr	None	30-33
29101672-7	2018	Likewise, a significant relationship was found between lower leptin concentrations and hydroxychloroquine consumption (p = 0.023).	Hydroxychloroquine	87-105	leptin	Homo sapiens	61-67
31082466-2	2019	We hypothesized that HCQ does not have toxic effects on the placenta and can modulate cytokine release in response to TLR7/9 activation.	Hydroxychloroquine	21-24	toll like receptor 7	Homo sapiens	118-122
31082466-5	2019	HCQ did not affect cell turnover, nutrient transport or cytokine release but increased IL-10 (anti-inflammatory) secretion and promoted syncytiotrophoblast regeneration.	Hydroxychloroquine	0-3	interleukin 10	Homo sapiens	87-92
29101672-9	2018	Similarly, an association between hydroxychloroquine consumption and low concentrations of IL-6 was found (p 0.005).	Hydroxychloroquine	34-52	interleukin 6	Homo sapiens	91-95
34864404-0	2022	Redox sensitive nano-capsules self-assembled from hyaluronic acid-hydroxychloroquine conjugates for CD44-targeted delivery of hydroxychloroquine to combat breast cancer metastasis in vitro and in vivo.	Hydroxychloroquine	66-84	CD44 antigen	Mus musculus	100-104
34864404-0	2022	Redox sensitive nano-capsules self-assembled from hyaluronic acid-hydroxychloroquine conjugates for CD44-targeted delivery of hydroxychloroquine to combat breast cancer metastasis in vitro and in vivo.	Hydroxychloroquine	126-144	CD44 antigen	Mus musculus	100-104
34920280-1	2022	We examined the effect of an immunomodulator hydroxychloroquine, also known as a Nurr1 ligand and an autophagy inhibitor, on a mouse model of intracerebral hemorrhage (ICH).	Hydroxychloroquine	45-63	nuclear receptor subfamily 4, group A, member 2	Mus musculus	81-86
34863995-4	2022	We found that R(-)HCQ and S(+)HCQ block human Kir2.1 and hERG potassium channels in the 1 muM-100 muM range with a 2-4 fold enantiomeric separation.	Hydroxychloroquine	18-21	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	46-52
34863995-4	2022	We found that R(-)HCQ and S(+)HCQ block human Kir2.1 and hERG potassium channels in the 1 muM-100 muM range with a 2-4 fold enantiomeric separation.	Hydroxychloroquine	18-21	ETS transcription factor ERG	Homo sapiens	57-61
34863995-4	2022	We found that R(-)HCQ and S(+)HCQ block human Kir2.1 and hERG potassium channels in the 1 muM-100 muM range with a 2-4 fold enantiomeric separation.	Hydroxychloroquine	30-33	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	46-52
34863995-4	2022	We found that R(-)HCQ and S(+)HCQ block human Kir2.1 and hERG potassium channels in the 1 muM-100 muM range with a 2-4 fold enantiomeric separation.	Hydroxychloroquine	30-33	ETS transcription factor ERG	Homo sapiens	57-61
34826419-0	2022	Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.	Hydroxychloroquine	0-18	angiotensin converting enzyme 2	Homo sapiens	52-56
34673141-6	2022	Furthermore, we found that autophagy suppression by hydroxychloroquine promotes apoptosis in a cancer cell model that had been treated with Src inhibitors.	Hydroxychloroquine	52-70	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	140-143
34580855-0	2022	Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.	Hydroxychloroquine	0-18	toll like receptor 7	Homo sapiens	65-69
34580855-6	2022	Whether HCQ can prevent endogenous TLR7 cleavage in primary immune cells, such as plasmacytoid dendritic cells (pDCs), had never been examined.	Hydroxychloroquine	8-11	toll like receptor 7	Homo sapiens	35-39
34580855-7	2022	Here, using a validated anti-TLR7 antibody suitable for biochemical detection of native TLR7 protein, we show that HCQ-treatment of fresh PBMCs, CAL-1 leukemic and primary human pDCs inhibits TLR7 cleavage and results in accumulation of full-length protein.	Hydroxychloroquine	115-118	toll like receptor 7	Homo sapiens	29-33
34580855-7	2022	Here, using a validated anti-TLR7 antibody suitable for biochemical detection of native TLR7 protein, we show that HCQ-treatment of fresh PBMCs, CAL-1 leukemic and primary human pDCs inhibits TLR7 cleavage and results in accumulation of full-length protein.	Hydroxychloroquine	115-118	toll like receptor 7	Homo sapiens	88-92
34580855-7	2022	Here, using a validated anti-TLR7 antibody suitable for biochemical detection of native TLR7 protein, we show that HCQ-treatment of fresh PBMCs, CAL-1 leukemic and primary human pDCs inhibits TLR7 cleavage and results in accumulation of full-length protein.	Hydroxychloroquine	115-118	toll like receptor 7	Homo sapiens	192-196
34580855-9	2022	Together, our finding suggests that the major pathway by which HCQ inhibits ssRNA-sensing by pDCs may rely on its capacity to inhibit endosomal acidification and the functional maturation of TLR7 protein.	Hydroxychloroquine	63-66	toll like receptor 7	Homo sapiens	191-195
34826419-0	2022	Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.	Hydroxychloroquine	0-18	transmembrane serine protease 2	Homo sapiens	58-65
34826419-0	2022	Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.	Hydroxychloroquine	0-18	neuropilin 1	Homo sapiens	70-74
34826419-7	2022	ACE2 protein expression was significantly decreased in both pterygium and conjunctival cells after hydroxychloroquine treatment.	Hydroxychloroquine	99-117	angiotensin converting enzyme 2	Homo sapiens	0-4
34826419-8	2022	Hydroxychloroquine also reduced NRP1 protein expression in conjunctival cells.	Hydroxychloroquine	0-18	neuropilin 1	Homo sapiens	32-36
34826419-10	2022	Notably, ROS production and SOD2 expression was significantly elevated in both pterygium and conjunctival cells after hydroxychloroquine treatment.	Hydroxychloroquine	118-136	superoxide dismutase 2	Homo sapiens	28-32
34826419-11	2022	In summary, this study revealed the reduction of ACE2 and NRP1 expression by hydroxychloroquine in human primary pterygium and conjunctival fibroblasts; yet with the increase in TMPRSS2 expression and oxidative stress and decrease in cell viability.	Hydroxychloroquine	77-95	angiotensin converting enzyme 2	Homo sapiens	49-53
34826419-11	2022	In summary, this study revealed the reduction of ACE2 and NRP1 expression by hydroxychloroquine in human primary pterygium and conjunctival fibroblasts; yet with the increase in TMPRSS2 expression and oxidative stress and decrease in cell viability.	Hydroxychloroquine	77-95	neuropilin 1	Homo sapiens	58-62
34729910-0	2022	Investigating of interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.	Hydroxychloroquine	50-68	angiotensin converting enzyme 2	Homo sapiens	102-133
34857478-8	2022	The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined.	Hydroxychloroquine	37-55	CD19 molecule	Homo sapiens	93-97
34857478-8	2022	The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined.	Hydroxychloroquine	37-55	sialic acid binding Ig like lectin 10	Homo sapiens	98-107
34857478-8	2022	The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined.	Hydroxychloroquine	57-60	CD19 molecule	Homo sapiens	93-97
34857478-8	2022	The effect of dexamethasone (DEX) or hydroxychloroquine (HCQ) treatment on the proportion of CD19+Siglec-10+ B cells in PBMCs from SLE patients was also determined.	Hydroxychloroquine	57-60	sialic acid binding Ig like lectin 10	Homo sapiens	98-107
34729910-6	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine.	Hydroxychloroquine	0-20	angiotensin converting enzyme 2	Homo sapiens	35-39
34729910-6	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine.	Hydroxychloroquine	70-90	angiotensin converting enzyme 2	Homo sapiens	35-39
34729910-6	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine.	Hydroxychloroquine	91-109	angiotensin converting enzyme 2	Homo sapiens	35-39
34729910-10	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine (racemate), while the effect of preventing SARS-CoV-2 pseudovirus from entering cells was weaker than R-hydroxychloroquine/hydroxychloroquine (racemate).	Hydroxychloroquine	0-20	angiotensin converting enzyme 2	Homo sapiens	35-39
34729910-10	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine (racemate), while the effect of preventing SARS-CoV-2 pseudovirus from entering cells was weaker than R-hydroxychloroquine/hydroxychloroquine (racemate).	Hydroxychloroquine	70-90	angiotensin converting enzyme 2	Homo sapiens	35-39
34729910-10	2022	S-hydroxychloroquine showed better ACE2 receptor binding ability than R-hydroxychloroquine/hydroxychloroquine (racemate), while the effect of preventing SARS-CoV-2 pseudovirus from entering cells was weaker than R-hydroxychloroquine/hydroxychloroquine (racemate).	Hydroxychloroquine	91-109	angiotensin converting enzyme 2	Homo sapiens	35-39
34979239-3	2022	OBJECTIVE: To ascertain the effects of acidosis and hydroxychloroquine (HCQ) on the action potential duration (APD) in a patient-specific induced pluripotent stem cell cardiomyocyte (iPSC-CM) model of p.S1103Y-SCN5A.	Hydroxychloroquine	52-70	sodium voltage-gated channel alpha subunit 5	Homo sapiens	210-215
34725193-6	2022	Here, we demonstrate that EAD1, a synthesized analogue of HCQ, is a more effective therapeutic for sensitizing PDAC tumors of various KRAS mutations to RT.	Hydroxychloroquine	58-61	KRAS proto-oncogene, GTPase	Homo sapiens	134-138
34979239-3	2022	OBJECTIVE: To ascertain the effects of acidosis and hydroxychloroquine (HCQ) on the action potential duration (APD) in a patient-specific induced pluripotent stem cell cardiomyocyte (iPSC-CM) model of p.S1103Y-SCN5A.	Hydroxychloroquine	72-75	sodium voltage-gated channel alpha subunit 5	Homo sapiens	210-215
34979239-9	2022	Similarly, with 24h 10 muM HCQ treatment, the fold-change of APD90 was significantly higher in p.S1103Y-SCN5A iPSC-CMs compared to IC iPSC-CMs (p < 0.0001).	Hydroxychloroquine	27-30	sodium voltage-gated channel alpha subunit 5	Homo sapiens	104-109
34979239-10	2022	CONCLUSIONS: Although the African-specific p.S1103Y-SCN5A common variant had no effect on APD90 under baseline conditions, the physiologic stress of either acidosis or HCQ treatment significantly prolonged the APD90 in patient-specific, re-engineered heart cells.	Hydroxychloroquine	168-171	sodium voltage-gated channel alpha subunit 5	Homo sapiens	52-57
34842499-8	2021	For instance, the binding affinity of complex (Ni(L)(DMF))(1) is found to be better than that of recently docking results of anti-SARS-CoV-2 drugs like chloroquine (-6.293 kcal/mol), hydroxychloroquine (-5.573 kcal/mol) and remdesivir (-6.352 kcal/mol) when targeted to the active-site of SARS-CoV-2 Mpro.	Hydroxychloroquine	183-201	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	300-304
34952594-5	2021	The tumor cell-specific ligand TRAIL was bioengineered to be stably expressed on HUVECs and the resultant membrane vesicles were wrapped on OXA/HCQ-loaded PLGA nanocores.	Hydroxychloroquine	144-147	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	31-36
34658419-9	2021	For instance, the binding affinity of ligand and complex was found to be better than docking results of chloroquine (-6.293 kcal/mol), hydroxychloroquine (-5.573 kcal/mol) and remdesivir (-6.352 kcal/mol) with Mpro protein.	Hydroxychloroquine	135-153	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	210-214
34901280-1	2021	Introduction: The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria.	Hydroxychloroquine	71-89	CD79a molecule	Homo sapiens	99-102
34901280-1	2021	Introduction: The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria.	Hydroxychloroquine	91-94	CD79a molecule	Homo sapiens	99-102
34901280-5	2021	IgA nephropathy patients who received HCQ were at a lower level of mean proteinuria at 6 months.	Hydroxychloroquine	38-41	CD79a molecule	Homo sapiens	0-3
34901280-8	2021	Conclusion: HCQ might play a role in the reduction of proteinuria in IgA nephropathy patients.	Hydroxychloroquine	12-15	CD79a molecule	Homo sapiens	69-72
34302047-8	2021	The high prevalence of variants in the G6PD gene found in this analysis suggests that it may be a significant interaction factor in clinical trials of chloroquine and hydroxychloroquine for treatment of COVID-19 in Africans.	Hydroxychloroquine	167-185	glucose-6-phosphate dehydrogenase	Homo sapiens	39-43
33820486-7	2021	Pretreating cells with CQ, but not DEX, attenuated poly IC-induced MCP-1 and CCL5 expression; however, HCQ pretreatment attenuated poly IC-induced CCL5, but not MCP-1.	Hydroxychloroquine	103-106	C-C motif chemokine ligand 5	Homo sapiens	147-151
33820486-10	2021	Interestingly, CQ is a rather powerful inhibitor compared with HCQ on TLR3 signaling-induced chemokine expression in GECs.	Hydroxychloroquine	63-66	toll like receptor 3	Homo sapiens	70-74
34343626-10	2021	Generalized linear models adjusted for prevalence of lupus nephritis and usage of hydroxychloroquine confirmed the observed association between African ancestry and IFI27, IFI44L, IFIT1, PRKR and RSAD2, whereas disease activity was associated with expression of IFI27 and RNASE2.	Hydroxychloroquine	82-100	interferon alpha inducible protein 27	Homo sapiens	165-170
34343626-10	2021	Generalized linear models adjusted for prevalence of lupus nephritis and usage of hydroxychloroquine confirmed the observed association between African ancestry and IFI27, IFI44L, IFIT1, PRKR and RSAD2, whereas disease activity was associated with expression of IFI27 and RNASE2.	Hydroxychloroquine	82-100	interferon induced protein 44 like	Homo sapiens	172-178
34343626-10	2021	Generalized linear models adjusted for prevalence of lupus nephritis and usage of hydroxychloroquine confirmed the observed association between African ancestry and IFI27, IFI44L, IFIT1, PRKR and RSAD2, whereas disease activity was associated with expression of IFI27 and RNASE2.	Hydroxychloroquine	82-100	interferon induced protein with tetratricopeptide repeats 1	Homo sapiens	180-185
34343626-10	2021	Generalized linear models adjusted for prevalence of lupus nephritis and usage of hydroxychloroquine confirmed the observed association between African ancestry and IFI27, IFI44L, IFIT1, PRKR and RSAD2, whereas disease activity was associated with expression of IFI27 and RNASE2.	Hydroxychloroquine	82-100	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	187-191
34343626-10	2021	Generalized linear models adjusted for prevalence of lupus nephritis and usage of hydroxychloroquine confirmed the observed association between African ancestry and IFI27, IFI44L, IFIT1, PRKR and RSAD2, whereas disease activity was associated with expression of IFI27 and RNASE2.	Hydroxychloroquine	82-100	radical S-adenosyl methionine domain containing 2	Homo sapiens	196-201
34846713-9	2022	Hydroxychloroquine therapy was associated with a higher rate of anti-PLA2R reduction (< 20 U/ml) (HR 0.28, P = 0.031).	Hydroxychloroquine	0-18	phospholipase A2 receptor 1	Homo sapiens	69-74
34846713-11	2022	CONCLUSIONS: Hydroxychloroquine could be an option for patients with membranous nephropathy seeking to achieve proteinuria reduction and anti-PLA2R antibody reduction in addition to optimized RAASi.	Hydroxychloroquine	13-31	phospholipase A2 receptor 1	Homo sapiens	142-147
34921013-5	2022	To identify strategies that can improve PDAC sensitivity to HCQ, we applied a CRISPR-Cas9 loss-of-function screen and found that a top sensitizer was the receptor tyrosine kinase (RTK) insulin-like growth factor 1 receptor (IGF1R).	Hydroxychloroquine	60-63	ret proto-oncogene	Homo sapiens	154-178
34921013-5	2022	To identify strategies that can improve PDAC sensitivity to HCQ, we applied a CRISPR-Cas9 loss-of-function screen and found that a top sensitizer was the receptor tyrosine kinase (RTK) insulin-like growth factor 1 receptor (IGF1R).	Hydroxychloroquine	60-63	ret proto-oncogene	Homo sapiens	180-183
34921013-5	2022	To identify strategies that can improve PDAC sensitivity to HCQ, we applied a CRISPR-Cas9 loss-of-function screen and found that a top sensitizer was the receptor tyrosine kinase (RTK) insulin-like growth factor 1 receptor (IGF1R).	Hydroxychloroquine	60-63	insulin like growth factor 1 receptor	Homo sapiens	185-222
34921013-5	2022	To identify strategies that can improve PDAC sensitivity to HCQ, we applied a CRISPR-Cas9 loss-of-function screen and found that a top sensitizer was the receptor tyrosine kinase (RTK) insulin-like growth factor 1 receptor (IGF1R).	Hydroxychloroquine	60-63	insulin like growth factor 1 receptor	Homo sapiens	224-229
34948342-7	2021	To test whether activation of MMP-9 causes EE barrier dysfunction, we hypothesized that if that were the case then treatment with hydroxychloroquine (HCQ) could, in fact, inhibit MMP-9, and thus preserve the EE barrier/juxtacrine signaling, and synchronous endothelial-myocyte coupling.	Hydroxychloroquine	130-148	matrix metallopeptidase 9	Homo sapiens	179-184
34948342-7	2021	To test whether activation of MMP-9 causes EE barrier dysfunction, we hypothesized that if that were the case then treatment with hydroxychloroquine (HCQ) could, in fact, inhibit MMP-9, and thus preserve the EE barrier/juxtacrine signaling, and synchronous endothelial-myocyte coupling.	Hydroxychloroquine	150-153	matrix metallopeptidase 9	Homo sapiens	179-184
34948342-13	2021	Results suggest that MMP-9 activation, endocardial endothelial leakage, endothelial-myocyte (E-M) uncoupling, dyssynchronous mitochondrial fusion-fission (Mfn2/Drp1 ratio), and mito-myocyte uncoupling in the AVF heart failure were found to be rampant; however, treatment with HCQ successfully mitigated some of the deleterious cardiac alterations during CHF.	Hydroxychloroquine	276-279	matrix metallopeptidase 9	Homo sapiens	21-26
34948342-13	2021	Results suggest that MMP-9 activation, endocardial endothelial leakage, endothelial-myocyte (E-M) uncoupling, dyssynchronous mitochondrial fusion-fission (Mfn2/Drp1 ratio), and mito-myocyte uncoupling in the AVF heart failure were found to be rampant; however, treatment with HCQ successfully mitigated some of the deleterious cardiac alterations during CHF.	Hydroxychloroquine	276-279	mitofusin 2	Homo sapiens	155-159
34948342-13	2021	Results suggest that MMP-9 activation, endocardial endothelial leakage, endothelial-myocyte (E-M) uncoupling, dyssynchronous mitochondrial fusion-fission (Mfn2/Drp1 ratio), and mito-myocyte uncoupling in the AVF heart failure were found to be rampant; however, treatment with HCQ successfully mitigated some of the deleterious cardiac alterations during CHF.	Hydroxychloroquine	276-279	utrophin	Homo sapiens	160-164
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	Hydroxychloroquine	124-142	paraoxonase 1	Homo sapiens	188-192
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	Hydroxychloroquine	124-142	paraoxonase 1	Homo sapiens	209-213
34537554-0	2021	Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study.	Hydroxychloroquine	39-57	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	88-92
34537554-4	2021	Virtual screening is employed to find out best analogs of HCQ, molecular docking is used for water displacement from catalytic region of Mpro, and finally, MD simulations are conducted for validation of these findings.	Hydroxychloroquine	58-61	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	137-141
34844627-9	2021	Interestingly, the sensitization mediated by HCQ could not be phenocopied by treatment with other autophagy inhibitors (Spautin-1, 3-MA and bafilomycin A1) or knockdown of the essential autophagy genes Atg5/Atg7, suggesting that the sensitizing effect might be mediated independent of autophagy status.	Hydroxychloroquine	45-48	autophagy related 5	Mus musculus	202-206
34844627-9	2021	Interestingly, the sensitization mediated by HCQ could not be phenocopied by treatment with other autophagy inhibitors (Spautin-1, 3-MA and bafilomycin A1) or knockdown of the essential autophagy genes Atg5/Atg7, suggesting that the sensitizing effect might be mediated independent of autophagy status.	Hydroxychloroquine	45-48	autophagy related 7	Mus musculus	207-211
34844627-10	2021	Mechanistically, HCQ induced ROS production and activated the transcription factor NRF2.	Hydroxychloroquine	17-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	83-87
34844627-12	2021	In addition, HCQ activated ATM to enhance HR repair, a high-fidelity repair for DNA double-strand breaks (DSBs) in cells, while BKM120 inhibited HR repair by blocking the phosphorylation of ATM and the expression of BRCA1/2 and Rad51.	Hydroxychloroquine	13-16	ataxia telangiectasia mutated	Mus musculus	27-30
34844627-12	2021	In addition, HCQ activated ATM to enhance HR repair, a high-fidelity repair for DNA double-strand breaks (DSBs) in cells, while BKM120 inhibited HR repair by blocking the phosphorylation of ATM and the expression of BRCA1/2 and Rad51.	Hydroxychloroquine	13-16	ataxia telangiectasia mutated	Mus musculus	190-193
34741481-0	2022	Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.	Hydroxychloroquine	126-144	angiotensin converting enzyme 2	Homo sapiens	107-111
34844627-12	2021	In addition, HCQ activated ATM to enhance HR repair, a high-fidelity repair for DNA double-strand breaks (DSBs) in cells, while BKM120 inhibited HR repair by blocking the phosphorylation of ATM and the expression of BRCA1/2 and Rad51.	Hydroxychloroquine	13-16	breast cancer 1, early onset	Mus musculus	216-223
34844627-12	2021	In addition, HCQ activated ATM to enhance HR repair, a high-fidelity repair for DNA double-strand breaks (DSBs) in cells, while BKM120 inhibited HR repair by blocking the phosphorylation of ATM and the expression of BRCA1/2 and Rad51.	Hydroxychloroquine	13-16	RAD51 recombinase	Mus musculus	228-233
34837219-6	2022	KEY RESULTS: Chloroquine and hydroxychloroquine blocked hERG with IC50 of 1.47+-0.07 muM and 3.78+-0.17 muM respectively, indicating proarrhythmic risk at concentrations effective against SARS-CoV-2 in vitro.	Hydroxychloroquine	29-47	ETS transcription factor ERG	Homo sapiens	56-60
34837219-8	2022	Acidosis significantly reduced potency of all drugs, whereas increased temperature decreased potency of chloroquine and hydroxychloroquine against hERG but increased potency for azithromycin.	Hydroxychloroquine	120-138	ETS transcription factor ERG	Homo sapiens	147-151
34802170-8	2022	The logistic regression analyses demonstrated that the likelihood of serious ADR, QT prolongation and diarrhea significantly increased with hydroxychloroquine dosage.	Hydroxychloroquine	140-158	aldo-keto reductase family 1 member B	Homo sapiens	77-80
34802170-9	2022	Co-administration of lopinavir/ritonavir and hydroxychloroquine showed a positive correlation with diarrhea and hypertransaminasemia and a negative relationship with the ADR seriousness.	Hydroxychloroquine	45-63	aldo-keto reductase family 1 member B	Homo sapiens	170-173
34934928-2	2021	In CD4 T-cells, we found that a clinically relevant concentration of HCQ inhibited the mitochondrial antioxidant system triggered by TCR crosslinking, leading to increased mitochondrial superoxide, impaired activation-induced autophagic flux, and reduced proliferation of CD4 T-cells.	Hydroxychloroquine	69-72	CD4 molecule	Homo sapiens	3-6
34934928-2	2021	In CD4 T-cells, we found that a clinically relevant concentration of HCQ inhibited the mitochondrial antioxidant system triggered by TCR crosslinking, leading to increased mitochondrial superoxide, impaired activation-induced autophagic flux, and reduced proliferation of CD4 T-cells.	Hydroxychloroquine	69-72	CD4 molecule	Homo sapiens	272-275
34934928-5	2021	We explored the clinical relevance of these findings in patients with celiac disease-a prototypic CD4 T-cell-mediated disease-and found that HCQ limits ex vivo antigen-specific T cell responses.	Hydroxychloroquine	141-144	CD4 molecule	Homo sapiens	98-101
34787281-9	2021	The ROR remained significant when we restricted the analysis to hydroxychloroquine (4.31; 95%CI: 3.25-5.71) or tocilizumab (3.92; 95%CI: 2.51-6.12).	Hydroxychloroquine	64-82	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	4-7
34278709-0	2021	Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression.	Hydroxychloroquine	31-49	matrix metallopeptidase 2	Homo sapiens	112-138
34278709-4	2021	In this study, CQ and HCQ treatments inhibited the migration and invasion of two BC cell types (5637 and T24) through expression modulation of matrix metalloproteinase-2 (MMP-2), which belongs to the matrix MMP family and is a key mediator of cancer progression.	Hydroxychloroquine	22-25	matrix metallopeptidase 2	Homo sapiens	143-169
34278709-4	2021	In this study, CQ and HCQ treatments inhibited the migration and invasion of two BC cell types (5637 and T24) through expression modulation of matrix metalloproteinase-2 (MMP-2), which belongs to the matrix MMP family and is a key mediator of cancer progression.	Hydroxychloroquine	22-25	matrix metallopeptidase 2	Homo sapiens	171-176
34278709-4	2021	In this study, CQ and HCQ treatments inhibited the migration and invasion of two BC cell types (5637 and T24) through expression modulation of matrix metalloproteinase-2 (MMP-2), which belongs to the matrix MMP family and is a key mediator of cancer progression.	Hydroxychloroquine	22-25	matrix metallopeptidase 2	Homo sapiens	207-210
34278709-6	2021	In conclusion, our research demonstrated that CQ and HCQ regulated cell motility in BC through MMP-2 downregulation by targeting autophagy functions, providing a novel therapeutic strategy for BC treatment.	Hydroxychloroquine	53-56	matrix metallopeptidase 2	Homo sapiens	95-100
34763989-0	2021	Hydroxychloroquine induces matrix metalloproteinase 1 expression and apoptosis in neurofibromatosis type 1 Schwann cells.	Hydroxychloroquine	0-18	matrix metallopeptidase 1	Homo sapiens	27-53
34721412-7	2021	Treatment with hydroxychloroquine reduced weight and insulin resistance, accompanied by beneficial metabolic effects in the adipose tissue.	Hydroxychloroquine	15-33	insulin	Homo sapiens	53-60
34672012-5	2022	High-throughput virtual screening of FDA-approved drugs (8815), interaction analysis, and energy profiles had revealed that DB01102 (Arbutamine), DB01611 (Hydroxychloroquine), and DB09319 (Carindacillin) exhibited better binding affinity with TRR1, TOM40, and YHB1, respectively.	Hydroxychloroquine	146-153	tRNA-Arg (anticodon TCT) 2-1	Homo sapiens	243-247
34672012-5	2022	High-throughput virtual screening of FDA-approved drugs (8815), interaction analysis, and energy profiles had revealed that DB01102 (Arbutamine), DB01611 (Hydroxychloroquine), and DB09319 (Carindacillin) exhibited better binding affinity with TRR1, TOM40, and YHB1, respectively.	Hydroxychloroquine	155-173	tRNA-Arg (anticodon TCT) 2-1	Homo sapiens	243-247
34707799-10	2021	Conclusion: Hydroxychloroquine combined with Huangqi tablets in the treatment of DN showed the best efficacy, with better control of blood glucose and lipids, which can more effectively delay the progression of renal lesions and effectively inhibit the expression of VEGF, IGF, and TGF-beta1 in tethered cells with high safety.	Hydroxychloroquine	12-30	vascular endothelial growth factor A	Homo sapiens	267-271
34707799-10	2021	Conclusion: Hydroxychloroquine combined with Huangqi tablets in the treatment of DN showed the best efficacy, with better control of blood glucose and lipids, which can more effectively delay the progression of renal lesions and effectively inhibit the expression of VEGF, IGF, and TGF-beta1 in tethered cells with high safety.	Hydroxychloroquine	12-30	transforming growth factor beta 1	Homo sapiens	282-291
34593436-7	2021	Combined treatment with Rapalink-1 and hydroxychloroquine enhanced the antitumor effect compared to treatment with Rapalink-1 alone by blocking the autophagy-inducing effect of mTOR inhibitors.	Hydroxychloroquine	39-57	mechanistic target of rapamycin kinase	Homo sapiens	177-181
34380260-6	2021	In the protein-protein interaction network analysis, AZT showed a putative interaction with different cytochrome P450 molecules, while HCQ demonstrated interaction with caspase-3.	Hydroxychloroquine	135-138	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	169-178
34380260-8	2021	Moreover, we also demonstrated an increase in the AChE activity followed by a reduction in the neuromasts of the head when zebrafish were exposed to the mixture AZT + HCQ.	Hydroxychloroquine	167-170	acetylcholinesterase	Danio rerio	50-54
34400126-8	2021	AAV8-IRF8-I/R mice pretreated with autophagy inhibitor hydroxychloroquine and NF-kappaBeta signal pathway inhibitor secukinumab could drastically reverse the IRF8-mediated increase of neutrophil infiltration and chemokine release at different degrees.	Hydroxychloroquine	55-73	interferon regulatory factor 8	Mus musculus	5-9
34400126-8	2021	AAV8-IRF8-I/R mice pretreated with autophagy inhibitor hydroxychloroquine and NF-kappaBeta signal pathway inhibitor secukinumab could drastically reverse the IRF8-mediated increase of neutrophil infiltration and chemokine release at different degrees.	Hydroxychloroquine	55-73	interferon regulatory factor 8	Mus musculus	158-162
34681066-0	2021	Hydroxychloroquine Attenuates Acute Inflammation (LPS)-Induced Apoptosis via Inhibiting TRPV1 Channel/ROS Signaling Pathways in Human Monocytes.	Hydroxychloroquine	0-18	transient receptor potential cation channel subfamily V member 1	Homo sapiens	88-93
34342813-2	2021	This study aimed to investigate the effects of Hydroxychloroquine (HCQ) on the expression of OLIG-2 and PDGFR-alpha markers during the myelination process.	Hydroxychloroquine	47-65	oligodendrocyte transcription factor 2	Mus musculus	93-99
34342813-2	2021	This study aimed to investigate the effects of Hydroxychloroquine (HCQ) on the expression of OLIG-2 and PDGFR-alpha markers during the myelination process.	Hydroxychloroquine	47-65	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	104-115
34342813-2	2021	This study aimed to investigate the effects of Hydroxychloroquine (HCQ) on the expression of OLIG-2 and PDGFR-alpha markers during the myelination process.	Hydroxychloroquine	67-70	oligodendrocyte transcription factor 2	Mus musculus	93-99
34342813-2	2021	This study aimed to investigate the effects of Hydroxychloroquine (HCQ) on the expression of OLIG-2 and PDGFR-alpha markers during the myelination process.	Hydroxychloroquine	67-70	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	104-115
34342813-6	2021	What is remarkable is the high rate of Olig2 + cells in the groups treated with 10 and 100 mg/kg HCQ in the demyelination phase and its decreasing trend in the remyelination phase.	Hydroxychloroquine	97-100	oligodendrocyte transcription factor 2	Mus musculus	39-44
34342813-8	2021	The number of PDGFR-alpha+ cells in the group treated with 10 mg/kg HCQ was significant in the first phase (p value < 0.05).	Hydroxychloroquine	68-71	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	14-25
34342813-9	2021	Considering that the 100 mg/kg HCQ group had the highest level of PDGFR-alpha as well as the highest level of myelin repair in LFB staining, it could be inferred that it was the most effective dose in inducing proliferation and migration of OPCs.	Hydroxychloroquine	31-34	platelet derived growth factor receptor, alpha polypeptide	Mus musculus	66-77
34681066-3	2021	Importantly, the protective action of hydroxychloroquine (HCQ) treatment via the inhibition of TRPV1 on the levels of inflammatory factors, cROS, and apoptosis in acute INF (lipopolysaccharide, LPS)-exposed neuronal cells was recently reported.	Hydroxychloroquine	38-56	transient receptor potential cation channel subfamily V member 1	Homo sapiens	95-100
34681066-3	2021	Importantly, the protective action of hydroxychloroquine (HCQ) treatment via the inhibition of TRPV1 on the levels of inflammatory factors, cROS, and apoptosis in acute INF (lipopolysaccharide, LPS)-exposed neuronal cells was recently reported.	Hydroxychloroquine	58-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	95-100
34681066-10	2021	However, treatment with HCQ and TRPV1 blocker (capsazepine) modulated the levels of cytokines, caspases, cROS, Ca2+ influx, and apoptosis through the modulation of TRPV1 in the U937 that were stimulated with LPS.	Hydroxychloroquine	24-27	transient receptor potential cation channel subfamily V member 1	Homo sapiens	164-169
34681066-11	2021	In summary, the present data suggest TRPV1 activation through the acute INF (LPS)-induced inflammatory, oxidant, and apoptotic adverse actions in monocyte cells, whereas HCQ prevented adverse actions via the modulation of TRPV1.	Hydroxychloroquine	170-173	transient receptor potential cation channel subfamily V member 1	Homo sapiens	222-227
34575683-10	2021	The treatment of female C57BL/6 mice with the autophagy inhibitor hydroxychloroquine-which promotes p62 expression-increased both phosphorylated p62 and ESR1 expression in uterine epithelial cells.	Hydroxychloroquine	66-84	nucleoporin 62	Mus musculus	100-103
34575683-10	2021	The treatment of female C57BL/6 mice with the autophagy inhibitor hydroxychloroquine-which promotes p62 expression-increased both phosphorylated p62 and ESR1 expression in uterine epithelial cells.	Hydroxychloroquine	66-84	nucleoporin 62	Mus musculus	145-148
34575683-10	2021	The treatment of female C57BL/6 mice with the autophagy inhibitor hydroxychloroquine-which promotes p62 expression-increased both phosphorylated p62 and ESR1 expression in uterine epithelial cells.	Hydroxychloroquine	66-84	estrogen receptor 1 (alpha)	Mus musculus	153-157
34475327-0	2021	Vitamin D and hydroxychloroquine reduce renal injury and Ki67 expression in a rat model of IgA nephropathy via TLR4.	Hydroxychloroquine	14-32	toll-like receptor 4	Rattus norvegicus	111-115
34588979-7	2021	Similar trends favoring HCQ treatment were observed for uSFR (p = 0.05), CRP (p = 0.0008), ESR (p < 0.00001), IgM (p = 0.007) and IgA (p = 0.05).	Hydroxychloroquine	24-27	C-reactive protein	Homo sapiens	73-76
34588979-9	2021	Conclusion: HCQ treatment showed moderate efficacy to improve oral symptoms, uSFR, ESR, CRP, IgM and IgA.	Hydroxychloroquine	12-15	C-reactive protein	Homo sapiens	88-91
34217752-8	2021	The inhibition of SARS-CoV-2 replication by chloroquine and hydroxychloroquine coincided with an inhibitory effect on the autophagy pathway as visualized by a dose-dependent increase in LC3-positive puncta.	Hydroxychloroquine	60-78	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	186-189
34407152-0	2021	Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-kappaB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.	Hydroxychloroquine	33-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	82-91
34080218-0	2021	Case of annular pustular psoriasis/circinate erythematous psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus: Possible association with CARD-14 mutation.	Hydroxychloroquine	79-97	caspase recruitment domain family member 14	Homo sapiens	172-179
34661080-3	2021	In patch clamped HEK293 cells expressing human cardiac ion channels, HCQ inhibited IKr and IK1 at a therapeutic concentrations (IC50s: 10 +- 0.6 and 34 +- 5.0 muM).	Hydroxychloroquine	69-72	IKAROS family zinc finger 1	Homo sapiens	91-94
34407152-0	2021	Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-kappaB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.	Hydroxychloroquine	33-51	NSFL1 (p97) cofactor (p47)	Mus musculus	143-146
34467247-5	2021	Hydroxychloroquine blocks TLR9 activation by mitochondrial DNA in vitro and may attenuate flares of rhabdomyolysis in 6 patients treated.	Hydroxychloroquine	0-18	toll like receptor 9	Homo sapiens	26-30
34407152-4	2021	In this paper, we determined the therapeutic efficacy of CQ/HCQ, as NF-kappaB inhibitors, in ATLL mediated by blockade of p47 degradation.	Hydroxychloroquine	60-63	nuclear factor kappa B subunit 1	Homo sapiens	68-77
34407152-4	2021	In this paper, we determined the therapeutic efficacy of CQ/HCQ, as NF-kappaB inhibitors, in ATLL mediated by blockade of p47 degradation.	Hydroxychloroquine	60-63	NSFL1 (p97) cofactor (p47)	Mus musculus	122-125
34182874-6	2021	METHODS: In this research, to explore the effect of HCQ for angiogenesis, we investigated: (1) Human umbilical vein endothelial cells (HUVECs) viability by CCK-8; (2) HUVECs migration by wound healing; (3) HUVEC angiogenesis by Matrigel assay in vitro; (4) mRNA expression of MMP-2 and VEGF by real-time quantitative Polymerase Chain Reaction (RT-PCR); (5) protein expression of VEGF, MMP-2 by western blot.	Hydroxychloroquine	52-55	matrix metallopeptidase 2	Homo sapiens	276-281
34337036-0	2021	Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19.	Hydroxychloroquine	45-63	angiotensin converting enzyme 2	Homo sapiens	67-71
34337036-3	2021	Based on three-dimensional structural similarities between HCQ and the known ACE2 specific inhibitor MLN-4760, we compared their modulation on ACE2 activity.	Hydroxychloroquine	59-62	angiotensin converting enzyme 2	Homo sapiens	143-147
34337036-4	2021	Here we describe, for the first time, in a cell-free in vitro system that HCQ directly and dose-dependently inhibits the activity of recombinant human ACE2, with a potency similar to the MLN-4760.	Hydroxychloroquine	74-77	angiotensin converting enzyme 2	Homo sapiens	151-155
34337036-7	2021	In summary, here we demonstrate the direct inhibitory action of HCQ over the activity of the enzyme ACE2.	Hydroxychloroquine	64-67	angiotensin converting enzyme 2	Homo sapiens	100-104
34337036-8	2021	Then, by determining the activity of ACE2, we reveal that the interaction with the spike protein of SARS-CoV-2 leads to structural changes that at least partially displace the interaction of the said enzyme with HCQ.	Hydroxychloroquine	212-215	angiotensin converting enzyme 2	Homo sapiens	37-41
34337036-8	2021	Then, by determining the activity of ACE2, we reveal that the interaction with the spike protein of SARS-CoV-2 leads to structural changes that at least partially displace the interaction of the said enzyme with HCQ.	Hydroxychloroquine	212-215	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	83-88
34350216-7	2021	Results: LCA identified five distinct AID usage classes: Class 1, generally low medication usage; Class 2, using either sulfasalazine or non-tumour necrosis factor (TNF) inhibitors; Class 3, methotrexate users; Class 4, TNF-inhibitor users; and Class 5, hydroxychloroquine users.	Hydroxychloroquine	254-272	activation induced cytidine deaminase	Homo sapiens	38-41
34345611-2	2021	The aim of this study was to predict in silico, using the comparative drug hydroxychloroquine, the working goal of brazilein sappan wood as a candidate for the antiviral drug SARS-CoV-2 against protein S, PLpro, and Mpro.	Hydroxychloroquine	75-93	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	205-210
34345611-2	2021	The aim of this study was to predict in silico, using the comparative drug hydroxychloroquine, the working goal of brazilein sappan wood as a candidate for the antiviral drug SARS-CoV-2 against protein S, PLpro, and Mpro.	Hydroxychloroquine	75-93	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	216-220
34182874-6	2021	METHODS: In this research, to explore the effect of HCQ for angiogenesis, we investigated: (1) Human umbilical vein endothelial cells (HUVECs) viability by CCK-8; (2) HUVECs migration by wound healing; (3) HUVEC angiogenesis by Matrigel assay in vitro; (4) mRNA expression of MMP-2 and VEGF by real-time quantitative Polymerase Chain Reaction (RT-PCR); (5) protein expression of VEGF, MMP-2 by western blot.	Hydroxychloroquine	52-55	vascular endothelial growth factor A	Homo sapiens	379-383
34182874-6	2021	METHODS: In this research, to explore the effect of HCQ for angiogenesis, we investigated: (1) Human umbilical vein endothelial cells (HUVECs) viability by CCK-8; (2) HUVECs migration by wound healing; (3) HUVEC angiogenesis by Matrigel assay in vitro; (4) mRNA expression of MMP-2 and VEGF by real-time quantitative Polymerase Chain Reaction (RT-PCR); (5) protein expression of VEGF, MMP-2 by western blot.	Hydroxychloroquine	52-55	matrix metallopeptidase 2	Homo sapiens	385-390
34182874-7	2021	RESULTS: We found that HCQ treatment significantly restored the expression of aPL-inhibited VEGF and MMP-2.	Hydroxychloroquine	23-26	vascular endothelial growth factor A	Homo sapiens	92-96
34182874-7	2021	RESULTS: We found that HCQ treatment significantly restored the expression of aPL-inhibited VEGF and MMP-2.	Hydroxychloroquine	23-26	matrix metallopeptidase 2	Homo sapiens	101-106
34396938-3	2021	Thus, the goal is to investigate the dynamic nature of HCQ derivatives against SARS-CoV-2 main protease and spike proteins.	Hydroxychloroquine	55-58	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	108-113
34379013-9	2022	Furthermore, I3C combined with HCQ induced apoptosis by highly upregulating cleaved caspase-3 and Bax while downregulating Bcl-2 proteins expression in EAC cells in comparison with each drug alone.	Hydroxychloroquine	31-34	caspase 3	Mus musculus	84-93
34379013-9	2022	Furthermore, I3C combined with HCQ induced apoptosis by highly upregulating cleaved caspase-3 and Bax while downregulating Bcl-2 proteins expression in EAC cells in comparison with each drug alone.	Hydroxychloroquine	31-34	BCL2-associated X protein	Mus musculus	98-101
34379013-9	2022	Furthermore, I3C combined with HCQ induced apoptosis by highly upregulating cleaved caspase-3 and Bax while downregulating Bcl-2 proteins expression in EAC cells in comparison with each drug alone.	Hydroxychloroquine	31-34	B cell leukemia/lymphoma 2	Mus musculus	123-128
34320905-7	2021	Henceforth, we have carried out extensive, one-microsecond long molecular dynamics simulations of the bound complex of hydroxychloroquine with main protease (Mpro) of SARS-CoV-2.	Hydroxychloroquine	119-137	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	158-162
34320905-8	2021	Our analysis found that HCQ binds within the catalytic pocket of Mpro and remains stable upto one-third of simulation time but further causes increased fluctuations in simulation parameters.	Hydroxychloroquine	24-27	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	65-69
34436052-0	2021	SPR-Based Kinetic Analysis of the Early Stages of Infection in Cells Infected with Human Coronavirus and Treated with Hydroxychloroquine.	Hydroxychloroquine	118-136	sepiapterin reductase	Homo sapiens	0-3
34759472-4	2021	Methods: EMBASE, COCHRANE, and PubMed databases were searched for studies on the use of hydroxychloroquine or chloroquine in the treatment of COVID-19.	Hydroxychloroquine	88-106	cochlin	Homo sapiens	17-25
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	0-18	toll like receptor 9	Homo sapiens	142-146
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	0-18	superoxide dismutase 1	Homo sapiens	147-151
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	0-18	microRNA 30a	Homo sapiens	152-163
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	0-18	beclin 1	Homo sapiens	167-175
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	20-23	toll like receptor 9	Homo sapiens	142-146
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	20-23	superoxide dismutase 1	Homo sapiens	147-151
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	20-23	microRNA 30a	Homo sapiens	152-163
34203465-0	2021	Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.	Hydroxychloroquine	20-23	beclin 1	Homo sapiens	167-175
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	83-101	toll like receptor 9	Homo sapiens	62-66
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	83-101	superoxide dismutase 1	Homo sapiens	181-185
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	83-101	autophagy related 5	Homo sapiens	239-243
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	83-101	beclin 1	Homo sapiens	248-256
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	103-106	toll like receptor 9	Homo sapiens	62-66
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	103-106	superoxide dismutase 1	Homo sapiens	181-185
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	103-106	autophagy related 5	Homo sapiens	239-243
34182874-6	2021	METHODS: In this research, to explore the effect of HCQ for angiogenesis, we investigated: (1) Human umbilical vein endothelial cells (HUVECs) viability by CCK-8; (2) HUVECs migration by wound healing; (3) HUVEC angiogenesis by Matrigel assay in vitro; (4) mRNA expression of MMP-2 and VEGF by real-time quantitative Polymerase Chain Reaction (RT-PCR); (5) protein expression of VEGF, MMP-2 by western blot.	Hydroxychloroquine	52-55	vascular endothelial growth factor A	Homo sapiens	286-290
34203465-4	2021	TLR9 overexpression increased HCC cell proliferation, whereas TLR9 inhibition from hydroxychloroquine (HCQ) decreased HCC cell proliferation, tumor growth, oxidative stress marker (SOD1), and the formation of autophagosome bodies (reduced ATG5 and Beclin-1 expression).	Hydroxychloroquine	103-106	beclin 1	Homo sapiens	248-256
34203465-7	2021	Both in vitro and in vivo results demonstrated the synergistic effect of the HCQ-sorafenib combination on sorafenib-resistant HCC (Huh7-SR) cells, increasing their sensitivity to treatment by modulating TLR9, autophagy (ATG5 and Beclin-1), oxidative stress (SOD1), and apoptosis (c-caspase3) expression and thus overcoming the drug resistance.	Hydroxychloroquine	77-80	toll like receptor 9	Homo sapiens	203-207
34121346-8	2021	The median (IQR) CS dose was lower for patients on HCQ (14 (9, 21) mg), compared to patients who were never prescribed HCQ (15 (9, 27) mg), or patients who discontinued HCQ after ESRD (17 (10, 27) mg), p=0.001.	Hydroxychloroquine	51-54	citrate synthase	Homo sapiens	17-19
34203465-7	2021	Both in vitro and in vivo results demonstrated the synergistic effect of the HCQ-sorafenib combination on sorafenib-resistant HCC (Huh7-SR) cells, increasing their sensitivity to treatment by modulating TLR9, autophagy (ATG5 and Beclin-1), oxidative stress (SOD1), and apoptosis (c-caspase3) expression and thus overcoming the drug resistance.	Hydroxychloroquine	77-80	autophagy related 5	Homo sapiens	220-224
34203465-7	2021	Both in vitro and in vivo results demonstrated the synergistic effect of the HCQ-sorafenib combination on sorafenib-resistant HCC (Huh7-SR) cells, increasing their sensitivity to treatment by modulating TLR9, autophagy (ATG5 and Beclin-1), oxidative stress (SOD1), and apoptosis (c-caspase3) expression and thus overcoming the drug resistance.	Hydroxychloroquine	77-80	beclin 1	Homo sapiens	229-237
34203465-7	2021	Both in vitro and in vivo results demonstrated the synergistic effect of the HCQ-sorafenib combination on sorafenib-resistant HCC (Huh7-SR) cells, increasing their sensitivity to treatment by modulating TLR9, autophagy (ATG5 and Beclin-1), oxidative stress (SOD1), and apoptosis (c-caspase3) expression and thus overcoming the drug resistance.	Hydroxychloroquine	77-80	superoxide dismutase 1	Homo sapiens	258-262
34120592-5	2021	CASE PRESENTATION: A 20-year-old Filipino male presented with acute dyspnea, pleuritic chest pain, fevers, and diffuse rash after being diagnosed with SLE six months ago and treated with hydroxychloroquine.	Hydroxychloroquine	187-205	immunoglobulin kappa variable 1-27	Homo sapiens	19-23
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	17-20	CD274 molecule	Sus scrofa	42-47
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	17-20	CD44	Sus scrofa	153-157
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	17-20	CD44	Sus scrofa	229-233
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	25-28	CD274 molecule	Sus scrofa	42-47
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	25-28	CD44	Sus scrofa	153-157
34181666-5	2021	Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8+CD44+PD-1+TCF1+ tumor infiltrating T cells (TILs) and the generation of CD8+CD44+PD-1+ effectors.	Hydroxychloroquine	25-28	CD44	Sus scrofa	229-233
34121346-8	2021	The median (IQR) CS dose was lower for patients on HCQ (14 (9, 21) mg), compared to patients who were never prescribed HCQ (15 (9, 27) mg), or patients who discontinued HCQ after ESRD (17 (10, 27) mg), p=0.001.	Hydroxychloroquine	169-172	citrate synthase	Homo sapiens	17-19
34106964-1	2021	BACKGROUND: Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19).	Hydroxychloroquine	12-30	antizyme inhibitor 1	Homo sapiens	63-66
34114349-9	2021	An autophagy inhibitor (hydroxychloroquine) or si-ELAVL1 transfection reversed CIRBP-enhanced ferritinophagy activation and ferroptosis in HK2 cells under HR.	Hydroxychloroquine	24-42	cold inducible RNA binding protein	Mus musculus	79-84
34106964-1	2021	BACKGROUND: Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19).	Hydroxychloroquine	59-62	antizyme inhibitor 1	Homo sapiens	63-66
34458558-10	2021	Binding of HCQ to HNMT is not a desired binding, and therefore this should be reduced during repurposing of HCQ.	Hydroxychloroquine	11-14	histamine N-methyltransferase	Homo sapiens	18-22
34130375-3	2021	Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex.	Hydroxychloroquine	167-185	angiotensin converting enzyme 2	Homo sapiens	328-332
34094861-5	2021	The mechanism underlying Andro-mediated regulation of TNFR2 distribution and nuclear factor-kappaB (NF-kappaB) expression was verified using endosome maturation inhibitor hydroxychloroquine (HCQ) through flow cytometry, immunofluorescence, and western blot analysis.	Hydroxychloroquine	171-189	TNF receptor superfamily member 1B	Rattus norvegicus	54-59
34094861-5	2021	The mechanism underlying Andro-mediated regulation of TNFR2 distribution and nuclear factor-kappaB (NF-kappaB) expression was verified using endosome maturation inhibitor hydroxychloroquine (HCQ) through flow cytometry, immunofluorescence, and western blot analysis.	Hydroxychloroquine	191-194	TNF receptor superfamily member 1B	Rattus norvegicus	54-59
34192120-6	2021	The age in the HCQ group is positively correlated with PR (R = 0.31, p < 0.01) and QTc (R = 0.34, p < 0.01) but not HR.	Hydroxychloroquine	15-18	transmembrane protein 37	Homo sapiens	55-57
34192120-9	2021	Electrocardiogram monitoring is suggested in aged patients due to the effects of HCQ on HR, PR, and QTc.	Hydroxychloroquine	81-84	transmembrane protein 37	Homo sapiens	92-94
34104100-3	2021	The anti-hyperglycaemic, anti-hyperlipidaemic, cardioprotective, anti-hypertensive, and anti-obesity effects of CQ and HCQ might be elicited through reduction of inflammatory response and oxidative stress, improvement of endothelial function, activation of insulin signalling pathway, inhibition of lipogenesis and autophagy, as well as regulation of adipokines and apoptosis.	Hydroxychloroquine	119-122	insulin	Homo sapiens	257-264
34568544-0	2021	Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach.	Hydroxychloroquine	119-137	angiotensin converting enzyme 2	Homo sapiens	174-178
34810388-2	2021	Aims: To quantitatively evaluate the effect of administration of enteral hydroxychloroquine (HCQS) as a monotherapy for six months on the extent and severity of erosive OLP using reticular score, erythema score and ulcerative score (REU score), and to subjectively evaluate the success of HCQS as a therapeutic drug for OLP-e using Tel Aviv-San Francisco Scale, visual analogue scale (VAS) and severity of burning sensation (BURN score).	Hydroxychloroquine	289-293	ETS variant transcription factor 6	Homo sapiens	332-335
34568544-6	2021	The calculations revealed that cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibit main protease and ACE2 receptors more effectively than the well-known drug hydroxychloroquine when used against COVID-19.	Hydroxychloroquine	178-196	angiotensin converting enzyme 2	Homo sapiens	121-125
35229402-1	2022	RATIONALE: In this study, a derivatization-switchable solvent liquid-liquid microextraction-quadruple isotope dilution-gas chromatography-mass spectrometry (D-SS-LLME-ID4 -GC-MS) method was presented for the determination of hydroxychloroquine sulfate in human biofluids.	Hydroxychloroquine	225-251	inhibitor of DNA binding 4, HLH protein	Homo sapiens	167-170
34630972-9	2021	Besides, we showed that the incubation of rabbit MSCs with HCQ increased cellular aging by induction of PARP-1 while Metformin increased rejuvenating factor Sirt-1 comparing with the normal group (P < 0.05).	Hydroxychloroquine	59-62	poly(ADP-ribose) polymerase 1	Homo sapiens	104-110
34630972-9	2021	Besides, we showed that the incubation of rabbit MSCs with HCQ increased cellular aging by induction of PARP-1 while Metformin increased rejuvenating factor Sirt-1 comparing with the normal group (P < 0.05).	Hydroxychloroquine	59-62	sirtuin 1	Homo sapiens	157-163
35485606-4	2022	The expression of autophagy proteins (LC3A/B and Beclin-1) and UPS protein (ubiquitin) in MDA-MB-231 and MCF-7 cells following doxorubicin, ixazomib, and/or hydroxychloroquine were determined by western blot.	Hydroxychloroquine	157-175	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	38-44
35462097-0	2022	Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway.	Hydroxychloroquine	0-18	thymoma viral proto-oncogene 1	Mus musculus	81-84
35462097-9	2022	HCQ treatment additionally blunted EMT in UUO kidneys and TGF-beta1-treated renal tubular epithelial cells, and alleviated ECM deposition in kidney tissue.	Hydroxychloroquine	0-3	transforming growth factor, beta 1	Mus musculus	58-67
35462097-11	2022	Mechanistically, HCQ treatment suppressed the activation of the PI3K/Akt and NF-kB pathways.	Hydroxychloroquine	17-20	thymoma viral proto-oncogene 1	Mus musculus	69-72
35462097-12	2022	This study demonstrated that HCQ ameliorated renal fibrosis by inhibiting the PI3K/AKT and NF-kappaB signaling pathways to attenuate inflammatory factors and the apoptotic function of renal tubular epithelial cells, thus providing renewed theoretical evidence for HCQ treatment of renal fibrosis.	Hydroxychloroquine	29-32	thymoma viral proto-oncogene 1	Mus musculus	83-86
35377866-2	2022	Hydroxychloroquine can prevent autophagy-driven resistance and improve the efficacy of BRAF-/MEK-inhibitors in preclinical melanoma models.	Hydroxychloroquine	0-18	Braf transforming gene	Mus musculus	87-91
35386046-4	2022	RESULTS: Compared with remdesivir, HCQ/CQ was associated with increased reporting of SCAEs (reporting odds ratio (ROR) 2.1; 95% confidence interval (CI) 1.8-2.5), torsade de pointes (TdP)/QTc prolongation (ROR 35.4; 95% CI 19.4-64.5), and ventricular arrhythmia (ROR 2.5; 95% CI 1.6-3.9); similar results were found in comparison with other therapeutic alternatives.	Hydroxychloroquine	35-38	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	114-117
35386046-4	2022	RESULTS: Compared with remdesivir, HCQ/CQ was associated with increased reporting of SCAEs (reporting odds ratio (ROR) 2.1; 95% confidence interval (CI) 1.8-2.5), torsade de pointes (TdP)/QTc prolongation (ROR 35.4; 95% CI 19.4-64.5), and ventricular arrhythmia (ROR 2.5; 95% CI 1.6-3.9); similar results were found in comparison with other therapeutic alternatives.	Hydroxychloroquine	35-38	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	206-209
35386046-4	2022	RESULTS: Compared with remdesivir, HCQ/CQ was associated with increased reporting of SCAEs (reporting odds ratio (ROR) 2.1; 95% confidence interval (CI) 1.8-2.5), torsade de pointes (TdP)/QTc prolongation (ROR 35.4; 95% CI 19.4-64.5), and ventricular arrhythmia (ROR 2.5; 95% CI 1.6-3.9); similar results were found in comparison with other therapeutic alternatives.	Hydroxychloroquine	35-38	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	263-268
35377866-2	2022	Hydroxychloroquine can prevent autophagy-driven resistance and improve the efficacy of BRAF-/MEK-inhibitors in preclinical melanoma models.	Hydroxychloroquine	0-18	midkine	Mus musculus	93-96
35377866-3	2022	This clinical trial investigated the use of combined BRAF-/MEK-inhibition with dabrafenib and trametinib plus hydroxychloroquine in patients with advanced BRAFV600 mutant melanoma who previously progressed on prior treatment with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.	Hydroxychloroquine	110-128	mitogen-activated protein kinase kinase 7	Homo sapiens	236-239
35543153-8	2022	The upregulation of LC3-II, a classical autophagy marker, and the downregulation of mTOR and its downstream molecule Beclin1 were observed in established D-allose-resistant LLC cells, which were more sensitive to cell death induced by HCQ.	Hydroxychloroquine	235-238	mechanistic target of rapamycin kinase	Mus musculus	84-88
35543153-8	2022	The upregulation of LC3-II, a classical autophagy marker, and the downregulation of mTOR and its downstream molecule Beclin1 were observed in established D-allose-resistant LLC cells, which were more sensitive to cell death induced by HCQ.	Hydroxychloroquine	235-238	beclin 1, autophagy related	Mus musculus	117-124
35578850-6	2022	In relation to the role of G6PD and the neurological manifestations of COVID-19, it has been reported that the enzymatic deficiency in patients infected with SARS-CoV-2 exacerbates the disease, and, in some clinical reports, an increase in hemolysis and thrombosis was observed when patients were treated with hydroxychloroquine (OH-CQ), a drug with oxidative properties.	Hydroxychloroquine	310-328	glucose-6-phosphate dehydrogenase	Homo sapiens	27-31
35628472-7	2022	Favipiravir, hydroxychloroquine, lopinavir, and the combination of lopinavir with ritonavir were found to inhibit pannexin1 channel activity without affecting pannexin1 protein or mRNA levels.	Hydroxychloroquine	13-31	pannexin 1	Homo sapiens	114-123
35575468-0	2022	Hydroxychloroquine-induced acute generalized exanthematous pustulosis in an orofacial granulomatosis patient with homozygous IL36RN mutation.	Hydroxychloroquine	0-18	interleukin 36 receptor antagonist	Homo sapiens	125-131
35411132-11	2022	Results: Molecular docking analysis revealed four putative key targets (ACHE, PNMT, MC1R, and VDR) of HCQ played important roles in vitiligo treatment.	Hydroxychloroquine	102-105	acetylcholinesterase (Cartwright blood group)	Homo sapiens	72-76
35403913-9	2022	Regressions on IgG1, IgG2, and IgG3 revealed positive associations with HCQ therapy (p = 0.0043, 0.0037, and 0.0139, respectively).	Hydroxychloroquine	72-75	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	31-35
35403913-12	2022	IgG1, IgG2, and IgG3 were positively associated with HCQ therapy, after adjustment for other variables.	Hydroxychloroquine	53-56	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	16-20
35522252-11	2022	However, HCQ decreased alpha-synuclein and MDA levels while increased TAC levels and GPx activity.	Hydroxychloroquine	9-12	synuclein alpha	Rattus norvegicus	23-38
35499740-6	2022	She had been on medications including hydroxychloroquine before onset.	Hydroxychloroquine	38-56	Src homology 2 domain containing E	Homo sapiens	0-3
35073454-9	2022	Moreover, encapsulation of HCQ influenced particle hydrodynamic diameter and PDI in a PVA concentration dependent manner.	Hydroxychloroquine	27-30	peptidyl arginine deiminase 1	Homo sapiens	77-80
35403913-8	2022	Women with combined subnormal IgG1/IgG3 who took HCQ had greater median IgG2 than women who did not take HCQ (4.89 g/L (range 4.43, 4.94) vs. 2.57 g/L (1.21, 6.44), respectively; p = 0.0123).	Hydroxychloroquine	49-52	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	35-39
35411132-11	2022	Results: Molecular docking analysis revealed four putative key targets (ACHE, PNMT, MC1R, and VDR) of HCQ played important roles in vitiligo treatment.	Hydroxychloroquine	102-105	phenylethanolamine N-methyltransferase	Homo sapiens	78-82
35411132-11	2022	Results: Molecular docking analysis revealed four putative key targets (ACHE, PNMT, MC1R, and VDR) of HCQ played important roles in vitiligo treatment.	Hydroxychloroquine	102-105	melanocortin 1 receptor	Homo sapiens	84-88
35411132-11	2022	Results: Molecular docking analysis revealed four putative key targets (ACHE, PNMT, MC1R, and VDR) of HCQ played important roles in vitiligo treatment.	Hydroxychloroquine	102-105	vitamin D receptor	Homo sapiens	94-97
35411132-12	2022	According to the transcriptomic results, the melanosomal biogenesis-related gene BLOC1S5 was upregulated 138005.020 fold after HCQ treatment.	Hydroxychloroquine	127-130	biogenesis of lysosomal organelles complex 1 subunit 5	Homo sapiens	81-88
35411132-13	2022	Genes related to protein repair (MSRB3) and anti-ultraviolet (UV) effect (UVSSA) were upregulated 4.253 and 2.603 fold, respectively, after HCQ treatment.	Hydroxychloroquine	140-143	methionine sulfoxide reductase B3	Homo sapiens	33-38
35411132-13	2022	Genes related to protein repair (MSRB3) and anti-ultraviolet (UV) effect (UVSSA) were upregulated 4.253 and 2.603 fold, respectively, after HCQ treatment.	Hydroxychloroquine	140-143	UV stimulated scaffold protein A	Homo sapiens	74-79
35411132-14	2022	Conclusion: The expression of the BLOC1S5 gene is significantly upregulated, indicating upregulated melanosomal biogenesis after HCQ treatment.	Hydroxychloroquine	129-132	biogenesis of lysosomal organelles complex 1 subunit 5	Homo sapiens	34-41
35411132-15	2022	In addition, HCQ yields a protective effect on melanocytes by upregulating genes associated with damaged protein repair (MSRB3) and anti-UV effect (UVSSA).	Hydroxychloroquine	13-16	methionine sulfoxide reductase B3	Homo sapiens	121-126
35411132-15	2022	In addition, HCQ yields a protective effect on melanocytes by upregulating genes associated with damaged protein repair (MSRB3) and anti-UV effect (UVSSA).	Hydroxychloroquine	13-16	UV stimulated scaffold protein A	Homo sapiens	148-153
35411132-16	2022	The protective effects of HCQ are mediated by binding to putative targets ACHE, PNMT, MC1R, and VDR according to network pharmacology and docking verification.	Hydroxychloroquine	26-29	acetylcholinesterase (Cartwright blood group)	Homo sapiens	74-78
35411132-16	2022	The protective effects of HCQ are mediated by binding to putative targets ACHE, PNMT, MC1R, and VDR according to network pharmacology and docking verification.	Hydroxychloroquine	26-29	phenylethanolamine N-methyltransferase	Homo sapiens	80-84
35411132-16	2022	The protective effects of HCQ are mediated by binding to putative targets ACHE, PNMT, MC1R, and VDR according to network pharmacology and docking verification.	Hydroxychloroquine	26-29	melanocortin 1 receptor	Homo sapiens	86-90
35411132-16	2022	The protective effects of HCQ are mediated by binding to putative targets ACHE, PNMT, MC1R, and VDR according to network pharmacology and docking verification.	Hydroxychloroquine	26-29	vitamin D receptor	Homo sapiens	96-99
35258358-10	2022	CLASI scores of the HCQ+QC-nonresponder group positively correlated with CD69+CCR7+ circulating activated T cells (r = 0.6335, p < 0.05) and MAC387+ cells (r = 0.5726, p < 0.05).	Hydroxychloroquine	20-24	C-C motif chemokine receptor 7	Homo sapiens	78-82
35443454-14	2022	Pre and post treatment CRP was also compared for Tocilizumab, Fevipiravir, Hydroxychloroquine, Doxycyline, but none of them were able to decrease CRP significantly (p > 0.05) in the severe or critical group but these drugs were effective in reducing CRP significantly (p<0.05) when given in mild-moderate group or if the treatment was started early.	Hydroxychloroquine	75-93	C-reactive protein	Homo sapiens	23-26
35472798-0	2022	Decrease in Visual Acuity in a 77-Year-old Woman with Age-Related Macular Degeneration after a SARS-CoV-2 Infection Treated with Hydroxychloroquine.	Hydroxychloroquine	129-147	renin binding protein	Homo sapiens	54-57
35258358-10	2022	CLASI scores of the HCQ+QC-nonresponder group positively correlated with CD69+CCR7+ circulating activated T cells (r = 0.6335, p < 0.05) and MAC387+ cells (r = 0.5726, p < 0.05).	Hydroxychloroquine	20-24	S100 calcium binding protein A9	Homo sapiens	141-147
35258358-13	2022	CONCLUSION: An increased number of CD69+CCR7+ circulating activated T cells and a strong correlation with CLASI scores in the HCQ+QC-nonresponders suggest these cells are involved in antimalarial-refractory skin disease.	Hydroxychloroquine	126-130	C-C motif chemokine receptor 7	Homo sapiens	40-44
35258358-14	2022	STAT3 is also increased in HCQ+QC-nonresponders and may also be a potential target for antimalarial-refractory skin disease.	Hydroxychloroquine	27-31	signal transducer and activator of transcription 3	Homo sapiens	0-5
35353333-3	2022	METHODS: In a single-blind randomized clinical trial, 92 patients with acute brucellosis were randomly divided in two treatment groups who received a triple drug regimen including doxycycline, streptomycin, and hydroxychloroquine (DSH) for 4 and 6 weeks.	Hydroxychloroquine	211-229	dishevelled segment polarity protein 1 pseudogene 1	Homo sapiens	231-234
35135554-0	2022	Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.	Hydroxychloroquine	80-98	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31
35346242-0	2022	Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-kappaB signaling pathway.	Hydroxychloroquine	0-18	toll-like receptor 4	Mus musculus	99-103
35346242-0	2022	Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-kappaB signaling pathway.	Hydroxychloroquine	0-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	104-113
35346242-6	2022	The aim of the current study was to elucidate whether HCQ could improve the neurological recovery of mice post-TBI by inhibiting the inflammatory response via the TLR4/NF-kappaB signaling pathway.	Hydroxychloroquine	54-57	toll-like receptor 4	Mus musculus	163-167
35346242-6	2022	The aim of the current study was to elucidate whether HCQ could improve the neurological recovery of mice post-TBI by inhibiting the inflammatory response via the TLR4/NF-kappaB signaling pathway.	Hydroxychloroquine	54-57	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-177
35346242-15	2022	CONCLUSIONS: HCQ reduced proinflammatory cytokine expression, and the underlying mechanism may involve suppressing the TLR4/NF-kappaB signaling pathway, suggesting that HCQ is a potential therapeutic agent for TBI treatment.	Hydroxychloroquine	13-16	toll-like receptor 4	Mus musculus	119-123
35346242-15	2022	CONCLUSIONS: HCQ reduced proinflammatory cytokine expression, and the underlying mechanism may involve suppressing the TLR4/NF-kappaB signaling pathway, suggesting that HCQ is a potential therapeutic agent for TBI treatment.	Hydroxychloroquine	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	124-133
35346242-15	2022	CONCLUSIONS: HCQ reduced proinflammatory cytokine expression, and the underlying mechanism may involve suppressing the TLR4/NF-kappaB signaling pathway, suggesting that HCQ is a potential therapeutic agent for TBI treatment.	Hydroxychloroquine	169-172	toll-like receptor 4	Mus musculus	119-123
35346242-15	2022	CONCLUSIONS: HCQ reduced proinflammatory cytokine expression, and the underlying mechanism may involve suppressing the TLR4/NF-kappaB signaling pathway, suggesting that HCQ is a potential therapeutic agent for TBI treatment.	Hydroxychloroquine	169-172	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	124-133
35401507-9	2022	In systemic immune response, HCQ inhibited the activation of naive CD4+T cells and frequencies of T effector cells, and promoted T regulatory cells.	Hydroxychloroquine	29-32	CD4 antigen	Mus musculus	67-70
35401507-11	2022	Further studies established that TNF-alpha induced RVECs to express inflammatory cytokines, chemokines, and adhesion molecules, whereas HCQ alleviated the alterations via the LOX-1/NF-kappaB pathways.	Hydroxychloroquine	136-139	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	175-180
35401507-11	2022	Further studies established that TNF-alpha induced RVECs to express inflammatory cytokines, chemokines, and adhesion molecules, whereas HCQ alleviated the alterations via the LOX-1/NF-kappaB pathways.	Hydroxychloroquine	136-139	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	181-190
35401507-12	2022	Conclusions: HCQ alleviates EAU by regulating the Teff/Treg balance and ameliorating RVECs dysfunction via the LOX-1/NF-kappaB axis.	Hydroxychloroquine	13-16	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	111-116
35401507-12	2022	Conclusions: HCQ alleviates EAU by regulating the Teff/Treg balance and ameliorating RVECs dysfunction via the LOX-1/NF-kappaB axis.	Hydroxychloroquine	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	117-126
35236729-8	2022	Low certainty evidence suggests that hydroxychloroquine may increase the risk of cardiac toxicity (RD 10 more per 1000, 95% CI 0 more to 30 more) and cognitive dysfunction/delirium (RD 33 more per 1000, 95% CI 18 fewer to 84 more), whereas moderate certainty evidence suggests hydroxychloroquine probably increases the risk of diarrhoea (RD 106 more per 1000, 95% CI 48 more to 175 more) and nausea and/or vomiting (RD 62 more per 1000, 95% CI 23 more to 110 more) compared with standard care or placebo.	Hydroxychloroquine	37-55	NADH:ubiquinone oxidoreductase subunit S4	Homo sapiens	207-212
35201948-7	2022	In summary, IGF1R and MAPK/ERK signaling promotes resistance to CQ/HCQ in PDAC, and their dual inhibition increases sensitivity to autophagy inhibitors.	Hydroxychloroquine	67-70	insulin like growth factor 1 receptor	Homo sapiens	12-17
35201948-7	2022	In summary, IGF1R and MAPK/ERK signaling promotes resistance to CQ/HCQ in PDAC, and their dual inhibition increases sensitivity to autophagy inhibitors.	Hydroxychloroquine	67-70	mitogen-activated protein kinase 3	Homo sapiens	22-26
35201948-7	2022	In summary, IGF1R and MAPK/ERK signaling promotes resistance to CQ/HCQ in PDAC, and their dual inhibition increases sensitivity to autophagy inhibitors.	Hydroxychloroquine	67-70	mitogen-activated protein kinase 1	Homo sapiens	27-30
35022320-0	2022	BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma.	Hydroxychloroquine	103-121	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	6-10
35022320-0	2022	BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma.	Hydroxychloroquine	103-121	mitogen-activated protein kinase kinase 7	Homo sapiens	25-28
35335157-2	2022	In this study, the binding interactions of phenylamino-phenoxy-quinoline derivatives and six commercially available drugs (hydroxychloroquine, ritonavir, remdesivir, S-217622, N3, and PF-07321332) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) were investigated using molecular docking and the ONIOM method.	Hydroxychloroquine	123-141	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	278-282
35156519-3	2022	Here we highlight the results of a recently published single-arm phase I/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.	Hydroxychloroquine	155-158	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	236-240
35135554-2	2022	This study aimed to investigate the relationship of cytochrome P450 (CYP450) gene polymorphisms with blood concentrations of HCQ and its metabolites and adverse drug reactions (ADRs) in patients with SLE and RA.	Hydroxychloroquine	125-128	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
35135554-8	2022	RESULTS: Among 29 candidate SNPs, we found that CYP3A4 (rs3735451) was significantly associated with blood levels of HCQ and its metabolites in both the unadjusted model and adjusted model (patients taking HCQ for > 10 years) (P < 0.05).	Hydroxychloroquine	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
35135554-8	2022	RESULTS: Among 29 candidate SNPs, we found that CYP3A4 (rs3735451) was significantly associated with blood levels of HCQ and its metabolites in both the unadjusted model and adjusted model (patients taking HCQ for > 10 years) (P < 0.05).	Hydroxychloroquine	206-209	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
35135554-11	2022	CONCLUSIONS: The CYP2C8 (rs1058932 and rs10882526) and CYP3A5 (rs776746) polymorphisms are likely involved in the ADRs of HCQ.	Hydroxychloroquine	122-125	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	17-23
35135554-11	2022	CONCLUSIONS: The CYP2C8 (rs1058932 and rs10882526) and CYP3A5 (rs776746) polymorphisms are likely involved in the ADRs of HCQ.	Hydroxychloroquine	122-125	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	55-61
35000060-5	2022	Molecular docking of HCQ under physiological condition with spike protein, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp) of SARS-CoV2 showed - 8.52 kcal/mole binding score with RdRp, while the other two proteins showed relatively weaker binding affinity.	Hydroxychloroquine	21-24	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	60-65
35058480-2	2022	In particular, while recent studies examined COVID-19 associated arrhythmic risks from cardiac injury and/or from pharmacotherapy such as the combination of azithromycin (AZM) and hydroxychloroquine (HCQ), the role of IL-6 per se in increasing the arrhythmic risk remains poorly understood.	Hydroxychloroquine	180-198	interleukin-6	Cavia porcellus	218-222
35058480-2	2022	In particular, while recent studies examined COVID-19 associated arrhythmic risks from cardiac injury and/or from pharmacotherapy such as the combination of azithromycin (AZM) and hydroxychloroquine (HCQ), the role of IL-6 per se in increasing the arrhythmic risk remains poorly understood.	Hydroxychloroquine	200-203	interleukin-6	Cavia porcellus	218-222
35215332-7	2022	Mechanistic insights underlying the synergistic effects of AZM and HCQ on iPSC-CM functionality are provided based on increased cellular accumulation of HCQ and AZM as well as increased Cx43- and Nav1.5-protein levels.	Hydroxychloroquine	67-70	gap junction protein alpha 1	Homo sapiens	186-190
35215332-7	2022	Mechanistic insights underlying the synergistic effects of AZM and HCQ on iPSC-CM functionality are provided based on increased cellular accumulation of HCQ and AZM as well as increased Cx43- and Nav1.5-protein levels.	Hydroxychloroquine	67-70	sodium voltage-gated channel alpha subunit 5	Homo sapiens	196-202
35184387-5	2022	The elevated levels of propionate in Acss3-/- mice similarly drive adipocyte autophagy, and pharmacological inhibition of autophagy using hydroxychloroquine ameliorates obesity, hepatic steatosis and insulin resistance of the Acss3-/- mice.	Hydroxychloroquine	138-156	acyl-CoA synthetase short-chain family member 3	Mus musculus	37-42
35184387-5	2022	The elevated levels of propionate in Acss3-/- mice similarly drive adipocyte autophagy, and pharmacological inhibition of autophagy using hydroxychloroquine ameliorates obesity, hepatic steatosis and insulin resistance of the Acss3-/- mice.	Hydroxychloroquine	138-156	acyl-CoA synthetase short-chain family member 3	Mus musculus	226-231
35192518-8	2022	C-reactive protein levels of the standard of care plus hydroxychloroquine group were significantly lower than that of the standard of care group at discharge (p = 0.034).	Hydroxychloroquine	55-73	C-reactive protein	Homo sapiens	0-18
35192518-11	2022	CONCLUSIONS: Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and greater C-reactive protein reduction.	Hydroxychloroquine	13-31	C-reactive protein	Homo sapiens	149-167
35000060-5	2022	Molecular docking of HCQ under physiological condition with spike protein, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp) of SARS-CoV2 showed - 8.52 kcal/mole binding score with RdRp, while the other two proteins showed relatively weaker binding affinity.	Hydroxychloroquine	21-24	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	136-140
35000060-5	2022	Molecular docking of HCQ under physiological condition with spike protein, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp) of SARS-CoV2 showed - 8.52 kcal/mole binding score with RdRp, while the other two proteins showed relatively weaker binding affinity.	Hydroxychloroquine	21-24	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	198-202
34980245-7	2022	Unexpectedly, HCQ preadministration significantly increased susceptibility to and delayed the recovery of AKI complicated by LN, as demonstrated by an increase in PTEC apoptosis and expression of the tubular injury marker KIM-1 as well as the retardation of PTEC replenishment.	Hydroxychloroquine	14-17	hepatitis A virus cellular receptor 1	Mus musculus	222-227
35463861-8	2022	HCQ drastically reduced both HbA1c levels, from 10.3 to 7.5%, and the insulin doses required without altering the doses of glucocorticoid or hypoglycemic agents, although body weight increased slightly.	Hydroxychloroquine	0-3	insulin	Homo sapiens	70-77